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 Application of modeling and simulation has been growing significantly in 
different stages of drug development, from early discovery to late clinical trials, in the 
past decade.  Mechanistic physiologically-based models to predict transport and 
accumulation of small molecules in organisms provide such a way to integrate 
information from different resources, including physiological / biological parameters and 
drug specific properties, for hypothesis testing, mechanisms exploration, guiding 
experimental design, pharmacokinetic prediction, and extrapolation of pharmacokinetic 
profiles across species.  With the continuously increasing interests and extensive research 
conducted in areas of systems biology, transporters, metabolic enzymes, and 
pharmacogenomics, the next step would be quantitatively integrating such information to 
guide drug development. Cellular pharmacokinetic modeling aims to predict 
pharmacokinetic behaviors of compounds at cellular / subcellular level by integrating 
physiological parameters of cells, as well as drug specific information, such as 
physicochemical properties (pKa, logP), unbound fraction, active transport, and metabolic 
information, etc.  This review will be focused on recent development of cellular 
pharmacokinetic models including empirical and mechanistic models.  Advantages and 
disadvantages of each type of models will be discussed. Relationship of cellular 
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pharmacokinetics (PK) with systemic PK and pharmacodynamics (PD), and potential 
applications of cellular pharmacokinetic modeling in physiologically-based 
pharmacokinetic (PBPK) modeling will be included.  
 
Keywords: Modeling and simulation; Cellular pharmacokinetics; Subcellular 
localization; Physiologically-based pharmacokinetic (PBPK) modeling; Cell 
permeability; Passive diffusion; Transporters; Metabolic enzymes; Site of action; 
Absorption, distribution, metabolism, excretion, and toxicity (ADMET) 
 




 With the development of combinatorial chemistry synthesizing a large number of 
potential drug candidates is no longer a bottleneck in the drug discovery process.  High 
throughput pharmacological screening methods have also been developed to quickly 
assay drug biological activity.  Besides biological activities the high throughput methods 
for absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction are 
desired and become a major challenge in early drug discovery and development stages.  
Predictive physiologically-based pharmacokinetic (PBPK) models are mechanism-based 
mathematical models integrating prior knowledge in a quantitative way to predict 
pharmacokinetic properties of drugs in organisms (1-3).  PBPK modeling covers a wide 
range of models and address ADMET properties at different levels, from subcellular 
level, cellular level, tissue, organ, to the whole body (4-12).   
Cellular pharmacokinetics describes distribution and accumulation of compounds 
at cellular / subcellular level.  Subcellular distribution may play an important role in 
determining drug efficacy and toxicity.  If the site of the action is located in specific 
subcellular organelles, while the drug accumulates extracellularly or in other organelles, 
that might decrease the efficacy and induce non-specific toxicity.  Similarly, if a drug 
targets receptors on extracellular membrane surface, but it accumulates intracellularly 
due to non-optimized physicochemical properties, it might lead to toxicity as well.  
Pulmonary toxicity of amiodarone, an antiarrhythmic agent, is observed after chronic 
administration. One of the explanations of the side effects is intralysosomal accumulation 
and its main metabolites desethylamiodarone and the drug-induced intracellular storage 
of phospholipids (13, 14).  Recently research shows that in drug-resistant cancer cells, the 
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intracellular drug concentration often remains high (15, 16). One of the explanations for 
lack of efficacy is pH dependent ion trapping of weak basic agents to acidic intracellular 
compartment, extracting drugs away from their intracellular site of action (17-19).  
Having observed the impact of subcellular distribution on efficacy and toxicity, 
interests of quantitatively describing cellular pharmacokinetics have been increasing, and 
computational models have been developed as tools for understanding drug transport at 
cellular level, rationale drug design for specific subcellular targeting, and predicting 
absorption, tissue distribution, and clearance (4, 6, 7, 20-24).  A variety of strategies have 
been adapted to develop cellular pharmacokinetic models to predict subcellular 
accumulation or drug transport kinetics intracellularly.  In general, there are two major 
classes of mathematical techniques used for predicting cellular pharmacokinetics: 
empirical models, such as applying statistical analyses to determine the relationship 
between structures and subcellular localization of small molecules, quantitative structure-
activity relationships approaches, or fitting experimental data to get kinetic rate constant 
in compartmental models (21-31); and  mechanism based physiological models (4, 6, 7).  
This review will be focused on mathematical models have been developed to analyze or 
predict cellular / subcellular pharmacokinetics rather than summarizing subcellular 
localization properties of small molecules.  Features of each type of models and their 
potential contribution to systemic PK/PD modeling will be discussed.  
Subcellular compartment --- How do you define it? 
The definition of subcellular compartment may vary from models to models.  
Some cellular PK models treat the whole cell as one homogeneous compartment. 
Subcellular organelles have their unique functions and properties, such as intralumenal 
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pH, electrochemical potential, lipid bilayer composition, and proteins (17). Thus it is 
natural to treat each subcellular organelle as independent compartment, such as 
mitochondria, lysosomes, nuclei, endoplasmic reticulum, and Golgi apparatus.  For 
example, F. Rashid and R. W. Horobin developed a simplistic Chinese box (SCB) model, 
which defined the cellular / subcellular compartment as boxes (30, 32, 33).  They defined 
‘a box is a region of an organism considered discrete by a biologist’ (33). Some boxes 
may contain another box, such as nuclei may contain nucleoli (33).  Besides using 
organelles as subcellular compartment, another strategy to define subcellular 
compartment is to divide cellular compartment into N compartments, composed of a 
catenary chain of alternating aqueous and lipid phase as described by S. Balaz et al. (24, 
34-36).  The model developed by V. Y. Chen et al. defines the subcellular compartment 
other than cytosol as vesicles (23).  
pH-partition theory and ion-trapping mechanism 
Physiology of some subcellular organelles has been well studied to date.  
Mitochondria and lysosomes are relatively independent and membrane-enclosed 
organelles.  Mitochondria are involved in the intrinsic pathway of apoptosis, and thus 
become a target of anticancer agents (37-39).  The respiratory chains located in the 
mitochondrial inner membrane generate a proton gradient across the membrane, which 
yields a transmembrane potential and a pH gradient (40, 41).  Depending on the cell types 
and differentiation stages, the ratio of membrane potential and pH gradient might differ 
(40).  Many lipophilic cations have been observed accumulating in mitochondria as a 
function of the transmembrane electrical potential, which can be predicted by the Nernst 
equation (21, 40, 42-44), such as rhodamine 123 (40, 42, 45, 46), F16 (37, 38), and the 
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styryl family (47-50).  Lysosomes function as the digestive system of the cell.  Many 
degradative enzymes are located in lysosomes.  Lysosomal storage diseases are caused by 
the mutations in the genes that encode those enzymes (51).  Many clinically used drugs 
target lysosomes, such as antimalarial drug chloroquine (52-54), and antidepressant drugs 
(55).  Lysosomes are acidic intracellular organelles with intralumenal pH of 4.6-5.0 (56), 
while the cytosolic pH is near neutrality (~7.2) (17).  The low pH is caused by the 
activity of a proton ATPase rather than by a Donnan potential for protons, as originally 
proposed (56).  As a result, acidification is accompanied by the generation of an interior 
positive membrane potential (56).   
 One of the well-studied mechanisms of lysosomal accumulation of weakly basic 
molecules is the ion-trapping mechanism, which was described by De Duve et al. as early 
as in the Seventies (57).  For molecules with at least one ionizable group, the proportion 
of neutral species and ionized species may differ significantly in different pH 
environment,  depending on the acid dissociation constant (pKa) and pH, which can be 
described by the Henderson-Hasselbalch equation.  For weakly basic molecules with pKa 
close to physiological pH, they exist predominantly as neutral species in cytosol (pH ~ 
7.2).  After neutral molecules enter the acidic subcellular organelles, they become 
protonated due to the acidic environment. Generally the lipophilicity may differ three 
orders of magnitude between neutral species and ionized species (7). Thus after entering 
the acidic compartment, transmembrane permeability of the molecules is reduced due to 
the protonation, and accumulation is induced.  
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The Goldman-Hodgkin-Katz equation 
 The flux of ionic molecules across a biomembrane is a function of the 
transmembrane electrical potential and the concentration gradient of the molecules across 
the biomembrane.  It can be described by Nernst-Planck equation (equation 1.1).   
( ) ( )[ ( ) ]dC x zF dV xJ D C x
dx RT dx
= − +  ,     (1.1) 
 The first term is corresponding to the Fick’s law of diffusion, which gives the 
diffusion down the concentration gradient. The second term reflects the flux due to the 
transmembrane electrical potential.  D is the diffusion coefficient (area per time unit).  F, 
R, T, and z are the Faraday constant, molar gas constant, temperature (in Kelvin), and 
electric charge, respectively. Assume the transport direction (denoted by x) being 
perpendicular to the membrane, then dC(x)/dx reflects the concentration change along the 
membrane, and dV(x)/dx reflects the voltage change along the membrane. C(x) indicates 
the concentration at point x. If transmembrane electrical potential is assumed to be 
constant along the membrane, and the membrane thickness is d, equation 1.1 is rewritten 
as equation (1.2) and rearranged to obtain equation 1.3. 
( )[ ( ) ]dC x zF VJ D C x
dx RT d
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 Reorganize equation 1.4, one can obtain equation 1.5, which is the explicit 
expression of flux of ionic molecules across a biomembrane with transmembrane 
electrical potential and concentration gradient.  








 ,    (1.5) 
where D/d can be written as permeability (length per time unit), C(0) is the concentration 
at outer membrane surface, and C(d) is the concentration at inner membrane surface.  
Empirical and semi-empirical models  
Statistic based formulas are widely used in predicting different ADME properties, 
from basic physical properties of drug substances such as in vitro solubility (58-62) to 
more complex biological properties of drug-organism interaction, such as in vivo 
bioavailability (63-65).  Statistically based empirical formulas are usually built from 
databases of molecules that have been screened by a specific assay.  The assay data is 
related to the chemical structure of the molecules using probabilistic regression 
techniques.  This probabilistic regression can be summarized as an equation that specifies 
the relationship between the resulting physicochemical or biological property of interest 
(the dependent variable of the equation) to different parameters related to the chemical 
structure of the molecule (the dependent variables of the equation).  Using a training set 
of molecules, quantitative structure-activity relationship (QSAR) equations can be used 
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to predict the behavior of a previously untested test set of molecules. While QSAR 
models have been developed to study the physiochemical properties or pharmacological 
activities of small molecules extensively (66-75), models about structure – subcellular 
localization relationships (QSLR) are relatively underdeveloped (27-30, 32, 33, 76-78). 
Pseudo-equilibrium models 
In early nineties, F. Rashid and R. W. Horobin were aware of the importance of 
physicochemical properties, such as hydrophilicity / lipophilicity (logP), pKa (and thus 
electrical charges z), molecular size, and the properties of biological systems, in 
determining the localization of fluorescent molecules, and developed decision tree – like 
model, which comprised sets of nested if/then rules (79) to predict subcellular 
accumulation in various organelles.  At the beginning, a simple and generalized model, 
named the simplistic Chinese box (SCB) model, was developed to describe the 
interaction of molecular probes within living cell system (30, 32, 33).   The SCB model 
was applied to 41 cationic probes to study their mitochondrial localization as a function 
of logPoct (logarithm of octanol / water partition coefficient) (32).  LogP values fell 
between -3.6 and 21.0.  They observed that cationic molecules with logP between 0 and 5 
were expected to accumulate in the mitochondrial inner membrane.  Cationic molecules 
with logP < 0 would be excluded outside cells, and with logP > +5 would bind to external 
membrane irreversibly (32).  The model then was tested with 10 fluorescent 
mitochondrial probes and 7 vital dyes of mitochondria and the same trend was observed.  
Later on a library with 50 fluorescent probes with various physicochemical 
characteristics was studied for their lysosomal accumulation by the same group (30).  The 
conjugated bound number (CBN) was introduced to model non-specific protein binding.  
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Several scenarios were included: entry of cells, entry of lysosomes, retention in 
lysosomes, and selectively accumulate in lysosomes.  Probes that could enter the cells 
had 0 < logP < 5 and CNB < 40.  Probes with logP > 15, and / or CNB > 40 (regardless 
of hydrophilicity could also enter the cell by adsorptive pinocytosis. Markers of fluid 
phase pinocytosis could also enter the cells and were found having logP < 0, z <0, and 
CBN < 40. After the probes entered the cells, they accumulated in lysosomes and could 
be categorized into two groups: (1) Probes accumulating in lysosomes by ion trapping 
mechanisms had z ≤ 0, logPcation < 0, but logP free base > 0, pKa ~ 7, and CBN < 40; (2) 
Probes comprised of hydrolysable lipophilic esters, usually weak acids, had z ≤ 0, logP 
free base > 0, pKa ~ 7, and CBN < 40.  Those probes were converted into immobile free 
acids by lysosomal esterases and trapped in lysosomes by precipitation of insoluble weak 
acids in low pH environments (30).  To expend the same strategy to other organelles, 
such as endoplasmic reticulum, nuclear chromatin, and plasma membrane, amphipathic 
character (AI), the largest conjugated fragment value (LCF), and LCF/CBN ratio were 
introduced to the empirical model (29, 79, 80).   
Unlike the decision tree – like model, additive models were developed for a 
combinatorial library of cationic styryl dyes for their chemical properties (e.g. peak 
emission or excitation wavelength) and subcellular localization properties (mitochondria 
or non-mitochondria) (21, 81).  Model parameters for peak excitation and emission were 
obtained using least squares to minimize the additive function over all compounds having 
experimental data (21, 81).  The binary localization data were analyzed using factorial 
logistic regression. Cross-validation was carried out for both the spectral and localization 
analyses to obtain unbiased estimates of the prediction performance (21, 81).  
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Back to the Sixties, Hansch et al. published a series of papers describing the 
relationship between concentration and hydrophobicity (82-85).  A representative 
equation can be expressed by equation 1.7.  
log logx x HP Pπ = − ,     (1.6) 
21log a b c
C
π π ρσ= − + + ,   (1.7) 
where, Px and PH are the partition coefficients of a derivative and the parent molecule, 
respectively; C is the molar concentration; a, b, ρ and c are constants determined by 
minimizing least squares.  Later on, the Hansch-Fujita equations were extended and 
applied to a multi aqueous / lipid biosystem to study drug disposition and activity (35, 86, 
87).  Rather than using organelles as subcellular compartments, the QSAR models divide 
cellular compartment into continuous aqueous / lipid phases.  An empirical disposition 
equation was used to reduce the number of adjustable parameters, which expressed the 
concentration after a predetermined time of exposure as a function of octanol/water 
partition coefficient (35).  Adjustable parameters in the final equation were optimized by 
a combination of linear and non-linear regression analyses (35).  Simulated bioactivity - 
lipophilicity curves agreed well with observer data for 10 compounds.  The model could 
potentially be used to construct concentration - time profiles in smaller biosystems, such 
as bacterial or mammalian cells (35); or serve as a base for the development of 




While the empirical models described above were focused on steady state 
distribution, kinetic models are always desired to describe the transport as a function of 
time.   
The time of exposure was integrated in the QSAR model discussed above by 
employing kinetics of the drug-receptor interaction based on mass action law (31). The 
kinetic model was named QSTAR model.  Adjustable parameters in the model were 
obtained by non-linear regression for 36 compounds (31).  The simulated inhibitory 
potency versus lipophilicity curve agreed well with the observed data (31).  This time 
course of drug concentration in the receptor surroundings serves as the base for 
constructing the differential equations for the receptor modification proceeding by any 
proposed mechanisms. 
The QSTAR subcellular pharmacokinetic model was further extended by 
integrating Michaelis-Menten kinetics of enzymatic reactions with respect to its two 
boundary cases, membrane accumulation, non-covalent protein binding, and excretion 
(88).  Differential equations were solved analytically, so the explicit parameters, such as 
elimination rate constant, maximal rate, and the Michaelis-Menten constant, were lumped 
together to form adjustable parameters in the final equation (88). The adjustable 
parameters were obtained by non-linear regression (88). In the discussion, the authors 
mentioned that the model “can not be applied to a broader series of compounds having 
diverse structures since it describes merely the structurally non-specific steps a 
compound has to undergo in microbial culture and does not incorporate the structural 
specificity of the enzyme-substrate interaction.”(88) 
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A two-compartment model, cytosol and vesicles, was developed for a library 
consisting of 80 fluorescent-tagged triazine compounds (23).  First-order kinetics was 
assumed between each compartment. Coefficients of variation (CV) of pixel intensities 
were linked to intracellular concentration by a statistical model. Rate constants in the 
model were obtained by optimization and the solutions within 5% of the best fit were 
chosen. With the help of subcellular pharmacokinetic modeling, the partition coefficients 
from the extracellular medium to the cytosol, and from the cytosol to the intracellular 
vesicles, could be quantitatively defined, which indicated the subcellular sequestration 
phenomenon.  Furthermore it provided bases for analyses of correlation of subcellular 
transport with chemical structures and physicochemical properties (23). 
Fluorescent microscopic imaging technique is one of the most often used methods 
to detect subcellular localization of small molecules (N. Zheng, manuscript in 
preparation). However, those methods are mainly applied to fluorescent molecules, which 
limit the method application to certain class of chemicals.  Drug-induced morphology 
changes of subcellular organelles can be detected using light microscopy or electron 
microscopy and can be used as surrogate evidence for subcellular localization.  Other 
techniques to determine subcellular localization include cell fractionation, radiography, 
uptake competition, and metabolic study, which could be labor intensive experiments.  
Limited information of subcellular localization and less diverse structures of small 
molecules might limit the development and predictive accuracy of empirical models.  
Thus mechanism based cellular pharmacokinetic models are developed.  
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Mechanistic physiologically-based models 
 Basic principles or mechanisms used in developing mechanistic physiologically-
based cellular pharmacokinetic models include: mass balance, Fick’s law of diffusion, 
pH–partitioning theory, ion-trapping mechanism, Henderson-Hasselbalch equation, 
Nernst–Planck equation, Michaelis–Menten equation, and other specific mechanisms 
involved.  In mechanistic physiologically-based cellular PK models, for the part that is 
difficult to be modeled with mechanistic strategy, empirical methods are often employed.  
If some parameters in the mechanistic models are difficult to be measured 
experimentally, regression methods will also be used to get the estimation.  
Generic models --- The History of 1CellPK 
 Generic models usually only include general mechanisms, such as passive 
diffusion, and thus can be applied to a large number of molecules.   
 Mechanistic models were developed for non-polarized suspension cells including 
cytosol, mitochondria and lysosomes as subcellular compartments (4-7).  Many of the 
equations originally were developed to predict plant uptake (92). The uptake of 
electrolytes into a single plant cell was modeled.  The plant cell was separated into the 
compartments, cytoplasm and vacuole, and was surrounded by the apoplast (92). Later on 
the model was applied to tumor cells (7).  Passive diffusion was modeled by Fick’s law 
of diffusion for neutral molecules, and by combination of Fick’s law of diffusion and 
Nernst–Planck equation for ionized molecules.  Those models considered both the 
physiological properties of the cells and physicochemical properties of the small 
molecules, and gave quantitative predictions of concentration-time profiles in functional 




 Other than generic models which have been developed for certain classes of 
molecules, specific cellular pharmacokinetic models also have been developed to study 
single compounds to understand their transport or effects at cellular level. In specified 
models, more mechanisms are included other than passive diffusion, such as multiple 
transporters, specific binding, metabolic enzymes, and pharmacodynamic models.  
A series of papers were published to model cellular PK of paclitaxel capturing the 
effect of P-gp mediated efflux and intracellular binding to tubulins/microtubules (20, 93, 
94). Quantification of paclitaxel intracellular pharmacokinetics is important because it is 
closely related to its pharmacodynamics. At a starting point, the model first assumed 
passive diffusion of paclitaxel across the cell membrane (93). The model took account 
into saturable binding to extracellular proteins, saturable and nonsaturable binding to 
intracellular components, cell density variation, and enhancement of tubulin 
concentration.  The model was validated in human breast MCF7 tumor cells, which had 
negligible P-gp expression.  Later on the effect of P-gp mediated efflux was added into 
the model and validated in human breast carcinoma BC19 cells that  were derived from 
MCF7 cells transfected with mdr1 (94). Their study indicated that the P-gp mediated drug 
efflux accounted for more than 70% of total drug efflux when extracellular concentration 
was less than 200nM, but less than 30% of total efflux when extracellular concentration 
was 1000nM. Translating to clinical impact, their findings suggested that if the patient 
had similar P-gp expression level in tumor as BC19 cells in this study, then the role of P-
pg in the efflux was limited since the clinically relevant concentration range was larger 
than 200nM. They also found the dissociation constant (Km) of paclitaxel from P-gp 
measured in this study was three orders of magnitude different from previous 
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measurement in Caco-2 cell monolayer.  That could be due to different cell lines. More 
importantly, it indicated that the intracellular concentration played a role in determining 
the real Km.  After being experimentally validated, a parametric study was performed to 
study the effects of extracellular drug concentration, intracellular drug binding capacity 
and affinity, and P-gp expression level on the intracellular drug accumulation 
independently and simultaneously (20). The study showed that the four biological factors 
determine paclitaxel intracellular concentration interpedently. Among the four factors, 
extracellular concentration was the most sensitive factor, followed by intracellular 
binding capacity and affinity. The effect of P-gp expression was relatively minor, 
suggesting that to improve clinical efficacy, effective delivery of paclitaxel to tumor cells 
was more important than other factors, such as inhibition of P-gp efflux. 
Besides P-gp, other transporters also have been included in cell-based PK 
modeling. Poirier et al. reported a mechanism-based model including active uptake, 
nonspecific binding, and passive diffusion (95) to help better determine the Michaelis-
Menten parameters: Vmax and Km. The model was applied to estimate kinetic parameters 
of in vitro transport data from organic anion-transporting peptide (OATP) substrates and 
substrates of multiple uptake transporters. Compared with conventional two-step 
approach, the mechanism-based model showed significant improvement of accuracy and 
precision in Vmax and Km estimation.  Ranitidine absorptive transport in Caco-2 cells 
involved carrier-mediated uptake, P-gp mediated efflux, paracellular transport and 
transcellular transport (96). To capture the complex transport mechanisms, a PK model 
was developed by Bourdet et al. (96).  Meanwhile transport experiment of ranitidine was 
performed in Caco-2 cells in the absence or presence of uptake and efflux inhibitors as a 
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function of concentration. Parameters in the model were estimated by fitting the 
experimental data simultaneously using nonlinear least-squares regression.  Their 
simulations suggested that paracellular transport contributed to 60% of total transport. 
When the P-gp mediated efflux was inhibited, paracellular transport contribution was 
decreased to 40% of total transport. When the cation-selective apical uptake transporters 
were inhibited, paracellular transport contributed to 70% of total transport. Modeling and 
measuring ranitidine transport at different concentrations suggested that paracellular 
transport was concentration dependent and saturable. 
Metabolism is another interested component to be added in cell-based PK models.  
Theoretically, if the metabolic enzymes are located in cytosol, the substrate concentration 
points to the intracellular concentration and thus developing cell-based PK model is 
especially important. A catenary model was developed by Sun et al. (97) including 
passive diffusion, cellular binding, carrier-mediated and efflux transporters-mediated 
transport, and metabolic enzymes. The model was applied to study the transport and 
metabolism of baicalein in Caco-2 cells (98).   
Some of the advanced cell-based PK models have been linked to PD models (99). 
A cell-level mathematical model describing the cytokine granulocyte colony-stimulating 
factor (GCSF) / GCSF receptor (GCSFR) dynamics was developed by Sarkar et al. (99).  
The model started with the trafficking of GCSF/GCSFR system at molecular level. 
Extracellular GCSF molecules bound to GCSFR at cell surface becoming internalized 
and undergoing endocytic pathway. At cellular level, the model variables were 
extracellular ligand concentration, free surface receptors per cell, surface complexes per 
cell, intracellular ligand concentration per cell, free intracellular receptors per cell, 
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intracellular complexes per cell, degraded ligand per cell, and cell density, which was 
ligand dependent cell growth. Those variables changed over time and could be written in 
ordinary differential equations mechanistically. The cellular PK model was validated 
experimentally using wild-type GCSF and two single Asp->His mutants. The two 
mutants had similar affinity to cell-surface receptor as wild-type GCSF, but lower affinity 
to endosomal receptor, resulting in enhanced ligand recycling and ligand half-life. The 
PD model was an indirect model and the direct response from GSCF therapy was 
neutrophil production. In the original PK/PD model, two doses of GCSF were 
administered subcutaneously.  The PK part was fit by a bisegmental absorption model 
connected with a conventional two-compartment model. The cell-level PK model was 
integrated in the central compartment in replace of the saturable clearance. By integrating 
the cell-level model into PK/PD model, the effects of cellular / molecular parameters on 
pharmacodynamics could be studied mechanistically, such as the effects of endosomal 
binding affinity and extracellular binding affinity in the absence and presence of 
nonspecific clearance.  Such a model could be valuable in determining important 
parameters in PK/PD models. And the model was a first attempt to link cell-level PK 
model to systemic level PD model (99). 
Specific cellular pharmacokinetic models require more knowledge about the 
compounds interested.  While generic mechanistic cellular pharmacokinetic models are 
more useful in early drug discovery for high throughput screening and drug candidate 
identification, specific cellular pharmacokinetic models will be more useful for 
compounds in late drug development stage.   
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Comparison of empirical models with mechanistic models 
Both empirical models and mechanistic models have advantages and 
disadvantages.  Empirical models could be developed without knowing the details of how 
the compounds transport in biosystem, the mechanisms of action, but just based on 
observations.  Many principles or physical laws used in mechanistic models were 
developed as empirical models, such as Newton’s three Laws.  Started from simple linear 
regressions, empirical models become more and more complex with the rapid 
development of computational tools, new statistical methodology, more and more 
interactions among scientists with diverse background.  However, it requires a large 
amount of datasets and is difficult to be extrapolated to different scenarios, such as to 
different classes of molecules.  Mechanistic cellular pharmacokinetic models take into 
account physiological parameters and physicochemical properties of small molecules. 
Mechanism-based modeling does not require a large dataset of small molecules, but 
requires knowledge of all input parameters and usually the amount of input parameters is 
large.  Because of the large amount of input parameters, when the predicted values are 
not close to the observations, it is possible that there are too many adjustable parameters 
that could be adjusted to make the prediction close to observation.  However, the adjusted 
parameters need to be chosen carefully and based on scientific judgment.  Otherwise the 
model will lead to misinterpretation.  It is not encouraged to adjust the parameters just for 
fitting the observed data.  Neither the empirical model nor the mechanistic model is 
universally applicable in predicting cellular pharmacokinetics.   
A comparison of QSAR models with a mechanistic model was conducted by 
Horobin R.W et al. for more than 100 mitochondriotropic agents (79).  Both methods 
could predict lipophilic permanent cations and lipophilic weak acids and had 
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considerable agreement (79).  For electrically neutral species, including two zwitterions, 
QSAR model did a better prediction than the mechanistic model, because the mechanistic 
model considered biomembrane as a bulk lipid phase, so did not expect any abrupt 
increase in uptake about logP = 5 and no accumulation was predicted (79).  For lipophilic 
cations of partially ionized bases, the mechanistic model failed to predict 
mitochondriotropic behavior in eight of nine cases, while QSAR model successfully 
predicted all nine cases (79).  One of the explanations of the failure of mechanistic model 
might be that it did not include the complex formation between lipophilic cationic 
xenobiotics and the cardiolipin presented in the inner mitochondrial membrane (79, 100).  
Both methods failed to predict mitochondrial accumulation for four partially ionized 
hydrophilic compounds, among which two compounds were metabolized (79).  For five 
strong acids, which were reported accumulating in isolated mitochondria, both models 
also failed to predict mitochondrial accumulation  (79).  And that could be because 
neither model was intended to handle the isolated organelles (79).  Comparison of both 
types of models in terms of prediction accuracy showed that both approaches were useful 
but neither one was superior.  Nevertheless, to improve the prediction accuracy, 
mechanistic models could be extended according to the behavior of specific classes of 
molecules.  
Balaz B. et al. also performed a study to compare the predictive ability of a 
mechanistic model with empirical QSAR models using a dataset of toxicities against 
Tetrahymena pyriformis of 129 phenolic compounds (101). The response was 
concentration dependent toxicity and descriptors were logP and pKa. Predictive sum of 
squares of deviations between the calculated and experimental values of the omitted 
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points (PRESS) were calculated as a measurement of predictive ability.  For the 
mechanistic model, concentration was modeled with a disposition function which had 
physicochemical properties (i.e. logP and pKa) and the exposure time t as variables (87, 
101).  The model was further extended to include accumulation in the membranes and 
protein binding, hydrophobicity-dependent elimination, and hydrophobicity-independent 
elimination (89, 91).  Toxicity T was expressed as the reciprocal concentration (101).  For 
the QSAR modeling, polynomials with cross-terms of logP and pKa, and their inverse 
values were used.  A total of 113 empirical models were generated that had better 
statistics (i.e. the correlation coefficient, the fit standard error, and the value of the Fisher 
test) than the mechanistic model.  The best two models were chosen to be compared with 
the mechanistic model in terms of predictive ability.  The mechanistic model had slightly 
higher PRESS values than the empirical models (leave-one-out cross-validation and two 
types of leave-several-out cross-validation) (101). To further test the extrapolation ability 
of different models, the leave-extremes-out (LEO cross-validation) technique was applied 
to omit compounds with extreme logP and pKa values and 97 compounds were included 
with logP between 1.0 and 5.3 and pKa between 5.0 and 11.0.  A total of 105 empirical 
models were generated that had better statistics than the mechanistic model for the 
reduced dataset. However the mechanistic based model predicted much better than the 
empirical models for the compounds falling outside of the parameters space (101).  To 
summarize their findings, all empirical models had similar surface curves in the 
parameters space generated by the data but very different shapes in the areas outside the 
parameters space; predictive ability of the mechanism-based model was much better than 
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empirical models for compounds outside the parameters space.  Their study also 
suggested that mechanistic models could be extended to molecules outside of the dataset. 
Although it is difficult to judge which types of model is superior, the comparison 
of empirical models with mechanistic models performed by different groups using 
different dataset suggests that mechanistic models could be extended by adding new 
mechanism, could be extrapolated to compounds not included in the studying dataset, and 
could be well explained if discrepancies are observed.  For empirical models a large 
dataset including various classes of molecules is critical. Recently, a database containing 
945 molecules with various subcellular distribution properties was constructed in our 
group, which would serve as a starting point for further computational modeling of 
subcellular distribution (N. Zheng, manuscript in preparation).  
Cellular pharmacokinetics modeling in relation to macroscopic ADMET 
Scientists have done many in vitro and in vivo studies to show the contribution of 
subcellular sequestration on systemic distribution (102-106).  Propranolol was found to 
accumulate in mitochondrial and microsomal fractions in liver, lung, and kidney in rats 
after i.v. injection (102).  The antimalarial drug, mefloquine, showed significant 
accumulation in lysosomes in rat liver in an in vivo study (106).  High volume of 
distribution of mefloquine can be explained by lysosomal trapping (106).  Subcellular 
distribution of basic drugs chlorpromazine, imipramine, and biperiden in rat liver was 
studied 10 minutes after i.v. administration (103). The relative specific contents (the drug 
concentration per protein of each fraction divided by that of the total homogenate in 
lysosomes were found to the be highest compared with in other organelles (103).  And 
their contribution to subcellular distribution depends on the intralysosomal pH (103, 104, 
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107).  Extensive distribution in the lung has been observed for many lipophilic bases 
(108-113). Lysosomal trapping was proposed as a mechanism contributing to high 
accumulation in the lung (105, 111-114).   
However, quantitative relationship between subcellular distribution and tissue 
distribution is still under development. Quantitative prediction of subcellular 
pharmacokinetics itself can be challenging because of the multiple factors, such as the 
membrane potential, volume, surface area, intralumenal pH values, and intralumenal lipid 
contents of subcellular compartment, as well as the physicochemical properties of small 
molecules, and potential interaction / competition among different transport pathways.  
However, a predictive physiologically-based cellular pharmacokinetic model can be 
useful in optimization design of small molecules, hypothesis testing, guiding 
experimental design, and predicting outcomes that are difficult to be measured 
experimentally.  And most importantly cellular pharmacokinetic models could be 
extrapolated to organ /tissue and systemic levels to be related to macroscopic ADMET 
properties.  Cell-based PK models have been integrated into permeability limited whole 
body PBPK models to predict concentration-time profiles for a variety of compounds, 
such as methotexate (115, 116), cyclosporine A and its derivative SDZ IMM 125 (117-
119), terbinafine (120), FTY720 (121), everolimus (RAD001) (122), domperidone, a p-
glycoprotein (P-gp) substrate (123), and many macromolecules, such as phosphorothioate 
oligonucleotide ISIS1082 (124),  monoclonal antibodies (mAbs) (125-131). 
Conclusions 
 Biodistribution of small molecules at cellular / subcellular level has showed 
important effects on systemic distribution (102-106).  Extensive research that has been 
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conducted in areas of systems biology, transporters, metabolic enzymes, and 
pharmacogenomics brings up a question that how that information can be used in drug 
development efficiently. Modeling and simulation can help to bridge the gap between 
cellular / subcellular pharmacokinetics and systemic ADMET properties in a quantitative 
manner.  While physiologically-based models have the advantages of being flexible, 
interpretable, extendable, and extrapolatable; they also have the disadvantage that 
involves too many parameters, which may induce misinterpretation. Uncertainties and 
sensitivities associated with model parameters will be two issues in physiologically-based 
PK modeling.   
Specific aims 
The intestinal epithelial cells are the absorptive cells responsible for the majority of 
drug absorption (132).  Drugs transport through intestinal epithelium by several routes: 
passive transcellular transport, carrier-mediated transcellular transport, receptor-mediated 
endocytosis, paracellular passive transport and transporter-mediated efflux pathways such 
as P-glycoprotein (P-gp) (132, 133).  Among these transport routes passive transcellular 
process is the predominant pathway for most orally absorbed drugs based on a literature 
survey (134).   Studies show that paracellular pathway is molecular size and charge 
selective (134-136).  Paracellular passive permeability might play a major role in small 
molecules’ transport with molecular weight less than 200 Da  (137). Usually passive 
intestinal permeability is mainly determined by drug physicochemical properties and 
intestinal physiological properties.  To have favorable intestinal permeability drugs 
should be designed with proper physicochemical properties.   
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Computational tools to predict drug intestinal permeability are fast and cost 
effective and thus are promising and desired in early drug development.  Computational 
methods developed for intestinal permeability or oral absorption prediction can be 
classified into empirical models and mechanism-based models.  In early stage of 
modeling, a single physicochemical property such as octanol-water partition coefficient 
was used to predict intestinal permeability / oral absorption (138, 139).  It is generally 
admitted that the molecules with higher lipophilicity have higher intestinal permeability 
(140), however, this is not always valid (141), which indicates that models using a single 
parameter might be limited in several groups of compounds.  Lipinski and coworkers 
(142) established a simple empirical model, known as the ‘rules of 5’, to predict good 
oral absorption molecules based on the physicochemical properties of more than 2000 
drug candidates that had entered clinical phase II trials.  In this model, molecular weight, 
lipophilicity, numbers of hydrogen bond donors and acceptors were used as descriptors. 
Recently quantitative structure-property / activity relationships (QSPR / QSAR) have 
been introduced to oral absorption, intestinal permeability, and Caco-2 permeability 
prediction.  Descriptors can be classified as one dimensional (molecular weight, atom 
counts), two dimensional (fragment counts, topological indices, connectivity, flexibility), 
and three dimensional (molecular surface areas, molecular volume, interaction energies) 
descriptors (143).  However, as discussed above QSAR models require a training set with 
large diversity to be readily extrapolated to unrelated compounds.  
Considering the importance of both permeability and biodistribution at cellular / 
subcellular levels of small molecules, the aim of this project is to develop a mechanism 
based cellular pharmacokinetic model to predict transcellular permeability and 
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subcellular distribution. Furthermore, the cell based PK model will be integrated into 
whole body physiologically-based PK model to illustrate the effects of subcellular 
pharmacokinetics on systemic PK.   
Passive transport will be considered as a starting point.  The following specific 
aims will be addressed in this study. 
(1). To develop a physiologically-based cellular pharmacokinetic model to 
characterize transcellular permeability and subcellular accumulation of small molecules 
as a function of concentration gradient. Model will include physiological parameters of 
cells as well as physicochemical properties of small molecules; to perform parametric 
study to illustrate the sensitivity of model parameters; and to validate the model using 
published PAMPA, Caco-2, and human permeability data.  
(2). To apply the model to analyze and understand relationships between the chemical 
diversity and intracellular distributions of lysosomotropic monobasic amines.  
(3).  To illustrate how a mechanistic model can be used for guiding experimental 
design and hypothesis testing, using chloroquine as a model drug. 
(4).  To integrate the cell-based PK model to whole body physiologically-based PK 





Table 1.1: Summary of empirical models for subcellular localization prediction  
method Interested 
localization 
Descriptors Number of 
compounds  
Reference 
QSAR mito logP, Z 41 (32) 
QSAR lyso logP, pKa, CBN, Z 50 (30) 
QSAR nuclei logP, pKa, Z, CBN, AI, 
LCF, LCF/CBN ratio  
44 (27) 
QSAR ER logP, pKa, Z, CBN, AI, 
LCF 
37 (29) 
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logP: logarithm of the octanol/water partition coefficient 
pKa: negative logarithm of the acidic associate constant 
Z: electrical charge 
CBN: conjugated bond number 
AI: amphilicity index 
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A CELL-BASED MOLECULAR TRANSPORT SIMULATOR FOR 
PHARMACOKINETIC PREDICTION AND CHEMINFORMATIC 
EXPLORATION 
Abstract 
In the body, cell monolayers serve as permeability barriers, determining transport 
of molecules from one organ or tissue compartment to another. After oral drug 
administration, for example, transport across the epithelial cell monolayer lining the 
lumen of the intestine determines the fraction of drug in the gut that is absorbed by the 
body. By modeling passive transcellular transport properties in the presence of an apical 
to basolateral concentration gradient, we demonstrate how a computational, cell-based 
molecular transport simulator can be used to define a physicochemical property space 
occupied by molecules with desirable permeability and intracellular retention 
characteristics. Considering extracellular domains of cell surface receptors located on the 
opposite side of a cell monolayer as a drug’s desired site of action, simulation of 
transcellular transport can be used to define the physicochemical properties of molecules 
with maximal transcellular permeability but minimal intracellular retention. Arguably, 
these molecules would possess very desirable features: least likely to exhibit nonspecific 
toxicity, metabolism, and side effects associated with high (undesirable) intracellular 
accumulation; and most likely to exhibit favorable bioavailability and efficacy associated 
with maximal rates of transport across cells and minimal intracellular retention, resulting 
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in (desirable) accumulation at the extracellular site of action. Simulated permeability 
values showed good correlations with PAMPA, Caco-2, and intestinal permeability 
measurements, without “training” the model and without resorting to statistical regression 
techniques to “fit” the data. Therefore, cell-based molecular transport simulators could be 
useful in silico screening tools for chemical genomics and drug discovery.  
 
Keywords: Metoprolol; permeability; chemical space; computer aided drug design; 
virtual screening; chemical genomics; cellular pharmacokinetics; cheminformatics; drug 




Drug uptake and transport across cell monolayers is an important determinant of 
in vivo bioavailability, biodistribution and activity (1). However, enzymes of low 
selectivity metabolize drugs inside cells (2, 3).  High permeability-high solubility drugs 
administered at high concentrations diffuse across cells fast enough – saturating 
transporters and enzymes- that only an insignificant fraction is diverted (4, 5). However, 
high intracellular drug concentrations can also be toxic.  For example, unwanted 
accumulation of small molecules in mitochondria can interfere with mitochondrial 
function, inducing apoptosis (6, 7).  Similarly, unintentional accumulation of molecules 
in other organelles can induce phenotypic effects unrelated to a drug’s primary 
mechanism of action – manifesting as non-specific toxicity (8).  Nevertheless, many 
drugs are agonists or antagonists of cell surface receptors (9).  Since receptor ligand 
binding domains are extracellular, intracellular drug accumulation is not essential for 
bioactivity (10).  Thus, molecules designed to reach and accumulate at a desired 
extracellular site of action should combine high transcellular permeability with minimal 
intracellular accumulation.  These desirable biopharmaceutical properties can lead, in 
turn, to more potent, bioavailable, stable, and nontoxic drug candidates. 
Poor pharmacokinetics and toxicity are important causes of failure in later, 
clinical stages of drug development (4, 11, 12). Therefore, ADMET (absorption, 
distribution, metabolism, elimination, and toxicity) profiling is desirable as early as 
possible, before drug candidates are tested in patients.  High throughput in silico ADMET 
models are one way to predict favored pharmacokinetics and toxicity profiles, early in the 
design of new drugs (12).  Mapping chemical spaces occupied by molecules possessing a 
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desirable therapeutic activity and favored ADMET properties can be used to guide the 
design, synthesis, and selection of series of lead compounds (13-15).  Along these lines, 
we sought to develop a fast, flexible, and scalable computational tool for predicting 
epithelial transcellular passive permeability and intracellular accumulation, which are 
important determinants of oral absorption prediction and toxicity prediction, respectively 
(16-18).   
Drug solubility and intestinal permeability are the two key criteria for the FDA’s 
Biopharmaceutics Classification System (BCS) (19).  At early stages of drug 
development mathematical models built on the basis of data derived from in vitro 
experiments such as PAMPA (parallel artificial membrane permeation assay) and Caco-2 
assay are widely used to predict human intestinal permeability. Most existing 
mathematical models to predict intestinal permeability are based on statistical regression 
methods that correlate PAMPA, Caco-2, or rat or human intestinal permeability 
measurements to 2D and/or 3D molecular descriptors (20-22).  However, the predictive 
power of these statistical models is inherently dependent on the quality of training data 
set, as well as the variability and reproducibility of the experimental assay. Furthermore, 
because of the statistical nature of the regression relationship, large amounts of data are 
needed to generate good models covering large realms of chemical space. To 
complement statistical regression methods, we decided to pursue a mechanism-based, 
mathematical modeling strategy to predict transcellular passive permeability, while also 
predicting the intracellular concentration of drug and its accumulation in organelles. In 
addition, on the basis of permeability and intracellular concentration of a reference “
lead” compound, we also sought a nonstatistical method that could map cell-
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permeant/impermeant and cell-toxic/nontoxic chemical spaces relative to that compound, 
to help guide drug lead development efforts of pharmaceutical scientists and medicinal 
chemists. 
Here, we present a mechanism-based modeling strategy that can predict intestinal 
transcellular passive permeability, as well as drug accumulation within cells. 
Mathematically, the model describes transcellular transport of small molecules based on a 
physical, compartmental model of a cell, coupling sets of differential equations 
describing the physics of passive diffusion of small molecules across membranes 
delimiting the different compartments (23). Without incorporating enzymatic 
mechanisms or specific binding interactions, the current version of the model can predict 
the behavior of nonzwitterionic, monocharged small molecules possessing one ionizable 
functional group in the physiological pH range. Nevertheless, the behavior of more 
complex molecules and mechanisms such as carrier mediated transport, metabolic 
processes, or multiple ionizable groups can be incorporated one by one in subsequent 
versions of the model, to predict the transport of low permeability, natural product like 
molecules, and to mimic more complex, physiological conditions. 
Methods 
Starting with a cell-based, molecular mass transport model developed to study the 
accumulation of lipophilic cations in tumor cells (23), we adapted the Nernst-Planck and 
Fick equations to simulate transport of molecules across epithelial cell monolayers, in the 
presence of an apical-to-basolateral, transcellular concentration gradient. For weakly-
basic / acid, drug-like small molecule, the cellular pharmacokinetic model considers three 
physicochemical properties as the most important determinants of intracellular 
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accumulation and transport: (1) the logarithm of the lipid/water partition coefficient of 
the neutral form of the molecule, logPn; (2) the logarithm of the lipid/water partition 
coefficient of the ionized form of the molecule, logPd; (3) and the negative logarithm of 
the dissociation constant of the protonated functional group, pKa.  Drug concentrations in 
different intracellular compartments are coupled to each other according to the 
topological organization of the cell (Figure 2.1A, B).  Different organelles have different 
pHs and transmembrane electrical potentials, so a molecule’s charge in different 
organelles can vary according to the molecule’s pKa, and transport properties across the 
membranes delimiting different compartments can vary depending on the membranes’ 
electrical potential (24-27).  With the model developed herein, the concentration of 
molecules in different subcellular compartments and the transcellular permeability 
coefficient (Peff) can be calculated for different time intervals after cells are exposed to 
drug (see appendix A). 
For modeling drug accumulation in the cytosolic compartment, the mitochondrial 
compartment, and the basolateral compartment, the total mass change of the molecule 















,= , (2.3) 
where J is the net flux from the ‘positive’ side to the ‘negative’ side, m  is the 
total molecular mass, t is time, A is membrane surface area, subscripts c, a, b, and  m 
indicate cytosolic, apical, basolateral, and mitochondrial respectively.  The direction from 
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apical to basolateral compartment was defined from the ‘positive’ side to the ‘negative’ 
side. 
To solve the above equations, the relationships between fluxes and masses must 
be specified.  The bridge between these quantities is the concentration in each 
compartment.  Each side of equations 2.1, 2.2 and 2.3 is divided by the volumes of each 


































,= , (2.6) 
where Cc, Cm, and Cb are cytosolic, mitochondrial, and basolateral concentration 
and Vc, Vm, and Vb are volumes of cytosolic, mitochondrial, and basolateral compartments 
respectively. The passive diffusion flux of neutral molecules across membranes is 
described by Fick’s First Law:  
)( io aaPJ −= , (2.7) 
where J is the molecular flux from the out   side   to the inside (i) (‘negative’ side) 
of the membrane, P is the permeability of the molecules across cellular membranes, and a 
is the activity of the molecules.  For electrolytes the driving forces across cellular 
membrane are not only chemical potential but also electrical potential, which is described 
by the Nernst-Planck equation.  With the assumption of a linear potential gradient across 
the membrane, a net current flow of zero and with each ion flux is at steady state, an 









= , (2.8) 
where RTzEFN /= , z is the electric charge, F is the Faraday constant, E is the 
membrane potential, R is the universal gas constant, and T is the absolute temperature 
(23). If equations 2.7 and 2.8 are combined, the net fluxes across each membrane for both 








+−= , (2.9) 
where Pn is the permeability of neutral form across the membrane, Pd is the 
permeability of ionized form across the membrane, ao,n and ai,n are the activities of 
neutral form outside and inside respectively, ao,d and ai,d are the activities of ionized form 

































+−= , (2.12) 
where Ja,c, Jc,m, and Jc,b are net flux across apical membrane, mitochondrial 
membrane, and basolateral membrane, respectively;  aa,n, ac,n, am,n, and ab,n are the neutral 
molecular form activities in the apical compartment, cytosolic compartment, 
mitochondrial compartment and basolateral compartment, respectively; aa,d, ac,d, am,d, and 
ab,d are the ionized molecular form activities in the apical compartment, cytosolic 
compartment, mitochondrial compartment and basolateral compartment, respectively;  Na, 
Nm, and Nb are the N values for apical membrane, mitochondrial membrane and 
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basolateral membrane, respectively.  The Henderson-Hasselbalch equation (2.13) 






−= , (2.13) 
where ad and an are the ionized molecular form and the neutral molecular form, 
respectively, i is 1 for acids and -1 for bases; pKa is the negative logarithm of the 
dissociation constant.  Therefore, 
)(10 apKpHind aa
−×=  , (2.14) 
The relationship of the activities (an and ad) and the total molecular concentration 
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== , (2.15) 
)(10/ pKapHintdd fCaf
−== , (2.16) 
W is the volumetric water fraction, γ the activity coefficient, and Kn and Kd the 
sorption coefficients of the neutral and the ionized molecules respectively.  Kn and Kd are 
estimated by equation 2.17, where L is the lipid fraction in each compartment and 
/ ,log
, / 10 n d lip
P
ow n dK = (logPn,lip and logPn,lip calculated with equations  2.28-2.31).  
dnowdn KLK /,/ 22.1 ××= , (2.17) 
The activity coefficient of all neutral molecules (γn) is related to the ionic strength 
I (moles).  Using the Setchenov equation, at I = 0.3 mol, γn is 1.23.  The activity of ions 
(γd) is calculated with the Davies approximation of the modified Debye-Hückel equation 
(23).  For monovalent ions at I = 0.3 mol, γd is 0.74.  For conditions outside the cell, no 
corrections for the ionic strength are made, and activities are set approximately equal to 
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concentration (γ = 1) (23).  Plug equation 2.15 and 2.16 into equations 2.10, 2.11 and 2.12 


































+−= ,   (2.20) 
Plug equations 2.18, 2.19 and 2.20 into equations 2.4, 2.5, and 2.6 to get 








































































































+−= , (2.23) 
The membrane permeability P (23) can be estimated using: 
xDKP Δ= / , (2.24) 
D is the diffusion coefficient which is about 10-14 m2 / s for organic molecules in 
biomembranes.  K is the partition coefficient, and approximates Kow.  xΔ is the membrane 
thickness and is considered about 50 nm for biomembranes.  Plugging these estimated 
numbers into equation 2.24 and doing a logarithm conversion gives equation 2.25. 
7.6loglog −= owKP , (2.25) 
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= , (2.26) 
where Aaa is the cellular monolayer area, dCb the total concentration change in 
basolateral compartment with time dt, and Ca the concentration in apical compartment, 
which is assumed to be constant in this model. 
MATLAB® was used to solve the system of coupled differential equations 
(equations 2.21, 2.22, and 2.23).  The concentrations in cytosol (Cc), mitochondria (Cm), 
basolateral compartment (Cb), and transcellular permeability coefficient (Peff) were solved 
numerically.  Cellular parameters describing the intestinal epithelial cell were obtained 
from the literature.  The MATLAB® solver, graphics scripts, and model parameters are 
included as appendix A. 
Using this model, permeability and intracellular concentration of 36 compounds 
were calculated (Figures 2.2, 2.3). These compounds were selected on the basis of the 
following criteria: (1) they are monoionized or neutral in the physiological pH 
environment; (2) their logPn, pKa, and Caco-2 permeability were experimentally 
measured and published. The octanol/water partition coefficients (logPn) were obtained 
from SRC PhysProp Database and other references in the scientific literature (29-31), and 
pKa values were also experimental data obtained from several published articles (10, 32-
40).  The partition coefficients of the ionized state of the molecules (logPd) were 
estimated from logPn according to equation 2.27 (23).   
7.3loglog −= nd PP , (2.27) 
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Equations 2.28-2.31 were used to obtain the liposomal partition coefficient for 
both neutral forms and ionic forms of bases and acids (34).  For ampholytes to get the 
liposomal partitioning, the equation for neutral forms of bases was applied. 
for neutral forms of bases: 2,log 0.33log 2.2, 0.69n lip nP P R= + = ,  (2.28) 
for cationic forms of bases: 2,log 0.37log 2, 0.49d lip dP P R= + = , (2.29) 
for neutral forms of acids: 2,log 0.37log 2.2, 0.89n lip nP P R= + = , (2.30)  
for anionic forms of acids: 2,log 0.33log 2.6, 0.72d lip dP P R= + = , (2.31) 
Additional literature references, logPn, logPd, pKa values, and calculated 
permeability and intracellular concentration obtained with our model are included in the 
appendix A. 
Linear regression was used to compare predicted permeability values with the 
Caco-2, PAMPA, and human intestinal permeability adopted from the literature (1, 12, 
40-47).  As noticed, Caco-2 permeability data obtained from different references differ 
even for the same drug, thus the mean values of Caco-2 permeability obtained from 
different literature sources were used to compare with the predicted permeability. 
Cell-permeant nontoxic chemical space, cell-permeant toxic chemical space, cell-
impermeant chemical space, cell-permeant chemical space, cell-toxic chemical space, and 
cell-nontoxic chemical space were defined by calculating  Peff, Cc, and Cm of weakly basic 
monocationic molecules spanning pKa from 1 to 14, logPn from -5 to +5, and logPd from 
-5 to +5.  Each one of these physicochemical parameters was varied independently in 0.1 
unit intervals, and combined with the other parameters.  To evaluate the robustness of the 
results obtained with the model, chemical space plots were visually inspected for 
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reproducibility and consistency after changing one parameter at a time while keeping the 
others unchanged.  The change of logPn and logPd were discussed under two conditions: 
(1). logPn and logPd changed independently; and (2). logPn and logPd linked to each other 
by equations 2.27 to 2.31.  Parameter values used in calculation are included in the 
appendix A.  . 
Results 
A cellular pharmacokinetic model of passive transcellular drug transport  
Transcellular permeability is a key property determining biodistribution of soluble 
drug molecules from one body compartment to another. For an orally administered drug 
with high solubility, the transcellular permeability of the cells lining the intestine 
determines the fraction of drug in the intestine that is absorbed by the body. In epithelial 
cells lining the lumen of the intestine (Figure 2.1A), apical microvilli make the apical 
surface area (48) much greater than the basolateral surface area (9).  The length of an 
epithelial cell is approximately 10 to 15 µm. Aaa is the effective cross-sectional area of 
each cell, corresponding to the total area of the cell monolayer across which transport 
occurs, divided by the total number of cells involved in the transcellular transport 
process.  Finally, the total volume of the cell V constrains its overall geometry in relation 
to Aa, Ab, and Aaa.  On the basis of these parameters, the apical-to-basolateral permeability 
of an intestinal epithelial cell can be calculated with equation 2.26. 
Setting cellular parameters to mimic an intestinal epithelial cell, the model 
captures the mass transport followed by a weak base or acid (nonzwitterionic molecule), 
through said cell (Figure 2.1B).  Such molecules exist as equilibrium mixtures of neutral 
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and ionic states, their proportions determined by the pH of the immediate environment.  
In the case of high solubility-high permeability molecules, passive diffusion is the 
dominant transcellular transport mechanism (4, 5, 46, 49), driven by concentration 
gradients of drugs and ions, and the transmembrane electrical potential.  Assuming that 
mixing of molecules within each subcellular compartment is faster than the rate at which 
they traverse the delimiting membranes, the mass of drug in each compartment can be 
modeled using a set of coupled differential equations based on an empirical relationship 
between lipophilicity and transmembrane permeability of small molecules, and Fick’s 
Law of diffusion (23). To traverse the cell, molecules first cross the apical membrane, 
distributing homogenously in the cytosol and partitioning into cytoplasmic lipids. From 
the cytosol, they also partition into and out of organelles, and exit the cell across the 
basolateral membrane.   
After simulating the transcellular transport process, the calculated permeability 
values were found to be consistent with the experimental values. Specifically, we first 
considered the intracellular concentration and permeability coefficient of molecules with 
physicochemical properties resembling β-adrenergic receptor blockers: metoprolol and 
related compounds (Figure 2.2; Table 2.1). Metoprolol is orally bioavailable, but less 
permeable and less toxic than more hydrophobic relatives, such as propranolol (50).  
Comparing the calculated results (Table 2.1) with the experimental data (Table 2.2), the 
calculated permeability coefficient of metoprolol is similar to the human permeability 
coefficient measured in intestinal perfusion experiments (51), and the coefficient of 
propranolol is 1 order of magnitude smaller than human permeability coefficients (51).  
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The in silico permeabilities are generally within an order of magnitude of experimentally 
measured Caco-2 and human intestinal permeability.  
Comparing the calculated permeabilities with experimental permeability data 
Correlation of predicted permeability with Caco-2 permeability and human 
intestinal permeability were plotted to evaluate the model.  Figure 2.2 is the scatter plot 
of predicted permeability and Caco-2 permeability of seven β-adrenergic receptor 
blockers - alprenolol, atenolol, metoprolol, oxprenolol, pindolol, practolol, and 
propranolol - possessing the same core structure (Table 2.1).  This homologous set of 
drugs has similar pKa values (Table 2.1).  A significant relationship was observed. 
Next, we examined the correlation of predicted and Caco-2 permeability of 36 
structurally unrelated compounds (including the 7 shown in Figure 2.2; Figure 2.3). By 
visual inspection, the predicted permeability of compounds shown in Figure 2.3 can be 
readily categorized into two groups: high permeability and low permeability. Using the 
predicted permeability of metoprolol (No. 18) as a reference (dashed horizontal line), 
compounds that fall into the dashed oval are predicted to be high permeability by the 
model and also exhibit high permeability in Caco-2 assays.  Most high permeability 
compounds transport predominantly by the transcellular pathway with some exceptions: 
for example, P-glycoprotein reportedly affects acebutolol (No. 1 in Figure 2.3) intestinal 
absorption (52).  In the scatter plot, the predicted permeability of acebutolol was higher 
than the Caco-2 permeability, which is consistent with P-glycoprotein efflux not being 
captured by the model.  In contrast, many (predicted) low permeability drugs and 
molecules possess a significant paracellular or active transport pathway. For example, 
mannitol (No. 17 in Figure 2.3) is widely used as a passive paracellular permeability 
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marker, so its measured permeability reflects paracellular transport - not only the passive 
transcellular diffusive permeability that is predicted by the model. Conversely, 
taurocholic acid and valproic acid are substrates of transporters (41), which leads to 
higher measured permeability, well above the passive permeability predicted by the 
model. 
Next, the calculated permeability of compounds that fell into the dashed oval in 
Figure 2.3 (those with correctly predicted, high Caco-2 permeability) were compared 
with PAMPA assay results, as reported in the scientific literature (Table 2.2). For each 
individual PAMPA assay result, compounds with higher-than-metoprolol permeability 
were defined “high permeability” and lower-than-metoprolol permeability were defined 
“low permeability” (53-55).  Table 2.2 shows that PAMPA permeability measured in 
different conditions is different and is affected by buffer conditions (54).  According to 
FDA waiver guidance (56) the reference drugs ketoprofen and naproxen would be 
misclassified in two PAMPA measurement, using metoprolol as the internal reference in 
the published data sets (Table 2.2).  Nevertheless, both naproxen and ketoprofen are 
correctly classified by our computational model.  
To compare the predicted permeability with human intestinal permeability, a 
scatter plot was graphed (Figure 2.4).  Since human intestinal permeability data are 
scarce, among the 36 compounds used in this study (those with experimentally measured 
logP, pKa, and possessing only one ionizable functional group in the physiological pH 
range) we only found 10 of them having human intestinal permeability data.  A 
significant linear relationship was obtained.  
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Probing the effects of drug physicochemical properties on cellular pharmacokinetics 
The physicochemical properties of drug molecules influence intracellular 
concentration and transcellular permeability.  For a monovalent cationic weak base, the 
model explicitly considers how three different parameters (the logarithm of the 
lipid/water partition coefficient of the neutral form of the molecule, logPn; the logarithm 
of the lipid/water partition coefficient of the ionized form of the molecule, logPd; and the 
negative logarithm of the dissociation constant of the protonated functional group, pKa) 
can affect these properties. In silico, one can change each property one at a time, keeping 
the others unchanged. Two conditions were considered here: (1) logPn and logPd vary 
independently (Figure 2.5A); and (2) logPn and logPd are linked by equations 2.27 to 
2.31 (Figure 2.5B).  Although the actual relationship between logPn and logPd of a 
molecule is neither perfectly linear nor completely independent, simulating these two 
extremes conditions linking logPn and logPd is one way to assess how physicochemical 
properties affect calculated permeability and intracellular concentration. For a 
metoprolol-like molecule cytosolic concentrations remain low and constant as logPn is 
varied between -5 and +3 (Figure 2.5A left and Figure 2.5B left). However, increasing 
logPn from +3 to +5 increases cytosolic concentration to levels that greatly exceed the 
extracellular drug concentration. For mitochondrial concentrations, as logPn increases 
from -5 to 5, there is a pronounced decrease in mitochondrial sequestration. For the 
transcellular permeability, there is an increase in permeability between logPn = 3 and 
logPn = 5, in parallel to the increase in cytosolic concentration. Thus, for a metoprolol-
like molecule, the desired logPn lies between 2 and 3, at which cytosolic and 
mitochondrial concentrations are minimal, whereas transcellular permeability is maximal. 
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Just as for the logPn parameter, the logPd values of a metoprolol-like molecule 
were varied to determine the effect on intracellular concentrations and permeability 
coefficients. For logPd values less than 2, the intracellular concentration of drug at the 
steady state is low and constant (Figure 2.5A middle and Figure 2.5B middle). However 
if logPd increases above 2, cytosolic concentrations increase and greatly exceed 
extracellular drug concentration. For logPd values greater than 3, there is more than a 10-
fold increase in mitochondrial concentration above the extracellular concentration. 
Nevertheless, increasing logPd has the greatest influence on the transcellular permeability 
value, with increasing logPd associated with the fastest rates of transcellular transport.  
Thus, according to these simulations, increasing logPd leads to the very desirable effects 
of increasing transcellular transport rates, although it also leads to the very undesirable 
effect of increasing cytosolic and mitochondrial drug accumulation.  
Finally, the pKa value of a metoprolol-like molecule was varied, to study the 
effect on subcellular transport and biodistribution properties.  Compared to the other two 
parameters, increasing pKa from 9 to 14 has little effect on transmembrane permeability 
(Figure 2.5A right and Figure 2.5B right).  However, decreasing it from 9 to 7 greatly 
increased the permeability. Lowering the pKa below 9 increased the cytosolic 
concentration, while increasing it above 9 increased the mitochondrial concentration. 
Thus the pKa of metoprolol is near the point where cytosolic and mitochondrial 
concentrations are minimized while transcellular permeability is maximized.  Again, by 
varying the physicochemical properties of a metoprolol-like molecule one at a time, the 
simulations suggests that the cellular pharmacokinetic properties of metoprolol are quite 
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good and would be difficult to improve by varying the physicochemical properties of the 
molecule, one at a time.  
Chemical space definitions and solutions 
Molecules with intracellular concentrations less than - and permeability values 
greater than - those for a molecule with metoprolol-like physicochemical properties 
would posses desirable phormacokinetic properties would be expected to lead to even 
higher oral bioavailability, improved biodistribution, and decreased metabolism, relative 
to metoprolol.  To identify the physicochemical properties associated with such 
molecules, we proceeded to calculate the intracellular concentrations and transcellular 
permeability values of over a million different possible combinations of pKa, logPn and 
logPd.  Four different regions of chemical space were defined relative to the steady-state 
permeability and intracellular concentration of a molecule with metoprolol-like properties 
as follows: (1) Permeant: Molecules with calculated Peff equal to or larger than Peff of the 
reference. (2) Impermeant: Molecules with calculated Peff less than the reference Peff. (3) 
Nontoxic: Molecules with both Ccyto and Cmito equal to or less than Ccyto and Cmito of the 
reference molecule. (4) Toxic: Molecules with either Ccyto or Cmito larger than Ccyto or 
Cmito of the reference molecule. Again, two independent set of simulations were carried 
out, to represent linearly correlated and uncorrelated logPn and logPd values. 
Complete analysis of regions of physicochemical property space surrounding 
molecules with metoprolol-like properties (Figure 2.6) reveal the extent to which cell 
permeability and intracellular accumulation may be related to the physicochemical 
properties of the molecules.  First, we consider the simulations in which logPn and logPd 
are varied independently from each other.  Note that about 42.7% of total chemical space 
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is occupied by combinations of pKa, logPn, and logPd that would make molecules more 
permeant than a molecule with metoprolol-like properties (Figure 2.6A). The remaining 
57.3% is occupied by combinations of pKa, logPn, and logPd that would make molecules 
less permeant than a molecule with metoprolol-like properties. Combinations of pKa, 
logPn, and logPd that lead to intracellular concentrations greater than those obtained with 
a molecule with metoprolol-like physicochemical properties lie within “toxic” chemical 
space, by definition. This region of chemical space comprises 60.6% of the total chemical 
space, with the remaining 39.4% falling in “nontoxic” space (Figure 2.6B).  If cellular 
permeability and toxicity were completely unrelated to each other, one would expect that 
16.8% of the molecules would fall under “permeantnontoxic” space (16.8% permeant 
nontoxic) 39.4% nontoxic 42.7% permeant). However, the actual fraction of molecules 
falling in cell permeant-nontoxic space (Figure 2.6C) is 1.5%, as permeability and 
intracellular accumulation are partly related to each other.  Thus, while combinations of 
pKa, logPn, and logPd promoting permeability and nontoxicity work against each other to 
some degree, there is a small chunk of physicochemical property space where molecules 
with greater permeability than metoprolol, but reduced intracellular accumulation, may 
reside. Indeed, there may be a small but significant number of molecules possessing a 
desirable combination of physicochemical properties leading to improved bioavailability 
and biodistribution properties relative to a molecule with metoprolol-like features. 
Last, we mapped the chemical space surrounding a molecule with metoprolol-like 
physicochemical properties, under conditions in which logPn and logPd are perfectly 
coupled to each other in a linear relationship (Figure 2.7).  Under these conditions, 
physicochemical property space is reduced to a plane, with a molecule of metoprolol-like 
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features sitting at the intersection of the boundary delimiting permeant-impermeant and 
toxic-nontoxic space (Figure 2.7).  The impermeant nontoxic and the impermeant toxic 
were 47.6% and 7.5% of the total space. Most importantly, while permeant toxic 
occupies 43.7% of the total space respectively, permeant nontoxic occupies 0.11% of this 
space.  Thus, our simulations also indicate that the extent to which logPn and logPd are 
coupled can severely restrict the ability to find a metoprolol-like molecule with improved 
biopharmaceutical features.  Furthermore, examining where permeant nontoxic space 
exists relative to metoprolol, one finds that lowering the pKa may be the only way to both 
increase the permeability and decrease the intracellular accumulation (toxicity) of 
metoprolol. For the β-blockers, the pKa of the molecule is determined by an isopropyl 
amine group that is shared by all the congeners (Table 2.1), and therefore this group may 
be essential for receptor binding.  One way around this constraint would be to change the 
ionization properties of the molecules by making them zwitterionic at physiological pH. 
However, the current model cannot capture the behavior of zwitterions, so a theoretical 
analysis of this optimization strategy must await development and validation of more 
advanced versions of the model. 
Discussion 
Transport of small molecules into and out of cells and organelles is determined by 
both passive and active transport mechanisms.  The cellular pharmacokinetic model 
elaborated in this study specifically captures passive transport mechanisms, determined 
by the physicochemical properties of small molecules, their interactions with 
phospholipid bilayers, and the concentration gradients of ions and macromolecules across 
cellular membranes (22, 48, 57, 58).  Empirical (12, 22, 59) and theoretical (60-62) 
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considerations establish three physicochemical properties of small molecules as key 
determinants of passive transport across membranes: size, charge, and lipophilicity.  Most 
molecules used for drug discovery and chemical genomics investigations are “small”, i.e. 
between 200 and 800 daltons, and therefore similar in size. Thus, the model is suitable for 
comparing the behavior of small molecules within this limited size range, where the main 
physicochemical properties influencing the distribution of molecules in cells are the 
multiple ionization states, and the lipophilicity of each ion. 
For model validation, metoprolol was used as a reference because it is an FDA-
approved drug that is 95% absorbed in the gastrointestinal tract (1), and it is 
recommended as an internal standard - to be included in experiments that assess drug 
permeability (56) - by the FDA. Metoprolol is generally included in published PAMPA, 
Caco-2, and intestinal permeability datasets, as a reference point with which to establish 
the threshold between high and low permeability compounds. Several metoprolol 
relatives - like atenolol - are orally bioavailable, moderate absorption, low metabolism, 
low toxicity, renally cleared (36, 63-66) with a well-characterized, passive-transport 
absorption mechanism (67), in vitro and in vivo permeability characteristics (51, 68) and 
measured micro pKa/(logP) properties (34).  Using the physicochemical properties of 
metropolol as a reference, cell-based molecular transport simulations were used to 
calculate the pharmaceutical properties of related β-adrenergic receptor antagonists.  
Setting cellular parameters and model geometry to mimic an intestinal epithelial cell, the 
simulations permitted testing the effects of different biological and chemical parameters 
on intracellular concentrations and transcellular permeability coefficients, through time.  
The steady-state values for high permeability compounds were comparable to 
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experimental measurements obtained through intestinal, in vivo perfusion experiments, 
and Caco-2, in vitro permeability assays (22, 69, 70).  In addition, running over a million 
different combinations of logPn, logPd, and pKa through the simulation allowed us to 
define a physicochemical property space leading to the most desirable biopharmaceutical 
characteristic (higher transcellular permeability with lower intracellular accumulation), 
relative to the simulated characteristics of a metoprolol-like molecule.   
We note that, since intracellular accumulation and permeability are related to each 
ther, optimizing a single biopharmaceutical property (permeability) of a compound at a 
time may lead to unfavorable biodistribution properties (intracellular accumulation) 
associated with toxicity or drug clearance by metabolism.  Indeed, complex properties 
like bioavailability may be predictable as nonlinear functions of the fundamental 
physicochemical properties of molecules, under conditions in which transcellular 
transport is maximized and intracellular concentrations are minimized.  Due to the 
limited experimental data available for fitting statistical models, and the relatively 
complex behaviors apparent in the simplified model presented in this study, our results 
suggest that purely empirical, statistical regression models built from human, Caco-2, or 
even PAMPA permeability data would be comparatively limited in their ability to predict 
bioavailability of small molecule drugs. Thus, cellular pharmacokinetic simulations could 
be used to complement to the more conventional, regression-based statistical approaches. 
This is especially true in situations when the statistical models lack power, such as when 
assay measurements are too variable or of low quality, or when a training dataset is 
unavailable, of dubious quality, or too sparse.  With continued validation and refinement, 
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cell-based mass transport simulators can become increasingly sophisticated in their 
ability to capture more complex phenomena of pharmaceutical importance.  
Admittedly the scope of the current, passive diffusion model is narrow, as its 
predictions apply only to nonzitterionic, monocharged molecules within a limited size 
range, administered at high concentrations so that they saturate specific binding sites on 
intracellular proteins, enzymes, and transporters.  However the therapeutic impact of the 
model could be substantial, since 80% of currently marketed therapeutic products are 
small molecules, administered orally and at high concentrations (19). Moreover the 
majority of these do target cell surface receptors or ion channels (9).  The FDA’s 
Biopharmaceutics Classification System (47) recognizes four classes of oral drug 
products: class I (high solubility-high permeability); class II (low solubility-high 
permeability); class III (high solubility-low permeability); and class IV (low solubility-
low permeability).  The model is mostly relevant to class I and II small molecule drugs, 
which turn out to be very common and well-behaved, encompassing about half of the 
drug products on the market (19).  Since extracellular receptor binding allows 
maximizing a drug’s transcellular permeability while minimizing intracellular 
accumulation, our model provides a mechanistic explanation as to why the major class of 
well-behaved, orally bioavailable drugs currently on the market does often target 
extracellular domains of cell surface receptors.  
To conclude, cell-based molecular transport simulators can be used to make other 
predictions in addition to transcellular permeability, which could also be experimentally 
tested.  Because each component that goes into the model can be studied and improved 
independently, more precise membrane transport equations including additional variables 
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(such as molecular weight)(60, 62) and additional subcellular compartments could be 
readily incorporated into the models, albeit at the expense of greater computational 
complexity.  Indeed, by checking predictions with experiments, the model can be 
gradually improved and evolved, and its scope can be extended to describe the transport 
of an increasing variety of molecules (such as zwitterions), under increasingly diverse 
conditions. Using single cells as pharmacokinetic units, it should be possible to model 
transport functions in multicellular organizations, simulating transport functions in tissues 
and even organs, and even incorporate intracellular enzymatic, transporter, and specific 
binding and nonspecific absorption activities through the Michaelis-Menten equation and 
binding isotherms.  By coupling cell-based, molecular transport simulators to other 
cheminformatic analysis tools (such as computational pKa and logP calculators), in silico 
screening experiments may be performed - rapidly, inexpensively, reproducibly, and 
reliably - on a large number of molecules, to explore the diversity of large collections of 





Table 2.1. Structures, physicochemical properties, average Caco2 permeabilities, and predictive permeabilities of seven β-















9.60 (40) 3.10 3.22 95.70 103.38 8.52 11.59 
atenolol 
 
9.60 (40) 0.16 2.25 1.07 8.42 2.23 8.76 
metoprolol 
 
9.70 (40) 1.88 2.82 40.15 36.63 4.13 12.95 
oxprenolol 
 
9.50 (40) 2.10 2.89 97.25 44.29 4.58 8.40 
pindolol 
 
9.70 (40) 1.75 2.78 54.53 32.56 3.86 12.65 
practolol 
 
9.50 (40) 0.79 2.46 2.91 14.35 2.60 7.29 
propranolol 
 




Table 2.2.  Comparison of predicted permeability with average Caco2 permeability and PAMA permeability of drugs within 
the predictive circle in Figure 2.3.    Permeability values are in unit of 10-6 cm/sec.  Metoprolol was chosen a reference compound. 
























alprenolol 103.38 H 11.50 H   15.1 H     
antipyrine 209.00 H 2.87 L 0.82 L 13.2 H 560 H H  
chlorpromazine 737.26 H     4.0 H    1 
clonidine 45.92 H 10.41 H   14.0 H     
desipramine 468.18 H 16.98 H   14.6 H 450 H   
diazepam 201.67 H           
diltiazem 127.52 H 19.21 H 14 H 18.5 H    2 
ibuprophen 280.35 H 21.15 H   6.8 H    2 
imipramine 442.66 H 19.36 H   8.4 H     
indomethacin 354.22 H     2.4 L     
ketoprofen 145.35 H 2.84 L 0.043 L 16.7 H 870 H H  
lidocaine 130.27 H           
metoprolol 36.63 ref 7.93 ref 1.2 ref 3.5 ref 134 ref H  
naproxen 152.87 H 5.01 L 0.23 L 10.6 H 850 H H  
oxprenolol 44.29 H 14.64 H         
phenytoin 90.53 H 38.53 H   5.1 H     
pindolol 32.65 L 4.91 L   4.9 H     
piroxicam 1542.75 H 10.87 H   8.2 H 665 H   
propranolol 92.47 H 26.33 H 12 H 23.5 H 291 H H 1 
trimethoprim 194.61 H 3.14 L 2.2 H 5.0 H    4 




verapamil 208.36 H 23.02 H 14 H 7.4 H 680 H H 1 




Table 2.3. Correlation of predicted permeability VS. human intestinal permeability.  











antipyrine 560.00 -3.25 209.00 -3.68 
atenolol 20.00 -4.70 8.42 -5.07 
desipramine 450.00 -3.35 468.18 -3.33 
ketoprofen 870.00 -3.06 145.35 -3.84 
metoprolol 134.00 -3.87 36.63 -4.44 
naproxen 850.00 -3.07 152.87 -3.82 
piroxicam 665.00 -3.18 1542.75 -2.81 
propranolol 291.00 -3.54 92.47 -4.03 
terbutaline 30.00 -4.52 24.15 -4.62 








Figure 2.1. Model of an intestinal epithelial cell.  A) Cell morphology. B)   The path of 
a hydrophobic weak base across an intestinal epithelial cell. The neutral form of the 
molecule is indicated as [M] and the protonated, cationic form of the molecule is 






Figure 2.2. Correlation of Caco2 permeability and predicted permeability of seven 
β-adrenergic blockers.   The X-axis indicates the logarithm values of average measured 
Caco2 permeability (cm/sec) and the Y-axis indicate the logarithm values of predicted 
permeability (cm/sec).  The dotted line is the linear regression line.  The linear regression 
equation is )76.0(4.244.0 2 =−= Rxy , the significance F of regression given by EXCEL 
is 0.011 (confidence level is 95%).  Numbers 1 through 7 indicate alprenolol, atenolol, 
metoprolol, oxprenolol, pindolol, practolol, and propranolol respectively.  The structures, 
physicochemical properties, average Caco2 permeability and predictive permeability 
were summarized in Table 2.1. 
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Figure 2.3. Correlation of Caco2 permeability and predicted permeability of thirty-
six drugs. The X-axis indicates the logarithm values of average measured Caco2 
permeability (cm/sec) and the Y-axis indicate the logarithm values of predicted 
permeability (cm/sec).  Metoprolol (No.18) was used as a reference drug. Details of 






Figure 2.4. Correlation of human intestinal permeability and predicted 
permeability. The X-axis indicates the logarithm values of measured human intestinal 
permeability (cm/sec) and the Y-axis indicate the logarithm values of predicted 
permeability (cm/sec).  A simple linear relation was obtained and expressed by the 
equation: 20.91 0.69( 0.71)y x R= − = , the significance F of regression given by EXCEL 
is 0.0016 (confidence level is 95%).  Calculated permeability and human intestinal 




Figure 2.5.   Effects of physicochemical properties on intracellular concentration at 
steady state, of a molecule with metoprolol-like properties (arrows). (A). logPn and 
logPd are not associated. (B). logPn and logPd are associated by a simple linear 
relationship expressed as equations 2.27-2.29.  The arrows indicate the liposomal logPn, 
lip and logPd, lip, which were used in permeability calculation.  (solid line = cytosolic; dark 






Figure 2.6.  The chemical space occupied by molecules with ideal pharmacokinetic 
properties:  A) permeability (defined as molecules with calculated Peff  equal or larger 
than Peff of a molecule with metoprolol-like properties); B) intracellular accumulation 
(defined as molecules with both calculated Ccyto and Cmito equal or less than that of the 
metoprolol-like reference molecule); and, C) permeability and intracellular accumulation 
(defined as molecules with calculated Peff equal or larger than Peff, and Ccyto and Cmito 
equal or less than Ccyto and Cmito calculated for a molecule with metoprolol-like 
properties.  Each row represents the same spaces with different rotating aspects.  logPn 
and logPd are not associated (change independently).  Numbers 1 through 7 are 
alprenolol, propranolol, oxprenolol, metoprolol, pindolol, practolol, and atenolol 
respectively.  The logPn and logPd values of each molecule were liposomal logPs used in 





Figure 2.7.  The chemical space defined by metoprolol-like reference molecule.    
logPn and logPd are associated by a simple linear relationship expressed as equations 
2.27-2.29.   Numbers 1 through 7 are alprenolol, propranolol, oxprenolol, metoprolol, 
pindolol, practolol, and atenolol respectively.  The logPn and logPd values of each 
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SIMULATION-BASED CHEMINFORMATIC ANALYSIS OF ORGANELLE-
TARGETED MOLECULES: LYSOSOMOTROPIC MONOBASIC AMINES 
Abstract 
Cell-based molecular transport simulations are being developed to facilitate 
exploratory cheminformatic analysis of virtual libraries of small drug-like molecules. For 
this purpose, mathematical models of single cells are built from equations capturing the 
transport of small molecules across membranes. In turn, physicochemical properties of 
small molecules can be used as input to simulate intracellular drug distribution, through 
time. Here, with mathematical equations and biological parameters adjusted so as to 
mimic a leukocyte in the blood, simulations were performed to analyze steady-state, 
relative accumulation of small molecules in lysosomes, mitochondria, and cytosol of this 
target cell, in the presence of a homogenous extracellular drug concentration. Similarly, 
with equations and parameters set to mimic an intestinal epithelial cell, simulations were 
also performed to analyze steady state, relative distribution and transcellular permeability 
in this non-target cell, in the presence of an apical-to-basolateral concentration gradient. 
With a test set of ninety-nine lysosomotropic small molecules gathered from the scientific 
literature, simulation results helped analyze relationships between the chemical diversity 
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Weakly basic molecules possessing one or more amine groups accumulate in 
lysosomes and other membrane-bound acidic organelles because of the well-known ion 
trapping mechanism (1-3). Amines generally have a pKa value in the physiological pH 
range. Accordingly, they exist as a combination of ionized (protonated) and neutral 
(unprotonated) species. Because the pH of lysosomes is one or more units lower than the 
pH of the cytosol, the relative concentration of neutral and ionized species inside the 
lysosomes shifts towards the protonated, ionized state. Conversely, because the pH of the 
cytosol is higher, the relative concentration of neutral and ionized species in the cytosol 
shifts towards the neutral, unprotonated state. Since charged molecules are less 
membrane-permeant, the protonated species become trapped inside the membrane-
bounded compartments, relative to the neutral species. Within an acidic lysosome, the 
concentration of the neutral, membrane-permeant species is lower than its concentration 
in the more basic cytosol. This leads to a concentration gradient of the neutral form of the 
molecule across the lysosomal membrane, further driving the uptake of the neutral 
species of the molecule into the acidic organelle.   
In medicinal chemistry, the ability to modify the chemical structure of small 
molecules so as to tailor lysosomotropic behavior may be important for decreasing 
unwanted side effects, as much as it may be important for increasing efficacy. For many 
monobasic amines that target extracellular domains of cell surface receptors and ion 
channels, lysosomal accumulation can be considered as a secondary effect of the 
physicochemical properties of the molecule (4-8).   Previously, many monobasic amines 
have been experimentally analyzed in cell-based assays, in terms of their ability to 
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accumulate in lysosomes (6, 9-12).  In response to ion trapping, cells exposed to 
monobasic amines swell and become replete with large vacuoles (6, 9, 10, 13-15).  With 
a phase contrast microscope, swollen lysosomes can be easily discerned and scored.  
Furthermore, as monobasic amines accumulate in lysosomes, they can increase the pH of 
the organelle through a buffering effect, or by shuttling protons out of the lysosome, 
across the lysosomal membranes (16). Therefore, such molecules “compete” with each 
other for lysosomal accumulation, providing another way to assay for lysosomotropic 
behavior (16, 17).  A third way to assay lysosomotropic behavior is by labeling 
lysosomes with fluorescent probes (e.g. LysoTracker® dyes) (17).  As lysosomes expand 
in response to accumulation of lysosomotropic agents, they accumulate increasing 
amounts of the LysoTracker® dye and the cells become brightly labeled.  By virtue of 
these effects on live cells, many monobasic amines have been positively identified as 
“lysosomotropic”.   
Nevertheless, different studies analyzing lysosomotropic monobasic amines have 
also identified molecules that deviate from expectations. Furthermore, there is a broad 
range of concentrations at which vacuolation becomes apparent, spanning several orders 
of magnitude (10, 18-20). In addition, there are monobasic amines that do not exhibit any 
vacuolation-inducing behavior (6, 9, 10, 13, 14, 21), and do not compete with the 
lysosomal uptake of other lysosomotropic probes (6, 16), or that are cytotoxic (21). Most 
importantly, some lysosomotropic molecules have been reported to accumulate in other 
organelles, such as mitochondria (22). Alprenolol, chlorpromazine, fluoxetine, 
propranolol and diltiazem are some of the FDA approved drugs in this category (6, 16, 
22, 23) that have been classified as being both lysosomotropic and mitochondriotropic by 
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different investigators. In addition, certain monobasic amines may accumulate in 
lysosomes to a much greater extent than ion trapping mechanisms would predict (20). 
These apparent discrepancies in terms of the lysosomotropic behavior prompted 
us to begin exploring the relationship between the phenotypic effects of monobasic 
amines, and their subcellular distribution in lysosomes vs. other organelles. We decided 
to use a cell-based molecular transport simulator (24, 25) to begin exploring the different 
possible behaviors of monobasic amines inside cells based on the ion trapping 
mechanism, paying special attention to their accumulation in lysosomes, cytosol and 
mitochondria. The simulations help assess the entire range of expected variation in 
intracellular transport behaviors, based solely on the biophysical principles underlying 
the ion trapping mechanism. In turn, the expected range of transport behaviors can be 
related to experimental observations of a lysosomotropic test set of molecules obtained 
from published research articles.  Because the ability to optimize the subcellular transport 
of small molecules could have practical applications in drug development, we also deem 
it important to analyze the distribution of molecules inside non-target cells mediating 
drug transport in the presence of a transcellular concentration gradient.  In fact, although 
direct experimental measurement of subcellular concentration in the presence of a 
transcellular concentration gradient would be difficult, this may be the most relevant 
condition for drug uptake and transport throughout the different tissues of the body.   
Methods 
Modeling cell pharmacokinetics of target cells in suspension: the T-model 
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For subcellular compartments delimited by membranes, passive transport of small 
molecules in and out of these compartments is determined by the interaction of the 
molecules with the membrane, the concentration gradient of molecules across the 
membrane, the local microenvironment on either side of the membrane, and the 
transmembrane electrical potential (24, 25). Drug-membrane interactions are largely 
dependent on the physicochemical properties of small molecules (such as pKa and 
lipophilicity) and the environmental condition (such as local pH values and membrane 
potentials). Based on the biophysics of membrane transport, mass transfer of drug 
molecules between different organelles in a cell surrounded by a homogeneous 
extracellular drug concentration has been modeled mathematically by Trapp and Horobin 
(25) (Figure 3.1a).  Accordingly, three coupled ordinary differential equations (3.1, 3.2, 
and 3.3) describe the concentration change with time in each subcellular / cellular 


































,×= , (3.3)  
where C indicates the concentration, J indicates the flux, A and V indicate the membrane 
surface area and volume respectively. The subscripts o,c,l, and m indicate extracellular 
compartment, cytosol, lysosomes, and mitochondria respectively. The directions of fluxes 
are indicated by the orders of the subscripts, e.g. mcJ ,  represents the flux from cytosol to 
mitochondria. Calculations for fluxes between each pair of compartments were the same as 
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described before (25). The ordinary differential equations were numerically solved 
(supplemental materials) (24). 
An important feature of this model is that at steady state, the drug accumulation in 
the cytosol is only dependent on the drug concentration outside the cell, the plasma 
membrane permeability properties, and the ionic conditions of the cytosol and the 
extracellular medium. Similarly, the drug accumulation inside any given organelle is only 
dependent on the drug concentration in the cytosol, the permeability properties of the 
membrane delimiting the organelle, the ionic conditions of the cytosol and the inner lumen 
of the organelle. Consequently, one can use the same equations to analyze steady state 
distribution drugs in lysosomes or mitochondria (and other organelles) simply by adjusting 
the pH of the organelle, the transmembrane electrical potential, and the organelle volume, 
surface area, and lipid fraction.  For mitochondria, the inner lumen pH was set at 8 (25) and 
the membrane potential was set at -150 mV (26).  Mitochondria were modeled as spheres 
with 1 µm radius. For lysosomes, the inner lumen pH was set at 5 (1, 27-29) and the 
membrane potential was set at +10 mV (30).  Leukocytes were modeled as spherical 
objects of 10 µm in diameter.  Plasma membrane potential was set at -60 mV (31) .  
Extracellular pH was set at 7.4 (blood).  Cytosolic pH was set at 7.0 (32).  Since we are 
more interested in the drug aqueous concentration in cytosol, the lipid fraction was set at 0 
in calculation. Other model parameters were adapted from literature (25). Hereafter, this 
cellular pharmacokinetic model applicable to free floating cells in suspension (e.g. 




Modeling cellular pharmacokinetics of non-target, polarized epithelial cells: the R-
model 
For modeling drug transport across polarized epithelial cells (24), the cell surface 
area is divided into apical and basolateral membrane domains (Figure 3.1b). Similarly, the 
extracellular space is divided into apical and basolateral extracellular compartments. 
Accordingly, drug uptake into the cell is represented by mass transfer of drug molecules 
from the apical extracellular medium into the cytosol, across the apical membrane.  Drug 
efflux from the cells is represented by mass transfer from the cytosol to the basolateral 
medium, across the basolateral membrane.  Because the apical membrane is normally 
covered with microvilli, the apical membrane surface area (Aa) can be adjusted 
independently from the basolateral membrane (Ab). Similarly, the extracellular pH of the 
apical (pHa) and basolateral compartments (pHb), and transmembrane electrical potentials 
across apical and basolateral membranes (Ea and Eb) can be independently adjusted, so as 
to mimic the local microenvironment of the epithelial cells.   
A cellular pharmacokinetic model for simulating intracellular concentration and 
passive transcellular permeability in the presence of a transcellular concentration gradient 
was developed previously by our group (24, 33).  Mass transport across the boundary of 
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The subscripts a and b indicate ‘apical’ and ‘basolateral’ respectively. Other 
symbols and subscripts mean the same as those in the T-model. As in the T-model, the 
inner lumen pH of mitochondria was set at 8 (25) and the mitochondrial membrane 
potential was set at -150 mV (26).  For lysosomes, the inner lumen pH was set at 5 (1, 27-
29) and the membrane potential was set at +10 mV (30).  Epithelial cells were modeled as 
cubical objects of 10 µm in length. Again since we are more interested in the drug aqueous 
concentration in cytosol the lipid fraction was set to 0. All other model parameters used in 
calculation were obtained from the literature (24), and can be found in the supplemental 
materials. To maintain sink condition in the basolateral compartment, we set the volume of 
the basolateral compartment (Vb) equal to the human blood volume (4.7 L).   
From simulating cytosol to basolateral flux of molecules in an intestinal epithelial 
cell, the transcellular permeability of the intestinal epithelial cell monolayer corresponds to 






= , (3.8) 
where Peff is the effective permeability, Ca is the initial concentration in the apical 
compartment and is considered to be constant, dmb/dt is the change in drug mass in the 
basolateral compartment per unit time, and Aaa is the apparent cross sectional area of the 
cell, which would approximately correspond to the total area of the surface over which 
drug transport is occurring divided by the number of cells that are effectively transporting 
drug. Henceforth, this cellular pharmacokinetic model that applies in non-target epithelial 
cells will be dubbed Rosania’s Model or ‘R-Model’.   
Analyzing organelle-targeting and transcellular permeability with R- and T-models 
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To analyze the intracellular distribution of monovalent weakly basic molecules 
possessing amine functionality, all different combinations of a) octanol : water partition 
coefficients of the neutral form of the molecule (logPn); b) octanol : water partition 
coefficients of the ionized form of the molecule (logPd); and c) pKa were used as input. 
LogPn and logPd spanned a range from -5 to +5, while logPd was constrained to a value 
less than or equal to logPn. pKa spanned a range from 0 to 14. pKa, logPn, and logPd were 
varied in 0.2 unit increments (24). The molecular charge (z) was set equal to 1, which 
means the simulated whole physicochemical space is specific for monovalent amine-
containing molecules. With R- and T-Model, simulations were performed until the 
system reached steady state (normally, at 106 seconds after beginning of the simulation). 
For R-Model simulations, initial apical drug concentration was set at 1 mM, and 
basolateral drug concentration was set at 0 mM. For T-model simulations, extracellular 
drug concentration was set at 1 mM, and kept constant. Accordingly, for each 
combination of pKa, logPn, and logPd used as input, there are seven output values: CcytoR, 
CmitoR, ClysoR (the steady-state cytosolic, mitochondrial and lysosomal concentration 
estimated with the R-model); Peff (the steady-state effective permeability estimated with 
the R-Model); and CcytoT, CmitoT, and ClysoT (the steady-state cytosolic, mitochondrial 
and lysosomal concentrations estimated with the T-Model). 
A test set of monobasic amines with associated lysosomotropic behaviors 
Focusing on lysosomal targeting, ninety-nine monobasic amines (Table 3.1) were 
found by searching PubMed abstracts and titles for articles containing the word 
“lysosome”, “lysosomal”, or “lysosomotropic”; from other articles referenced by these 
articles; and from current review articles describing the lysosomal accumulation of 
 
 90
weakly basic molecules (1). There are more lysosomotropic amine-containing molecules 
besides molecules included in our table (for example, zwitterions or dibasic amines). 
However since R- and T-Models have been validated mostly with molecules possessing 
one ionizable functional group, lysosomotropic amines with more than one ionizable 
functionality were not included. To estimate the pKa (at 37 ºC), logPn and logPd for each 
molecule, we used ChemAxon (http://www.chemaxon.com). A liposomal approximation 
(24, 34) was applied for logPn and logPd based on the values obtained from ChemAxon. 
Intracellular distributions were analyzed for those ninety-nine molecules at steady state 
with the T-model and R-model. Transcellular permeability was analyzed for the ninety-
nine molecules at steady state with the R-model. 
Interactive visualization of simulation results 
Visualization of simulation results was performed with the Miner3D® software 
package (Dimension 5, Ltd., Slovakia, EU). Simulation results were graphed as 3D 
scatter plots to shape the chemical spaces with logPn, logPd and pKa plotted on the three 
coordinate axes, and the analyzed steady state concentration or permeability determining 
the color and intensity of the points. For linking simulation results with the test set of 
lysosomotropic molecules, we used the pKa, logPn and logPd values obtained after 
liposomal approximations (24). 
To plot different chemical spaces we set a threshold concentration value to define 
accumulation in a specific subcellular compartment.  For intracellular concentration, the 
threshold lysosomal accumulation for lysosomotropic molecules was ClysoT ≥ 2 mM ( i.e. 
two-fold greater than extracellular concentration). The thresholds for selective lysosomal 
accumulation were ClysoT ≥ 2 mM; ClysoT / CmitoT ≥ 2 ; and ClysoT /CcytoT ≥ 2. The 
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threshold for mitochondrial accumulation was CmitoT ≥ 2 mM. The thresholds for 
selective mitochondrial accumulation were CmitoT ≥ 2 mM; CmitoT / ClysoT ≥2; and CmitoT 
/ CcytoT ≥2. The threshold for cytosolic accumulation was CcytoT ≥ 2 mM. The thresholds 
for selective cytosolic accumulation were CcytoT ≥ 2 mM; CcytoT / CmitoT ≥ 2; and CcytoT / 
CmitoT ≥ 2. The reason for using the two-fold concentration value as a threshold is 
because it gave the highest percentage of correct classification and lowest incorrect 
classification rate for the test set of lysosomotropic molecules (as detailed in the Results 
section).  
As recommended by the FDA, the permeability value of metoprolol was used as a 
threshold to distinguish high vs. low permeability molecules (24). Previously we 
calculated permeability for metoprolol, using the pKa and logPn obtained from 
experimental measurements, to be equal to 35 ×10-6 cm/sec (24). In the present study, we 
used this value as a threshold to distinguish high vs. low permeability molecules. In 
addition, we arbitrarily set a value of 1×10-6 cm/sec as a cut-off number to distinguish 
low from negligible permeability molecules. Accordingly, three permeability classes 
were defined as: negligible (Peff < 1×10-6 cm/sec); low (1 ≤ Peff < 35 ×10-6 cm/sec); and 
high (Peff ≥ 35 ×10-6 cm/sec).   
Results 
Defining a lysosomal accumulation threshold for lysosomotropic molecules 
We began by exploring the simulated property space occupied by monobasic 
amines, in relation to the test set of molecules obtained from published research articles 
(Table 3.1).  Three different lysosomal concentration thresholds (2, 4 and 8 mM) were 
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tested in terms of their ability to discriminate lysosomotropic vs. non-lysosomotropic 
compounds (Figure 3.2). For compounds with ≥ 2 mM accumulation in lysosomes 
(Figure 3.2a-d), eight (8) of the test compounds were below the accumulation threshold 
(Figure 3.2a, b), while ninety-one (91) were above the threshold (Figure 3.2c, d).  For 
compounds with ≥ 4 mM accumulation in lysosomes (Figure 3.2e-h), twelve (12) of the 
test compounds were below the accumulation threshold (Figure 3.2e, f), while eighty-
seven (87) were above the threshold (Figure 3.2g, h).  For compounds with a ≥ 8 mM 
accumulation in lysosomes (Figure 3.2i-l), fifty-six (56) lie below the accumulation 
threshold (Figure 3.2i, j) while forty-three (43) are above (Figure 3.2k, l).   
We established that a lysosomal accumulation threshold of 2 mM is best suited to 
distinguish lysosomotropic from non-lysosomotropic molecules, since it gave the highest 
correct classification in terms of matching simulation results with the experimentally-
observed, lysosomotropic behaviors. Accordingly, for a lysosomal accumulation 
threshold of 2mM, of the 8 molecules that were below the accumulation threshold, 5 
(62.5%) have been positively identified as non-lysosomotropic. Conversely, of the 91 
above the threshold, 8 (8.8%) non-lysosomotropic molecules have been incorrectely 
classified as lysosomotropic.  For a lysosomal accumulation threshold of 4 mM, of the 12 
below the threshold, 5 (41.7%) have been identified as non-lysosomotropic. Conversely, 
of the 87 above threshold, 8 (9.2%) non-lysosomotropic molecules have been 
incorrectely classified as lysosomotropic. For a lysosomal accumulation threshold of 8 
mM, of the 56 below the threshold, 9 have been positively identified as non-
lysosomotropic (16.1%).  Conversely, of the 43 above the threshold, 4 (9.3%) non-
lysosomotropic molecules have been incorrectly classified as lysosomotropic. 
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The test set appears highly clustered in relation to the available lysosomotropic, 
physicochemical property space 
Exploring the relationship between the physicochemical properties of the test set 
of molecules obtained from the literature with that of the theoretical physicochemical 
property space occupied by molecules that accumulate in lysosomes at the different 
threshold values, we observed that most of the test molecules tend to be clustered in very 
specific region of “lysosomotropic space”. In fact, physicochemical property space 
occupied by molecules that accumulate in lysosomes at ≥ 2 mM (Figure 3.2b) appears 
largely similar to the space of molecules that accumulate at ≥ 4 mM (Figure 3.2f) and at ≥ 
8 mM (Figure 3.2j). It was surprising that most lysosomotropic molecules in the 
reference set were calculated to have a lysosomal accumulation between 2- and 8-fold 
over the extracellular medium, although the largest portion of the calculated 
physicochemical property space that can be occupied by monobasic amines corresponds 
to > 8-fold lysosomal accumulation.  
Using simulation results to define the expected transport classes for monovalent 
weak bases 
Using a 2-fold or greater concentration of drug over the extracellular medium to 
distinguish high vs. low lysosomal, mitochondrial and cytosolic concentration, and by 
incorporating high vs. low permeability classification obtained with the R-model, a total 
of 16 classes of molecules can be  defined a priori (Table 3.1).  By mapping the test set 
of molecules to these 16 different classes, we find that some classes of molecules are 
well-represented by a number of molecules, while other classes of molecules are not 
represented at all (Table 3.1). However, according the simulation results, several of these 
a priori classifications are deemed to be “non-existent” by virtue of our being unable to 
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find a combination of physicochemical properties consistent with the corresponding class 
of molecules in simulations.  
Simulation results point to general trends in lysosomotropic behaviors 
For the test set of molecules, we observed that the simulated intracellular 
accumulation in non-target cells (R-Model) is much lower than the corresponding 
accumulation in target cells (T-model) (Table 3.1). The simulations yielded lysosomal 
accumulation occurring for a broad range of transcellular permeability values (Table 3.1). 
Unexpectedly, for most lysosomotropic molecules, the simulations indicate that 
mitochondrial accumulation may be much greater than lysosomal or cytosolic 
accumulation, suggesting that lysosomotropic behavior may not be exclusively related to 
selective accumulation in lysosomes. Lastly, we observed that none of the 
lysosomotropic molecules in the test set are able to accumulate in cytosol to a greater 
extent than they accumulate in mitochondria or in lysosomes (Table 3.1). In fact, plotting 
the physicochemical property space of such molecules yielded an empty space (data not 
shown), indicating that the lack of such type of molecules in the reference set is not 
because the test set is a biased sample, but rather it is expected based on the calculated 
cellular pharmacokinetic properties of monovalent weak bases.  
Calculating the physicochemical space occupied by selectively lysosomotropic 
molecules 
Selectively lysosomotropic molecules were defined as those that accumulate in 
lysosomes to a 2-fold (or greater) level over the extracellular medium, cytosol, and 
mitochondria. Out of the 91 reference lysosomotropic molecules (Figure 3.3a, out of 
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circle), only seventeen (17) (Figure 3.3c, d green circle) appear to be selective in terms of 
lysosomal accumulation. These 17 molecules (Figure 3.3c) appear clustered at the middle 
pKa value of the test set of molecules comparing with non-lysosomotropic molecules 
(Figure 3.3a, in blue circle) and non-selectively lysosomotropic molecules. Plotting the 
theoretical physicochemical property space occupied by selectively lysosomotropic 
molecules related to the reference molecules reveals that the test set of molecules that 
accumulate in lysosomes are highly clustered (Figure 3.3b) in the middle pKa and high 
logPd values. This can also be observed in the corresponding plot of non-selectively 
lysosomotropic and non-lysosomotropic physicochemical property space (Figure 3.3d). 
Analyzing the effect of transcellular permeability on selective lysosomal 
accumulation 
Next, we analyzed the relationship between selective lysosomal accumulation in 
target cells, and transcellular permeability in non-target cells, to determine if the ability to 
develop selective lysosomotropic agents may be constrained by desirably high 
transcellular permeability characteristics important for intestinal drug absorption and 
systemic tissue penetration (Figure 3.4).  As a reference, the permeability of metoprolol 
(Peff = 35×10-6 cm/sec) was used to distinguish high permeability from low permeability 
drugs. Accordingly, three permeability categories were defined: Negligible Permeability 
(Peff  < 1×10-6 cm/sec; Figure 3.4a, b); Low Permeability (1 ≤ Peff < 35×10-6 cm/sec; 
Figure 3.4c, d); and High Permeability (Peff  ≥ 35×10-6 cm/sec, Figure 3.4e, f).   
With increasing permeability, the simulation results indicate that physicochemical 
space occupied by selective lysosomotropic molecules shifts towards lower pKa values 
and higher logPd values. The position of selective lysosomotropic chemical space in 
 
 96
relation to the reference set of non-selective lysosomotropic or non- lysosomotropic 
molecules can be seen, for molecules with Peff < 1×10-6 cm/sec (Figure 3.4a); 1 ≤ Peff < 
35×10-6 cm/sec (Figure 3.4c); and Peff ≥ 35×10-6 cm/sec (Figure 3.4e). Accordingly, there 
is only one (1) selectively-lysosomotropic reference molecule with Peff < 1×10-6 cm/sec 
(Figure 3.4b; green arrow); five (5) with 1≤ Peff<35×10-6 cm/sec (Figure 3.4d; green 
arrow); and eleven (11) with Peff ≥ 35×10-6 cm/sec (Figure 3.4f; green arrow). Thus, high 
permeability and selective lysosomal accumulation are not mutually exclusive. 
Nevertheless, we observed that the selective lysosomotropic reference molecules with 
negligibly low and high permeability are tightly clustered in a small region of chemical 
space, at mid pKa and high logPd values. 
Demarcating the physicochemical property space of extracellular targeted molecules 
Extracellular-targeted molecules can be defined as those whose intracellular 
accumulation at steady state is less than the extracellular concentration (24). For drug 
development, such a class of molecules is important as many drug targets are 
extracellular. Accordingly, we analyzed simulation results to determine if there were 
molecules with low intracellular accumulation and high permeability, which would be 
desirable for the pharmaceutical design of orally absorbed drugs (Figure 3.5). By 
maximizing permeability and minimizing intracellular accumulation, (using Peff  ≥ 35×10-
6 cm/sec, Ccyto < 1mM, Cmito < 1mM, and Clyso < 1mM as thresholds in both the R and T 
models), we found five (5)  molecules falling into this class (Figure 3.5a, b, c; green 
circle): pyrimidine, benzocaine, β-naphthylamine, 8-aminoquinoline, and the anti-
epileptic drug candidate AF-CX1325XX. These are monobasic amines with pKa < 4.5. 
Molecules with pKa > 4.5 (the physicochemical property space shown in Figure 3.5c) 
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exhibit intracellular accumulation in lysosomes, cytosol or mitochondria to levels above 
those found in the extracellular medium.  Figure 3.5b shows the physicochemical space 
of molecules with high permeability and low intracellular accumulation. Figure 3.5c 
shows the physicochemical space of molecules with high intracellular accumulation 
regardless of permeability. Again we can see that molecules with low intracellular 
accumulation have a pKa < 4.5 and with high intracellular accumulation have a pKa > 4.5. 
Many reported lysosomotropic molecules appear to accumulate in mitochondria 
For the majority of the reportedly lysosomotropic monobasic amines in the test 
set, the model suggests that they accumulate in mitochondria more than they accumulate 
in lysosomes. In total, 56 of the 91 lysosomotropic molecules in the test set accumulate in 
mitochondria at 2-fold or greater levels than they accumulate in lysosomes, cytosol, or 
the extracellular medium (Figure 3.6a; Table 3.1, selectively mitochondrotropic 
compounds underlined). These molecules have a pKa of 8.2 or greater, a logPn of 1.5 or 
greater, and span a wide range of transcellular permeability values – from impermeant to 
very highly permeant. In addition, eighteen (18) lysosomotropic molecules also exhibit 
mitochondrial and high cytosolic accumulation, at concentrations comparable to the 
concentrations at which they accumulate in lysosomes (Figure 3.6b; Table 3.1). Again, 
these molecules span a broad range of transcellular permeability values, from impermeant 
to highly permeant.   Plotting the theoretical physicochemical property space occupied by 
lysosomotropic molecules with predicted, selective mitochondrial accumulation reveals 
that the molecules in the test set are clustered in this realm of physicochemical property 
space (Figure 3.6c). Similarly, plotting the physicochemical property space occupied by 
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lysosomotropic molecules that are predicted to accumulate in cytosol and mitochondria 
reveals that the molecules are clustered in this realm of chemical space.  
Calculated effect of pH in apical compartment on permeability and biodistribution 
Based on the simulations, the accumulation of monobasic amines in lysosomes is 
largely dependent on the difference in pH of between lysosome and extracellular medium 
(data not shown). While the pH of the medium bathing the target cells is expected to be 
rather constant, the pH surrounding an intestinal epithelial cell is expected to vary along 
the intestinal tract (35). To test if this variation would lead to major differences in the 
observed trends, we decided to test the extent to which the calculated chemical space 
occupied by selectively lysosomotropic molecules was affected by variation in the apical 
pH of non-target cells (Figure 3.7). We note that for selectively lysosomotropic 
molecules with negligible (Figure 3.7a), low (Figure 3.7b), and high (Figure 3.7c) 
permeability, the theoretical physicochemical property space occupied by selectively 
lysosomotropic molecules is similar, and the test molecules that fall into that region of 
chemical space tend to be the same. Similarly, other regions of physicochemical property 
space occupied with molecules of different permeability tend to be similar, with 
variations in the apical pH of the intestinal epithelial cell in a pH range of 4.5 to 6.8 (data 
not shown).   
Discussion 
Modeling the cellular pharmacokinetics of monobasic amines 
Over the past few years, mathematical models of cellular pharmacokinetics have 
been developed, based on coupled sets of differential equations capturing the 
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transmembrane diffusion of small molecules.  Previously, these models have been used to 
simulate the intracellular distribution of lipophilic cations in tumor cells (25), and the 
distribution and passage of small molecules across intestinal epithelial cells (24).  For a 
monovalent weakly acidic or weakly basic small molecule drug, three input physical-
chemical properties are used to simulate cellular drug transport and distribution: the 
logarithms of the lipid/water partition coefficient of the neutral form of the molecule 
(logPn) and ionized form (logPd), and the negative logarithm of the dissociation constant 
of the ionizable group (pKa). For monovalent weak bases, the transcellular permeability 
values calculated with this approach were comparable with measured human intestinal 
permeability and Caco-2 permeability, yielding good predictions (24). Similarly, the 
corresponding mathematical models were able to predict mitochondrial accumulation of 
lipophilic cationic substances in tumor cells (22, 25).  
For analyzing the lysosomotropic behavior of monovalent weak bases possessing 
amine functionality, we adapted these two mathematical models to simulate the cellular 
pharmacokinetic behavior of target cells exposed to a homogeneous extracellular drug 
concentration, and non-target cells mediating drug absorption in the presence of an 
apical-to-basolateral concentration gradient. The results we obtained establish a baseline, 
expected concentration of small drug-like molecules in mitochondria, lysosomes and 
cytosol of target cells, as well as permeability in non-target cells. With a test set of small 
molecules obtained from published research articles, the simulations permit exploring the 
relationship between physicochemical properties of the molecules, their simulated 
intracellular distributions and transport behavior, and experimentally reported cellular 
phenotypes.   
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Simulation-based analysis and classification of lysosomotropic behavior 
By analyzing the intracellular distribution and transcellular transport 
characteristics of a test set of molecules, together with more general physicochemical 
space plots covering all possible combinations of pKa, logPn and logPd, sixteen a priori 
classes of lysosomotropic behavior for monobasic amines were defined (Table 3.1). 
However, we noted that several of these classes are deemed to be non-existent by the 
simulations – meaning that there is no combination of pKa, logPn and logPd that will yield 
a molecule in such a class. For other classes, it was not possible to find a molecule in the 
reference set of lysosomotropic molecules whose calculated properties would lie within 
the physicochemical property space defining the hypothetical class of molecules. This is 
certainly the case for positively-identified, non-lysosomotropic molecules. These results 
argue for expanding the test set of monovalent, weakly basic molecules, so as to represent 
all possible classes of intracellular transport behaviors. 
An equally important observation from the simulation resides in the tight 
clustering of the reference molecules in constrained regions of physicochemical property 
space, in relation to the simulated physicochemical property space that is actually 
available for molecules in the different lysosomotropic and permeability categories. Thus, 
the diversity of lysosomotropic behaviors represented by the test set of molecules is 
significantly limited. Indeed, the simulations indicate that expanding the reference set of 
molecules to unexplored regions of physicochemical property space could be used to find 
molecules that better represent different types of expected cellular pharmacokinetic 
behaviors. For example, in the case of low or high permeability molecules that are 
selectively lysosomotropic, most of the molecules in the reference set are clustered at the 
high levels of pKa and high logP, whereas the simulations indicate that it should be 
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possible to find molecules with lower pKa and lower logP. The reason for the limited 
chemical diversity of reported lysosomotropic molecules is certainlly related to the 
choice of molecules that have been tested experimentally and reported in the literature:  
the emphasis has not been on the probing the chemical diversity of lysosomotropic 
character, but rather, in analyzing the lysosomotropic character in a related series of 
compounds (for example, studies looking at mono, bi, and tri-substituted amines, 
functionalized with various aliphatic groups (9)). In other cases, the emphasis has been 
on studying the lysosomotropic character of a specific type of compound developed 
against a specific drug target (6) (for example, beta-adrenergic receptor antagonists such 
as propranolol, atenolol, practolol, etc), rather than on the full chemical space occupied 
by lysosomotropic, monovalent weakly basic amines.  
Further experimental validation and testing of expected transport behaviors 
Using lysosomal swelling, cell vacuolation and intralysosomal pH measurements 
as phenotypic read outs, it may be possible to test both R- and T-model prediction about 
the varying extent of lysosomal accumulation of monovalent weak bases as a function of 
the molecule’s chemical structure or physicochemical properties.  For example, the 
models make quantitative predictions about the lysosomal concentration of molecules of 
varying chemical structure. Previous studies looking at the lysosomotropic behavior of 
various molecules have reported differences in vacuolation induction for different probes, 
at extracellular drug concentrations ranging from high millimolar to micromolar range 
(10, 13, 16).  Also, for some molecules vacuolation occurs after less than an hour 
incubation, while for other probes vacuolation occurs after twenty-four hour incubation, 
or longer (6, 9, 10, 13, 14, 16). Combinatorial libraries of fluorescent molecules are 
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available today (36, 37), offering yet another way to test predictions about the 
intracellular accumulation and distribution of probes. Furthermore, with organelle-
selective markers and kinetic microscopic imaging instruments, the rate and extent of 
swelling of lysosomes and other organelles could be monitored dynamically after 
exposure of cells to monovalent weakly basic molecules (37). For such studies, 
cheminformatic analysis tools are being developed to relate the intracellular distribution 
of small molecules as apparent in image data, with chemical structure and 
physicochemical features of the molecules, and the predicted subcellular distribution (38, 
39). Lastly, more quantitative assessments of model predictions can be made by directly 
monitoring the total intracellular drug mass (40, 41), as well as drug mass associated with 
the lysosomal compartment (20, 42, 43). Recently, methods are being developed to 
rapidly isolate the lysosomes and measure intralysosomal drug concentrations (43).   
To test model predictions about the lysosomotropic behavior of small molecules 
in the presence of an apical-to-basolateral concentration gradient, various in vitro cell 
culture models have been developed to assess drug intestinal permeability and oral 
absorption (44). These are Caco-2, MDCK, LLC-PK1, 2/4/A1, TC-7, HT-29, and IEC-18 
cell models (44). Among those models Caco-2 (human colon adenocarcinoma) cell 
monolayer is the most well-established cell model and has been widely accepted by 
pharmaceutical companies and academic research groups interested in studying drug 
permeability characteristics (44). In addition to Caco-2 cells, MDCK (Madin-Darby 
canine kidney) is a dog renal epithelia cell line and is another widely used cell line in 
studying cell permeability characteristics (45).  
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Towards a computer-aided design of organelle-targeted molecules: implications for 
drug discovery and development 
The ability to rationally tailor the transcellular permeability and subcellular 
distribution of monobasic amines can have important applications in medicinal chemistry 
efforts aimed at enhancing the efficacy of small molecules against specific targets, 
decreasing non-specific unwanted interactions with non-intended targets that lead to side 
effects and toxicity, as well as enhancing transcellular permeability for maximizing tissue 
penetration and oral bioavailability.  For many FDA approved drugs, lysosomal 
accumulation of the molecules would appear to be a non-specific effect of the molecule’s 
chemical structure. For example, in the case of the beta-adrenergic receptor antagonists 
like propranolol, the drug’s target is a cell surface receptor located at the plasma 
membrane. Thus, lysosomal (and any other intracellular) accumulation observed for this 
molecule is most likely an unintended consequence of its chemical structure (2, 6, 15, 16, 
43, 46).  In general, due to the abundance of lysosomotropic drugs (6, 9, 10, 16), 
lysosomal accumulation seems to be tolerated, although it may not be a desirable 
property.  
Nevertheless, there are certain classes of therapeutic agents where lysosomal 
accumulation may be highly desirable. For example, Toll-like receptor molecules are 
transmembrane proteins in the lysosomes of leukocytes (dendritic cells and 
macrophages). These receptors can be activated by endocytosed proteins, DNA and 
carbohydrates, and they generate inflammatory responses as part of the innate immune 
system (47, 48). Small molecule agents that either block or activate Toll-like receptors 
are being sought to inhibit inflammatory reactions (associated with autoimmune diseases) 
or promote resistance against viral infections, respectively (49, 50). A different class of 
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molecules where lysosomal accumulation would be highly desirable involves agents that 
affect lysosomal enzymes involved in tissue remodeling (51). Tissue remodeling is the 
basis of diseases like osteoporosis, which involves the loss of bone mass due to an 
imbalance in the rate of bone deposition and bone resorption.  
From the simulations, mitochondria also appear as an important site of 
accumulation of monobasic amines – even for many molecules that have been previously 
classified as being “lysosomotropic”. Our simulation results indicate that monovalent 
weak bases can selectively accumulate in mitochondria at very high levels –in fact, at 
much higher levels than they appear to be able to accumulate in lysosomes. From a drug 
toxicity standpoint, unintended accumulation of small molecules in mitochondria can 
interfere with mitochondrial function, leading to cellular apoptosis (52-54). Conversely, 
intentional targeting of small molecule therapeutic agents to mitochondria can be a 
desirable feature for certain classes of drugs: mitochondria dysfunction can cause a 
variety of diseases, so there is great interest in developing mitochondriotropic drugs (22, 
55-57).  
Nevertheless, perhaps the most important classes of subcellularly-targeted 
molecules are those that are aimed at extracellular domains of cell surface receptors (24). 
Many ‘blockbuster’ drugs in the market today target cell surface receptors, ion channels, 
and other extracellular enzymes, making extracellular space one of the most valuable 
sites-of-action for drug development (58).  Extracellular-acting therapeutic agents include 
anticoagulants that interfere with clotting factors in the blood, agents that interfere with 
pro-hormone processing enzymes, ion channel blockers for treating heart conditions, 
GPCR antagonists for hypertension, inflammation and a variety of other different 
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conditions, and many CNS-active agents that act on neurotransmitter receptors, transport 
and processing pathways. In order to target extracellular domains of blood proteins, cell 
surface receptors and ion channels, it is desirable that a molecule would have high 
transcellular permeability to facilitate absorption and tissue penetration. In addition, it 
would be desirable that the molecule would also have low intracellular accumulation so 
as to maximize extracellular concentration. The simulation results indicate that indeed, 
finding monovalent weak bases with high permeability and low intracellular 
accumulation in both target and non-target cells is possible, with several molecules in the 
reference set residing in this realm of physicochemical property space. 
To conclude, cell based molecular transport simulators constitute a promising 
cheminformatic analysis tool for analyzing the subcellular transport properties of small 
molecules. The ability to combine results from different models, visualize simulations 
representing hundreds of thousands of different combinations of physicochemical 
properties, and relate these simulation results to the chemical structure and phenotypic 
effects of specific drugs and small drug-like molecules adds a new dimension to the 
existing mathematical models. As related to the specific class of lysosomotropic 
monobasic amines analyzed in this study, interactive visualization of simulation results 
point to a richness in subcellular transport and distribution behavior that is otherwise 
difficult to appreciate. We anticipate that the complexity of subcellular transport 
behaviors will ultimately be exploited in future generations of small molecule drug 
candidates “supertargeted” to their sites of action (59), be it in the extracellular space, the 




Table 3.1. The test set of ninety-nine lysosomotropic monobasic amines.  Based on simulation results, compounds were classified 
by permeability (Peff  calculated with the R-model) and subcellular concentrations (calculated with the T-model) as follows: Low 
permeability: Peff  < 35×10-6 cm/sec; High permeability: Peff ≥ 35×10-6 cm/sec; Lyso: ClysoT > 2 mM; Mito: CmitoT > 2 mM; Cyto: 
CcytoT ≥ 2mM; Non-lyso: ClysoT < 2 mM; Non-mito: CmitoT < 2 mM; Non-cyto: CcytoT < 2mM.  Compounds appear in gray 
background if they were reported as non-lysosomotropic in published research articles; in italics if they appear as selective 
lysosomotropic in the simulations (ClysoT ≥ 2mM; ClysoT/CmitoT ≥ 2mM;  ClysoT/CcytoT ≥ 2mM); underlined if they appear as 
selectively mitochondriotropic in the simulations (CmitoT  ≥  2mM, CmitoT/ClysoT  ≥  2 mM, CmitoT/CcytoT ≥ 2 mM). In the table, a 
particular class “exists” if one can find a combination of physicochemical properties (within the range of pKa, logPn, and logPd input 
values) that yields the expected behaviour in the simulation. 
 
Category 1: Low Permeability, Non-lyso, Mito, Non-cyto Chemical space exists.    
Category 2: Low Permeability, Non-lyso, Non-mito, Non-cyto Chemical space exists.   
Category 3: Low Permeability, Non-lyso, Non-mito, Cyto     Chemical space does not exist.   
Category 4: Low Permeability, Non-lyso, Mito, Cyto   Chemical space exists.   
Category 5: Low Permeability, Lyso, Mito, Non-cyto Chemical space exists.      
Category 6: Low Permeability, Lyso, Non-mito, Non-cyto  Chemical space exists.   
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT Reference
lidocaine 7.2 2.71 1.16 0.15 0.06 1.74 26.67 1.87 0.81 22.26 (10) 
Category 7: Low Permeability, Lyso, Non-mito, Cyto  Chemical space exists.   
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
17-DMAG 7.31 2.46 0.87 0.15 0.06 1.69 13.01 2.05 0.81 22.73 (60) 
beta-dimethylaminoethylchloride 7.63 2.48 0.9 0.23 0.08 1.5 11.76 2.64 0.91 17.52 (21) 
diethylaminoethyl chloride 8.16 2.71 1.16 0.53 0.24 1.36 19.93 3.83 1.72 9.87 (21) 
triethanolamine 8.14 1.52 -0.18 0.4 0.14 1.39 0.91 3.57 1.25 12.35 (21) 
Category 8: Low Permeability, Lyso, Mito, Cyto   Chemical space exists.   
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
17-DMAP 8.3 2.47 0.89 0.62 0.31 1.35 10.79 4.17 2.08 9.07 (60) 




2-amino-2-methyl-1,3-propanediol 9.14 1.56 0 1.44 3.32 1.3 1.58 8.01 18.52 7.22 (21) 
2-amino-2-methyl-1-propanol 9.68 1.92 0.41 1.73 14.32 1.29 4.27 10.85 89.76 8.06 (21) 
2-aminoethanol(ethanolamine) 9.22 1.75 0.22 1.51 4.42 1.29 2.66 8.62 25.18 7.36 (21) 
2-diethylaminoethanol 9.22 2.23 0.62 1.46 3.58 1.29 6.62 8.19 20.09 7.27 (21) 
2-dimethylamino-2-methyl-1-
propanol 9.25 2.17 0.55 1.47 3.76 1.29 5.65 8.31 21.23 7.3 (21) 
2-dimethylaminoethanol 8.71 2.01 0.37 0.96 0.81 1.32 3.42 5.44 4.56 7.46 (21) 
2-methylaminoethanol 9.46 1.89 0.32 1.63 7.29 1.29 3.41 9.67 43.34 7.66 (21) 
3-amino-1-propanol 9.49 1.77 0.24 1.66 8.67 1.29 2.85 9.99 52.26 7.76 (21) 
3-aminopropanal 9.14 1.77 0.24 1.46 3.6 1.29 2.76 8.17 20.17 7.25 (61) 
3-dimethylamino-1-propanol 8.83 2.03 0.39 1.08 1.13 1.31 3.66 5.98 6.25 7.23 (21) 
4-amino-1-butanol 9.55 1.92 0.41 1.69 10.52 1.29 4.24 10.34 64.43 7.88 (21) 
ammonia 8.55 1.81 0.41 1.05 1.08 1.31 3.8 5.67 5.82 7.08 (21) 
atenolol 9.32 2.29 0.76 1.57 5.7 1.29 9.32 9.15 33.13 7.5 (6) 
atropine 9.02 2.67 1.23 1.44 3.36 1.3 26.87 7.98 18.66 7.18 (10), (16) 
benzylamine 9.17 2.58 1.24 1.6 6.38 1.29 28.25 9.32 37.22 7.52 (10) 
butylamine 9.84 2.39 0.95 1.78 24.35 1.28 14.95 11.54 157.56 8.31 (21) 
diethylamine 10.2 2.36 0.84 1.82 45 1.28 11.68 12.09 298.98 8.53 (10), (21) 
dimethylamine 10.15 2.13 0.59 1.81 38.7 1.28 6.56 11.98 255.81 8.48 (21) 
ethylamine 9.86 2.11 0.62 1.78 22.73 1.28 6.99 11.46 146.61 8.28 (21) 
guanidine 12.09 1.82 0.39 1.86 461.27 1.28 4.17 12.78 3164.97 8.8 (10), (21) 
hexylamine 9.84 2.66 1.24 1.79 25.48 1.28 29.17 11.59 165.24 8.33 (21) 
isobutylamine 9.87 2.4 0.95 1.79 25.47 1.28 14.96 11.59 165.19 8.33 (21) 
isopropanolamine 9.26 1.89 0.38 1.55 5.16 1.29 3.87 8.94 29.72 7.44 (21) 
isopropylamine 10.06 2.25 0.78 1.81 37.09 1.28 10.16 11.95 244.64 8.47 (21) 
methylamine 9.72 2 0.5 1.74 16.1 1.29 5.27 11.02 101.71 8.12 (21) 
metoclopramide 8.73 2.56 0.99 1.05 1.06 1.31 14.48 5.81 5.82 7.22 (14), (13) 
morpholine 8.21 2.02 1.25 1.36 2.95 1.3 27.55 6.62 14.36 6.31 (10) 
N-acetylprocainamide 8.73 2.51 0.93 1.04 1.02 1.31 12.59 5.76 5.66 7.25 (10),(13) 
NAMA 8.72 2.38 0.79 1.02 0.97 1.31 9.09 5.68 5.36 7.29 (14) 
N,N-dimethyl-3-




N,N-dimethyl-benzylamine 8.67 2.84 1.3 1.02 0.98 1.31 29.42 5.65 5.4 7.25 (10) 
pentylamine 9.84 2.53 1.09 1.78 24.35 1.28 20.64 11.54 157.56 8.31 (21) 
practolol 9.32 2.47 0.97 1.59 6.15 1.29 15.16 9.3 35.98 7.54 (6) 
propylamine 9.85 2.27 0.8 1.78 23.26 1.28 10.58 11.49 150.19 8.29 (21) 
s-butylamine 10.07 2.4 0.95 1.81 39.59 1.28 15.03 12 261.77 8.49 (21) 
t-butylamine 10.27 2.27 0.81 1.83 59.14 1.28 10.92 12.26 395.97 8.59 (21) 
triethylamine 9.84 2.59 1.02 1.76 18.05 1.29 17.49 11.18 114.96 8.18 (21) 
trimethylamine 9.23 2.25 0.64 1.47 3.67 1.29 6.94 8.25 20.66 7.28 (10) 
tris(hydroxymethyl)methylamine 8.64 1.2 -0.4 0.93 0.75 1.32 0.58 5.29 4.25 7.51 (10),  (21) 
Category 9: High Permeability, Non-lyso, Mito, Cyto  Chemical space does not exist. 
Category 10: High Permeability, Non-lyso, Non-mito, Cyto Chemical space does not exist.  
Category 11: High Permeability, Non-lyso, Mito, Non-cyto   Chemical space exists. 
Category 12: High Permeability, Non-lyso, Non-mito, Non-cyto Chemical space exists.  
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
3-aminoquinoline 4.63 2.65 2.00 0.73 0.73 1.12 398.87 0.82 0.82 1.25 (1) 
8-aminoquinoline 4.07 2.65 2.00 0.78 0.78 0.90 425.43 0.81 0.81 0.94 (1) 
AF-CX1325XX 1.95 2.18 0.7 0.8 0.8 0.8 148 0.81 0.81 0.81 (62) 
aniline 4.5 2.62 1.2 0.73 0.73 1.1 372.35 0.82 0.81 1.22 (10) 
benzocaine 2.7 2.78 1.41 0.8 0.8 0.8 588.46 0.81 0.81 0.82 (13) 
beta-naphthylamine 4.12 2.95 1.57 0.77 0.77 0.93 838.56 0.81 0.81 0.98 (10) 
pyrimidine 1.55 2.17 1.4 0.8 0.8 0.8 144.65 0.81 0.81 0.81 (10) 
pyridine 4.95 2.44 1.88 0.69 0.69 1.3 229.69 0.82 0.82 1.56 (10) 
Category 13: High Permeability, Lyso, Non-mito, Non-cyto  Chemical space exists. 
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
17-AEP 6.59 2.56 0.99 0.14 0.09 2.43 37.31 1.17 0.80 20.89 (60) 
1-aminoisoquinoline 6.88 2.74 1.94 0.36 0.30 1.45 123.44 1.53 1.28 6.16 (1) 
1-dodecylimidazole 6.56 3.65 3.3 0.64 0.81 1.36 2615.12 1.27 1.61 2.7 (21) 
eserine 6.46 3.03 1.51 0.15 0.11 2.51 137.8 1.09 0.81 17.74 (10) 




imidazole 6.73 2.12 1.59 0.51 0.56 1.39 52.47 1.41 1.53 3.81 (21) 
papaverine 6.07 3.1 2.39 0.37 0.35 1.72 489.43 0.94 0.91 4.42 (1) 
pilocarpine 6.39 2.38 1.89 0.48 0.51 1.44 109.54 1.1 1.18 3.32 (10) 
s-collidine 7.06 2.71 1.71 0.3 0.2 1.47 74.19 1.76 1.18 8.61 (21) 
Category 14: High Permeability, Lyso, Non-mito, Cyto  Chemical space exists.   
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
cyproheptadine 7.77 3.67 2.23 0.35 0.14 1.41 235.81 3.02 1.22 12.12 (63) 
diltiazem 7.89 3.08 1.57 0.37 0.14 1.4 51.38 3.23 1.25 12.07 (16) 
N-dodecylmorpholine 7.5 3.58 2.14 0.24 0.1 1.49 203.16 2.44 0.98 15.24 (21) 
Category 15: High Permeability, Lyso, Mito, Non-cyto   Chemical space exists.     
Category 16: High Permeability, Lyso, Mito, Cyto   Chemical space exists.   
Name pKa logPn logPd CcytoR CmitoR ClysoR Peff CcytoT CmitoT ClysoT  
4-aminopyridine 8.63 2.18 1.59 1.71 11.8 1.29 64.2 9.96 68.73 7.5 (10) 
4-aminoquinaldine 8.5 2.7 1.82 1.49 4.21 1.29 104.97 7.87 22.31 6.85 (10) 
4-aminoquinoline 7.98 2.65 2.00 1.29 2.56 1.30 152.07 5.73 11.40 5.79 (1) 
4-dimethylaminopyridine 8.47 2.53 1.98 1.67 9.26 1.29 156.25 9.28 51.49 7.16 (10) 
9-aminoacridine 8.97 3.11 2.4 1.76 18.6 1.28 419.24 10.96 115.66 7.99 (10) 
alprenolol 9.32 3.04 1.71 1.67 9.42 1.29 84.41 10.09 56.88 7.77 (6) 
amantadine 10.33 2.57 2.04 1.86 288.64 1.28 186.33 12.73 1973.95 8.77 (16) 
amiodarone 8.17 4.58 3.38 0.88 0.74 1.32 3439.62 4.69 3.96 7.07 (4) 
amitriptyline 9.41 3.7 2.27 1.67 9.14 1.29 306.28 10.07 55.23 7.78 (64) 
biperiden 8.97 3.25 1.76 1.36 2.57 1.3 89.81 7.43 14.07 7.1 (65) 
chlorphentermine 10.24 3 1.62 1.84 65.54 1.28 70.54 12.32 439.85 8.61 (66), (46) 
chlorpromazine 8.87 3.7 2.27 1.33 2.33 1.3 288.89 7.19 12.66 7.05 (16) 
desipramine 9.66 3.4 2.01 1.76 18.13 1.29 170.9 11.17 115.25 8.17 (12) 
dibutylamine 10.36 2.93 1.48 1.84 72.43 1.28 51.13 12.37 487.37 8.63 (21) 
dihydroalprenolol 9.32 3.11 1.69 1.63 7.53 1.29 80.09 9.69 44.73 7.65 (7) 
dizocilpine 8.3 3.29 1.89 0.80 0.55 1.33 110.20 4.61 3.18 7.70 (67) 
dodecylamine 9.84 3.44 2.12 1.8 31.89 1.28 221.84 11.8 208.84 8.41 (21) 




fluoxetine 9.45 3.58 3.01 1.84 69.46 1.28 1731.76 12.27 463.16 8.55 (4), (23) 
imipramine 8.87 3.52 2.07 1.31 2.21 1.3 181.73 7.09 11.95 7.04 (4) 
iprindole 9.36 3.54 2.09 1.64 7.71 1.29 201.32 9.74 45.89 7.67 (66) 
mecamylamine 10.49 2.93 2.27 1.86 297.05 1.28 316.44 12.73 2032.53 8.77 (10) 
memantine 10.31 2.85 1.46 1.84 73.92 1.28 48.83 12.38 497.49 8.63 (11) 
octylamine 9.84 2.92 1.53 1.79 27.27 1.28 56.92 11.66 177.38 8.35 (21) 
perhexiline 10.2 3.83 3.28 1.86 244.79 1.28 3237.19 12.7 1671.65 8.76 (4), (68) 
phentermine 10.25 2.83 1.43 1.83 64.21 1.28 45.54 12.31 430.76 8.61 (66) 
piperidine 10.03 2.37 1.64 1.85 148.62 1.28 74.09 12.6 1009.79 8.71 (10) 
promazine 8.87 3.53 2.08 1.31 2.21 1.30 185.96 7.09 11.95 7.04 (64) 
propranolol 9.32 3.03 1.59 1.62 7.16 1.29 63.51 9.59 42.38 7.62 (10) 
sertraline 9.5 3.85 2.51 1.73 14.07 1.29 537.84 10.79 87.84 8.02 (64) 
thioridazine 8.61 4.01 2.61 1.11 1.27 1.31 608.81 5.96 6.80 7.02 (64) 
tributylamine 10.44 3.45 2.1 1.85 102.49 1.28 213.44 12.51 694.01 8.68 (10) 







Figure 3.1. Diagrams showing the cellular pharmacokinetic phenomena captured by 
the two mathematical models used in this study: (left) the T-Model for a leukocyte-
like cell in suspension and (right) the R-Model for an epithelial-like cell.  
Key:  
ap: apical compartment; bl: basolateral compartment; cyto: cytosol; mito: mitochondria; 
lyso: lysosome; T1: flux of the ionized/unionized form between the cytosol and the 
extracellular compartment; T2: flux of the ionized/unionized form between the cytosol 
and lysosome; T3: flux of the ionized/unionized form between the cytosol and the 
extracellular compartment; R1: flux of the ionized/unionized form between the cytosol 
and the apical compartment; R2: flux of the ionized/unionized form between the cytosol 
and the basolateral compartment; R3: flux of the ionized/unionized form between the 








Figure 3.2. Visualizing the simulated physicochemical property space occupied by 
lysosomotropic monobasic amines. Individual molecules in the test set are indicated by 
yellow dots. To discriminate between lysosomotropic vs. non-lysosomotropic molecules, 
three lysosomal concentrations were explored as thresholds: 2 mM (a-d); 4 mM (e-h); 
and 8 mM (i-l). Columns show non-lysosomotropic molecules (a, e, i); non-
lysosomotropic molecules plus lysosomotropic space (b, f, j); lysosomotropic molecules 





Figure 3.3. Visualizing the simulated physicochemical property space occupied by 
selectively lysosomotropic monobasic amines. Individual molecules in the test set are 
indicated by yellow dots. The four graphs show: (a) non-lysosomotropic molecules 
(inside blue circle) and non-selective lysosomotropic molecules (outside blue circle); (b) 
physicochemical property space occupied by selectively lysosomotropic molecules, in 
relation to non-lysosomotropic molecules (inside blue circle) and non-selective 
lysosomotropic molecules (outside blue circle); (c) selectively lysosomotropic molecules 
(inside green circle); (d) selectively lysosomotropic molecules (yellow dots in green 
circle) in relation to the union of non-selective lysosomotropic and non-lysosomotropic 





Figure 3.4. Visualizing the relationship between transcellular permeability and 
lysomotropic character. Individual molecules in the test set are indicated by yellow 
dots. The six graphs show: (a) physicochemical property space occupied by molecules 
with Peff < 1 x 10-6 cm/s, in relation to non-selectively, lysosomotropic molecules; (b) 
selectively lysosomotropic molecules with Peff < 1 x 10-6 cm/s (yellow dots) in relation to 
the union of physicochemical property spaces occupied by non-selectively 
lysosomotropic, non-lysosomotropic, and selectively lysosomotropic molecules with Peff 
> 1 x 10-6 cm/s; (c) physicochemical property space occupied by molecules with 1 x 10-6  
cm/s < Peff < 35 x 10-6 cm/s, in relation to non-selectively lysosomotropic molecules; (d) 
selectively lysosomotropic molecules with 1 x 10-6  cm/s < Peff < 35 x 10-6 cm/s in relation 
to the union of physicochemical property spaces occupied by non-selectively 
lysosomotropic, non-lysosomotropic, and selectively lysosomotropic molecules 
excluding those with 1 x 10-6 cm/s < Peff < 35 x 10-6 cm/s; (e) physicochemical property 
space occupied by molecules with Peff > 35 x 10-6 cm/s, in relation to non-selectively, 
lysosomotropic molecules; (f) selectively lysosomotropic molecules with Peff > 35 x 10-6 
cm/s in relation to the union of physicochemical property spaces occupied by non-
selectively lysosomotropic, non-lysosomotropic, and selectively lysosomotropic 
molecules with Peff < 35 x 10-6 cm/s. Green arrow point to the general region of 







Figure 3.5. Visualizing the simulated physicochemical property space occupied by 
molecules with low intracellular accumulation and high permeability. Individual 
molecules in the test set are indicated by yellow dots. The three graphs show: (a) 
molecules with low intracellular accumulation and high permeability (inside green 
circle); (b) physicochemical property space occupied by molecules with calculated low 
intracellular accumulation and high permeability (green circle same as in Figure 3.5a); (c) 
the simulated physicochemical property space occupied by molecules with high 








Figure 3.6.  Visualizing the simulated physicochemical property space of various 
classes of non-selective, lysosomotropic molecules. Individual molecules in the test set 
are indicated by yellow dots. The four graphs show: (a) fifty-six selectively 
mitochondriotropic molecules; (b) 18 lysosomotropic, molecules which are not selective 
in terms of lysosomal, mitochondrial or cytosolic accumulation; (c) the simulated 
physicochemical property space occupied by lysosomotropic molecules that are also 
selectively mitochondriotropic; (d) the simulated physicochemical property space of non-







Figure 3.7. Visualizing the effect of extracellular pH on physicochemical property 
space occupied by selectively-lysosomotropic molecules.  Simulations were carried out 
using an apical pH of 4.5 (a-c) and 6.8 (d-f) in the R-Model. Yellow dots indicate 
individual molecules in the test set. Each row shows the physicochemical property space 
occupied by molecules in different permeability classes, as follows: (a) and (d) Peff < 1 x 
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CELLS ON PORES: A SIMULATION-DRIVEN ANALYSIS OF 
TRANSCELLULAR SMALL MOLECULE TRANSPORT 
Abstract 
 A biophysical framework for modeling cellular pharmacokinetics (1CellPK) is 
being developed for enabling prediction of the intracellular accumulation and 
transcellular transport properties of small molecules using their physicochemical 
properties as input. To demonstrate how 1CellPK can be used to generate quantitative 
hypotheses and guide experimental analysis of the transcellular transport kinetics of small 
molecules, epithelial cells were grown on impermeable polyester membranes with 
cylindrical pores. The effect of the number of pores and their diameter on transcellular 
transport of chloroquine (CQ) was measured in apical-to-basolateral or basolateral-to-
apical directions, at pH 7.4 and 6.5 in the donor compartment. Experimental and 
simulation results with CQ support a cell monolayer-limited, passive diffusion transport 
mechanism.  Consistent with 1CellPK simulations, CQ mass and the net rate of mass 
transport varied <2-fold although total pore area per cell varied >10-fold. Thus, by 
normalizing the net of rate of mass by the pore area available for transport, cell 
permeability on 3µm pore diameter membranes appeared to be more than an order of 
magnitude less than on 0.4µm pore diameter membranes. Transcellular transport 
predictions remained accurate for the first four hours of drug exposure, but CQ mass 
accumulation predictions were accurate only for short CQ exposure times (5 minutes or 
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less). The kinetics and total mass of intracellular CQ indicates that CQ-induced 
lysosomal volume expansion does not fully account for the total intracellular CQ mass 
accumulation , especially in the basolateral-to-apical direction, although it can partly 
account for the gradual increase in CQ mass observed in apical-to-basolateral direction. 
 
Keywords: Systems biology; Epithelial cells; Membrane transport; Mathematical 






The cell permeability of a small molecule (Pcell) is its rate of mass transport across 
an individual cell, as a function of the transcellular concentration gradient, normalized by 
the area over which transport occurs. Pcell is an important factor affecting the distribution 
of lipophilic nutrients (e.g. fat soluble vitamins), metabolites and signaling molecules 
(e.g. prostaglandins) inside and outside cells. Pcell can also influence the effects of 
lipophilic growth factors and morphogens (e.g. retinoids) affecting cell growth, 
differentiation, and motility. At the systemic level, Pcell can also affect the synthesis, 
uptake, distribution, metabolism and activity of lipophilic hormones (e.g. estrogen, 
testosterone), as well as that of xenobiotics and drugs.(1)  Several different molecular 
mechanisms may mediate transcellular mass transport including passive diffusion across 
membranes and protein channels, ATP-dependent transmembrane carriers and transporter 
proteins, paracellular transport, and vesicle-mediated transcytosis.(2)  Independently, the 
permeability of the matrix to which the cells are attached and the patterns - size and 
microscopic distribution of aqueous pores on this matrix - could affect the routes and 
rates of mass transport across cells.(2)  
Here, we used a biophysical model (3, 4) to analyze the transcellular transport 
route of a small molecule. Certainly, cell-substratum interactions can affect cell 
morphology, differentiation, gene expression and apoptosis,(5-7) and can impose steric 
constraints to the passive diffusion of small lipophilic molecules. Hence, we tested how 
cell monolayer architecture, as well as apical-to-basolateral (AP BL) and basolateral-to-
apical (BL AP) transport routes, may be influenced by the porosity properties of the 
underlying polyester membrane film to which cells are attached. For experiments, a 
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metabolically stable small molecule drug with high lipophilicity and high solubility (CQ) 
was used as a transport probe, while varying extracellular pH in drug donor or acceptor 
compartments. Our results demonstrate how a biophysical model like 1CellPK can be 
used to guide quantitative experimental analysis of transcellular transport properties of 
small molecules, potentially providing a framework for computational ab initio 
prediction of drug ADME properties. 
Materials and Methods 
Imaging of Cells on Pores.  
Madin-Darby canine kidney (MDCK) cells were purchased from ATCC (CCL-
34TM) and maintained in DMEM (Gibco 11995) plus 10% FBS (Gibco 10082), 1X non-
essential amino acids (Gibco 11140) and 1% penicillin/streptomycin (Gibco 15140), at 
37ºC with 5% CO2. Transwell® inserts (12-well, pore size is 3µm or 0.4µm) were 
purchased from Corning Incorporated (Cat No. 3460 and 3462). For confocal 
microscopy, a Zeiss LSM 510 microscope (Carl Zeiss Inc.) was used for both membrane 
and cells imaging with a 60X water immersion objective. Inserts (with or without cells) 
were put directly in the wells of two-well Lab-Tek®II chamber #1.5 coverglasses (Nalge 
Nunc International Corp., Naperville, IL) for imaging. Cells were pre-stained with 5 
µg/mL Hoechst 33342 (Molecular Probes H3570) for 30 minutes. LysoTracker® Green 
DND-26 (LTG, Molecular Probes L7526) and MitoTracker® Red (MTR, Molecular 
Probes M7512) were diluted with transport buffer (HBSS, 10mM HEPES, 25mM D-
glucose, pH 7.4) to 2.5 µM and 1 µM respectively. The insert with cells was put onto the 
Lab-Tek®II chamber’s cover glass. 1.5 mL of diluted dyes solution was added into the 
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chamber, and 0.5 mL of dyes free transport buffer was added into the apical compartment 
of the insert. After 10 minutes, the cells on the insert were imaged with the confocal 
microscope using enterprise laser (364 nm), argon laser (488 nm), helium neon 1 laser 
(543 nm) and the corresponding emission filters (BP 385-470, BP 505-530, and LP 560).  
Polyester Membrane Permeability Analysis.  
Polyester membranes without pores were purchased from AR Brown-US (One 
Oxford Centre 301 Grant Street, Ste: 4300, Pittsburgh, PA) and glued on the 12-well 
Transwell® inserts using ELMER’s instant glue. Trypan blue was used to test the leakage 
of the edges. Transport experiments of CQ and LY (Lucifer yellow, Sigma L0144) were 
performed at 8 different initial concentrations ranging from 0 to 7500 µM.  
Permeability Measurements of CQ on Membranes with MDCK Cells.   
Cells were seeded on Transwell® inserts (12-well, polyester membranes with 3µm 
or 0.4µm pores) with density at least 2×105 cells/cm2 for 1 or more days to form a 
monolayer. Transepithelial electrical resistance (TEER) values were measured both 
before and after transport experiments by Millipore Millicell® ERS. Cell monolayers 
were considered intact if both TEER values (background subtracted) were higher than 
100 Ω·cm2. CQ diphosphate (Sigma C6628) was dissolved in transport buffer, HBSS 
(Sigma H1387) without phenol red and sodium bicarbonate, supplemented with 25 mM 
D-glucose (Sigma G7021) and buffered with either 10 mM HEPES (pH 7.4) or 10 mM 
MES (pH 6.5). Inserts with cell monolayers were washed with drug free transport buffer 
(pH 7.4) twice, and then incubated for 20 minutes with 0.5 mL/1.5 mL transport buffer in 
apical/basolateral compartment (pH 7.4/7.4) respectively. After measuring TEER values, 
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0.5 mL/1.5 mL of CQ solutions (concentration ranges from 0-10 mM, pH 7.4 or 6.5) was 
added into the apical/basolateral compartment and 1.5 mL/0.5 mL of drug free buffer (pH 
7.4) was added into basolateral/apical compartment. 0.75 mL/0.4 mL of the donor 
solutions was taken out and replaced with the same volume of drug free transport buffer 
(pH 7.4) every 30 minutes. Transport experiments were performed at 37 ºC with shaking. 
Transport experiments were ended 4 hours after starting and both apical and basolateral 
solutions were collected for analyses. Every insert was washed twice with fresh buffer 
and TEER values were measured again. CQ concentration was determined with a 
standard curve, by absorbance measurement at 343 nm wavelength using a BioTek 
Synergy 2 plate reader (BioTek Instruments, Inc.).  
Intracellular CQ Mass Measurements.  
Cells on membrane inserts were quickly washed with buffer and then lyzed 1% 
Triton X-100 in transport buffer (pH7.4, 1.5 mL) for 1.5 hours following 5 minutes to 4 
hours CQ transport experiments in transwell inserts. CQ uptake was measured with 1mM 
concentration in the donor compartment The lysis solutions were centrifuged at 12,000 
rpm for 8 minutes. CQ concentration was measured with the aid of a standard curve, by 
absorbance at 343 nm wavelength using BioTek Synergy 2 plate reader. To normalize the 
intracellular mass by the density of cells on membranes, cell counts were performed by 
staining the cells on inserts with Hoechst dye. Cells were then imaged by Nikon 
TE2000S epifluorescence microscope using a 20X objective at DAPI channel. At least 
five 12-bit images were taken for every insert. Cell counts were automated with an 
imaging algorithm programmed in Metamorph® software (Molecular Devices 
Corporation, Sunnyvale, CA).  
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CQ Binding Measurements.  
Inserts were incubated with 1 mM CQ (pH 6.5 and pH 7.4) for 4 hours. Then 
inserts were washed with buffer for twice and incubated with 1.5 mL 1% Triton X-100 
for 1.5 hours. The solution was centrifuged at 12,000 rpm for 8 minutes and CQ 
absorbance in the supernatant was measured at 343 nm and the concentration established 
with a standard curve. In order to measure the binding of CQ to MDCK cells, cells were 
permeabilized with 60 µg/mL digitonin in HBSS-HEPES buffer (pH 7.4) or 1% Triton 
X-100 for 5 minutes on ice. Cells then were stained with trypan blue and checked under 
microscope to ensure that more than 95% cells were permeabilized with digitonin or 
Triton X-100 based on the appearance of stained nuclei. Cells were diluted with buffer 
and the same volume of CQ solutions (pH 7.4) were added into cell solutions. The 
mixture solutions of cells and CQ were incubated at 4ºC for 4 hours. The cells were 
centrifuged at 12,000 rpm for 8 minutes and the supernatant’s CQ absorbance was 
measured at 343 nm. CQ concentration in the supernatant was then calculated with a 
standard curve. The difference of the initial CQ mass and the final CQ mass in the 
supernatant was used as a measure of CQ binding to cells. 
Assessment of CQ Metabolism in MDCK Cells.  
A 1200 Series HPLC system (Agilent Technologies, Santa Clara, CA) coupled 
with a QTRAP 3200 mass spectrometer (Applied Biosystems, Foster City, CA) was 
employed for chemical analysis. Separation was performed on a Zorbax RX–C18 column 
(5 µm, 150 mm × 2.1 mm) (Agilent Technologies, Santa Clara, CA). The isocratic elution 
profile was 35% (v/v) of aqueous solution containing 5 mM ammonium acetate and 0.1% 
formic acid and 65% (v/v) of MeOH, maintained for 2.5 minutes. The flow rate was 1 
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mL/min and injection volume was 10 µL. An electrospray ionization source was used 
under positive ionization mode. Multiple reaction monitoring (MRM) scan was employed 
and ion transition is m/z 320.2→247.2. Data acquisition and processing were performed 
using Analyst® software (Applied Biosystems, Foster City, CA). To construct the linear 
calibration curves, the mixed working standard solutions at each concentration (0, 51, 
102, 204, 408, 816, 1020 ng/mL) were injected in triplicate. A 30 minutes gradient 
elution (the percentage of MeOH increased from 10% to 90% in 16 minutes and then 
maintained at 90% for additional 4 minutes and dropped to 10% at 21 minutes and 
maintained at 10% for another 9 minutes) and a full scan (m/z 150-500) were used to 
detect any possible metabolites of CQ. The MS parameters for full scan were similar with 
those of MRM scan except that CE is decreased to 20 units. The product ions of 
protonated CQ at m/z 179.1 and 247.1 were selected as the daughter ions for two 
precursor scans to detect the possible metabolites which also generate a product ion at 
m/z 179.1 or 247.1 or both of them. The scan range is m/z 150-800 and CE is 51 units. 
All the other LC and MS parameters of precursor scans were the same as those of full 
scan. Furthermore, based on a literature search,(8-10) 34 previously reported 
biotransformation processes were considered for CQ, such as mono- (+16 Da), di- (+32 
Da), trihydroxylation (or oxidation) (+48 Da), dehydrogenation (-2 Da) and oxidative 
dechlorination (-18 Da). The 4 most abundant product ions (m/z 247.1, 179.1, 142.2 and 
86.1) of protonated CQ were selected to generate 272 MRM scan channels by using 
Metabolite ID software (Applied Biosystems, Foster City, CA). With this method, no 
significant metabolism was detected through any one of the 34 possible CQ 
biotransformation processes.  
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Modeling CQ Transport.  
In 1CellPK (3, 4) we modeled five compartments: apical, cytosolic, mitochondria, 
lysosomes, and basolateral compartment. Simulations consider compartment volumes, 
pH, and membrane potential, and areas as constant.  Equations 4.1-4.4 are the 
concentration changing over time in each compartment express by net fluxes (J).  
, , , ,
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c c l c
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,    (4.4) 
In the above equations, C indicates the total concentration, J indicates the flux, A and V 
indicate the membrane surface area and volume respectively. The subscripts a, c, m, l, 
and b indicate apical compartment, cytosol, mitochondria, lysosomes, and basolateral 
compartment respectively. The directions of fluxes are indicated by the orders of the 
subscripts, e.g. Jc,m represents the flux from cytosol to mitochondria. Equation (4.1) to 
(4.4) expressed apical to basolateral transport. Basolateral to apical transport can be 
easily derived. A molecule with two ionizable groups can be an ampholyte, a diacid or a 
dibase. In the case of CQ, it is a bivalent base and the pKa values of the two ionizable 
groups are 7.47 and 9.96 calculated by ChemAxon®. Three main species exist in 
solutions with pH ranging from 0 to 14, the neutral form, ionized forms with one positive 
charge or two positive charges (Table 4.1). Thus the total flux across each membrane is 
contributed by those three species freely dissolved in solutions.  
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Considering membrane permeation as the main rate limiting step governing the 
intracellular distribution and transcellular transport of CQ, mass transport across the 
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where, subscripts o and i indicate outer- and inner- respectively. o could be a, b and c; i 
could be a, c, m, l, and b. Subscripts n, d1, and d2 indicate neutral form, ionized form 
with one charge, and ionized form with two charges, respectively. P represents the 
permeability across the bilayer membranes of each species and can be calculated from 
lipophilicity (logP) of that species (11, 12); f is the calculated activity coefficient of each 
species that can be calculated as described previously (11, 12); N = zEF/(RT), where z = 
+1 for Nd1 (ionized base with one charge), and z = +2 for Nd2 (ionized base with two 
charges); E, F, R, and T are membrane potential, Faraday constant, universal gas 
constant, and absolute temperature, respectively. Calculated logP values are 3.93, 0.43, 
and -0.91 for the neutral form, ionized form with one charge, and ionized form with two 
charges, respectively (Table 4.1), as calculated by ChemAxon®. After plugging in all 
parameters on the right hand of equation (4.1) to (4.4), the ordinary differential equations 
can be numerically solved. Once the concentration in the receiver compartment is 








,  (4.6) 
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Where, Cr and Vr are the concentration in the receiver compartment and volume of the 
receiver compartment respectively; Apore is the pore area underneath one cell; and Cd is 
the initial concentration in the donor compartment. The effective permeability can be 










Where, cellNo is the total cell number per insert, and Ainsert is the total area per insert. 
Monte Carlo Simulations.  
Monte Carlo simulations were performed with MATLAB®.  In 1CellPK the input 
parameters can be categorized into biological parameters and physiochemical parameters 
of the compounds. Physicochemical properties of CQ that used as input parameters are 
lipophilicity of neutral form and ionized forms with one or two charge (logPn, logPd1 and 
logPd2), and pKa values of two ionizable groups (pKa1 and pKa2). Biological parameters 
were apical membrane area (Aa), basolateral membrane area (Ab), mitochondrial 
membrane area (Am), lysosomal membrane area (Al), cytosolic volume (Vc), 
mitochondrial volume (Vm), lysosomal volume (Vl), volume of the receiver compartment 
(Vb for AP  BL transport and Va for BL  AP transport), pH value in the donor 
compartment (pHa for AP  BL transport and pHb for BL  AP transport), pH value in 
the receive compartment (pHb for AP  BL transport and pHa for BL  AP transport), 
pH value in mitochondria and lysosomes (pHm and pHl), apical membrane potential (Ea), 
basolateral membrane (Eb), mitochondrial membrane potential (Em), lysosomal 
membrane potential (El), lipid fraction in cytosol (Lc), mitochondria (Lm), and lysosomes 
(Ll), cell density, and pore density. Independent Monte Carlo simulations were performed 
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for pH 6.5 and pH 7.4, on 0.4µm- and 3µm- membranes, and in AP  BL and BL  AP 
transport directions. For each condition, 10,000 simulations were performed. In each 
simulation parameters were randomly sampled from uniform distributions (Table 4.2).   
Lipophilicity (logP) values for both neutral and ionized forms of CQ varied ± 0.5 log 
units based on weighted method prediction provided by ChemAxon®. Boundaries of 
lysosomal volume were determined based on experimental measurements.  Details of the 
calculations are described in legend of Table 4.2.  
Measurement of Lysosomal Volume Changes.  
MDCK cells were seeded on 96-well optical bottom glass-based plates (NuncTM Cat. 
164588) at the density of 1×105 cells/cm2 and let grown for 1 or 2 days in 150 µL fully 
supplemented DMEM. CQ diphosphate was dissolved in DPBS buffer (Gibco 14190) to 
a final concentration of 50 mM and diluted in cell culture medium to 50 µM.  Cells were 
incubated with 150 µL DMEM-CQ for 3.5 hours. LTG was added to CQ-treated and 
untreated cell culture to a final concentration of 0.5 µM for another 30 minutes 
incubation.  For fluorescence microscopy, a Nikon TE2000S microscope with a 100X oil 
immersion objective was used to image the lysosomes using the FITC filter set. Image 
analysis was carried out with MetaMorph® software. In calibration experiments, we 
determined this system could accurately resolve and measure objects >200 nm diameter, 
using fluorescent bead standards (Molecular Probes T14792) ranging from 100 to 4000 
nm diameters. We also determined the objective was capable of capturing fluorescent 
signals within 2 µm vertical spaces. For analysis, images were background subtracted, 
and each individual lysosome vesicle of each individual cell was manually outlined with 
the Circular Region Tool. Next, assuming spherical shape, the diameter of each 
 
135 
individual lysosome was estimated from the area of the regions. Because the height of 
cell monolayer was estimated to be 5-10 µm (Figure 4.1) and the depth of the focal plane 
is in the order of 2 µm , the total number of lysosomes associated with one cell was 
calculated by multiplying the region count by a factor of 2.5. The average diameter and 
total number of lysosomes in treated and untreated cells was calculated as the average 
value of those acquired from at least 5 images under the corresponding condition.  
Lysosomal pH Measurements.  
MDCK cells were seeded on 96-well optical bottom polymer-based plates 
(NuncTM Cat. 165305) at the density of 1×105 cells/cm2 and let grown for 1 to 2 days in 
150 µL fully supplemented DMEM. FITC-dextran (FD, Sigma FD150S) was dissolved in 
DPBS buffer to a final concentration of 10mg/mL and diluted in cell culture medium to 
0.2 mg/mL. Cells were incubated with 150 µL DMEM-FD for 24 hours to allow cell 
uptake of FD via endocytosis. To measure lysosomal pH during 50 µM CQ treatment, 
cells were washed twice with 100 µL DPBS buffer before incubation in 150 µL FD-free 
medium with or without CQ. At the end of 1 to 4 hours incubation, cells were washed 
with 100 µL DPBS buffer twice, immersed in 150 µL buffer, and scanned for fluorescent 
signal with BioTek Synergy 2 plate reader using Ex.485/20 and Em.528/20 filter set as 
well as Ex.450/50 and Em.528/20 filter set. For pH standard curves, FD pretreated cells 
were washed with 100 µL DPBS buffer twice, immersed in 150 µL DPBS-based 
solutions (pH 3 to 10) with 10 µg/mL Nigericin (Sigma N7143), let equilibrate for 10 
minutes and scanned for fluorescent signal with the same settings. Background 
fluorescence from MDCK cells without FD treatment was also recorded after wash. The 












=  (4.8) 
where F485i and F450 i standard for integrated fluorescent intensity from the ith well of 
cells under Ex.485 nm and Ex.450 nm, respectively, and subscript bg indicates 
background fluorescence signal without FD treatment. FR values were plotted against 
known pH values to create a standard curve, or compared with the standard curve to 
calculate the lysosomal pH. 
Results 
Microscopic Analysis of Cells on Polyester Membranes.  
Optically-transparent track-etched polyester membranes of similar membrane 
thickness (~10 µm) were used for experiments. The fractional pore area of the 3µm-
membranes was about 28 times higher than the 0.4µm-membranes based on the 
manufacturer’s specification, and >10 times higher based on our measurements (Figure 
4.1). TEER values of 0.4µm-membrane was similar to that of 3µm-membranes (mean ± 
SD: 126 ± 8 vs. 118 ± 9 Ω·cm2, n = 8; p value = 0.0784). MDCK cells grown on 
polyester 0.4µm- or 3µm-membranes formed regular monolayers (Figure 4.1). No 
difference in monolayer architecture was visually apparent on 0.4µm- and 3µm-
membranes. TEER value of cells grown on 0.4µm- membrane was higher than on 3µm-
membrane (mean ± SD: 221 ± 16 vs. 117 ± 16 Ω·cm2, n = 48, background subtracted; p 
value < 10-4). This behavior can be explained by the difference in pore area available for 
transport or by differences in tightness of intercellular junctions. Seeded at the same 
density (2×105cells/cm2) and grown for two days, the cell number on 0.4µm-membrane 
 
137 
was slightly higher than the cell number on 3µm-membrane (mean ± SD: 4.9×105 ± 
6.4×104 vs. 3.9×105 ± 4.5×104, n = 8), which almost corresponded to the difference in 
surface area available for cell attachment (Figure 4.1). We did not observe any MDCK 
cells migrating through the pores.  
CQ Transcellular Transport Is Nonsaturable and Directly Proportional to the 
Transcellular Concentration Gradient.  
CQ and Lucifer Yellow (LY) transport across polyester membranes without pores is 
negligible: in the absence of pores, the amount of CQ or LY in the receiver compartment 
was undetectable after a 6 hour transport experiment (data not shown). Therefore, 
transport of small molecules across cell monolayers on nucleopore polyester membranes 
is driven primarily by the flux of molecules through the pores (not through the polyester 
film). On 0.4µm- and 3µm-membrane, CQ mass transport rate linearly correlated with 
the initial concentration in the donor compartment at pH 7.4 or 6.5, both over low 
concentration range (Figure 4.2) and even at higher concentrations (data not shown). The 
intercepts of the regression lines were all zero, after statistical testing for the intercept 
values. LY, a hydrophilic, cell membrane-impermeant small molecule, was used as a 
control probe to assess paracellular transport. Average apparent permeability of LY (AP 
 BL) was 0.70 ± 0.33 nm/sec (mean ± SD, n = 27) and 1.7 ± 2.1 nm/sec (mean ± SD, n 
= 23) measured on MDCK cells grown on 0.4µm- and 3µm-membranes, respectively (p 
value = 0.0273) with an apical pH value of 7.4. This is consistent with LY transport 
occurring mostly through a paracellular route. The Papp of CQ was approximately two 
orders of magnitude greater than the Papp of LY. We conclude that CQ traverses MDCK 
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cells mainly through a transcellular pathway, with the rate of transport being directly 
proportional to the concentration gradient in either AP  BL or BL  AP directions.  
Effects of pH and Pore Geometry on CQ Transport Routes and Cellular Uptake in 
AP  BL or BL  AP Directions.  
Comparing cells on 3µm- or 0.4µm-diameter pore membranes was used to study 
how differences in the porosity of the substratum can affect the transport route small 
molecules through epithelial cells (Figure 4.2). Comparing the regression coefficients, if 
the other conditions are the same (such as the pH and the transport direction), the mass 
transport rate of CQ on 3µm diameter pore membranes was only slightly greater (< 2-
fold) than on 0.4µm-membranes. However, the total pore area of the 3µm diameter pore 
membranes is >10-fold greater than that of a 0.4µm-membrane. If Pcell was an intrinsic, 
invariant property of the cells, one would have expected the mass transport rate to be 
directly proportional to the total pore area available for transport. Thus, Pcell is greatly 
affected by the porosity of the substratum. 
CQ is a weak base, with two amine groups that can be protonated within 
physiological pH values. The fraction of CQ with two charges is higher at pH 6.5 relative 
to pH 7.4 (Table 4.1). Conversely, the proportion of neutral CQ species is higher at pH 
7.4 than at pH 6.5. Consistent with transmembrane transport being a function of the 
charge and lipophilicity of CQ, the pH of the donor compartment exerted a major effect 
on CQ transcellular transport rate (Figure 4.2) with the rate of transport at pH 7.4 being 
seven times greater than that at pH 6.5, as expected based on transmembrane diffusion 
being the rate limiting step of CQ transport across cells. 
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For CQ, the BL  AP transport rate is only slightly higher than AP  BL 
transport rate for the same pH values and same membranes. Linear relationship of 
transport rate with initial concentration in the donor compartment was observed as well. 
Thus, unidirectional active transport mechanisms cannot be invoked to explain CQ 
transport across MDCK cells. Overall, the experiments are consistent with passive 
diffusion and transmembrane gradients being primarily responsible for driving the bulk 
of CQ transport across MDCK cells. 
During transport experiments, intracellular mass accumulation of CQ was linearly 
correlated with the initial concentration when the concentration in the donor compartment 
was lower than 1 mM and reached a plateau when the concentration in the donor 
compartment was higher (Figure 4.3) after 4 hours exposure to the drug. This plateau was 
related to cytotoxicity of CQ at high concentrations, apparent as nuclear shrinkage, 
chromatin condensation and cell monolayer disintegration (Figure 4.4). At pH 6.5, the 
CQ accumulation plateau is reached when the apical concentration is higher than 8 mM 
for AP  BL transport (Figure 4.3A); however the plateau is reached when the 
basolateral concentration is higher than 2 mM (Figure 4.3B). When the pH is 7.4, the 
plateau is reached when the concentration in the donor compartment is higher than 1 mM 
for both AP  BL and BL  AP transport (Figure 4.5C and 4.5D). This pH sensitivity 
of the intracellular accumulation is consistent with higher CQ lipophilicity at higher 
apical pH values, leading to greater influx from the donor compartment into the cytosol, 
and presumably, higher cytosolic concentration. Comparing AP  BL transport with BL 
 AP transport for the same conditions, the intracellular accumulation is similar for pH 
6.5 and pH 7.4 (Figure 4.5). Intracellular accumulation of CQ on 3µm-membranes and 
 
140 
0.4µm- membrane is similar for the same conditions (Figure 4.5), except for BL  AP 
transport when pH = 7.4 (Figure 4.5D) where it is slightly different (which could be due 
to an experimental measurement outlier, evident in the larger error bars).   
Simulation-Driven Quantitative Analysis of CQ Transport and Uptake.   
Monte Carlo simulations were used to assess the effect of measurement variability, 
experimental errors and other uncertainties in the input variables of the 1CellPK model, 
on the calculated mass transport rate (dM/dt; Figure 4.5A) , Pcell (Figure 4.5B),  Papp, 
(Figure 4.5C ) and intracellular mass accumulation (Figure 4.5D). Because of the 
observed toxicity occurring upon 4h exposure to CQ (Figure 4.3 and 4.4) mass 
accumulation of CQ was measured after 5 minutes incubation with 1mM CQ in the donor 
compartment.  Results showed that CQ uptake after 5 minutes incubation (Figure 4.5D, 
red lines) is much lower than that after 4 hours transport experiment (Figure 4.3) under 
the same conditions. 
For simulations, the apparent permeability (Papp) was calculated from measured 
dM/dt by normalizing over the initial concentration in the donor compartment and the 
total insert area.  Unlike Pcell measurements which normalize mass transport rate over the 
aqueous pore area of the polyester membrane, Papp measurements normalize the mass 
transport rate over both pore and non-pore regions of the polyester membrane. 
Comparing permeability normalized by the pore area (Pcell; Figure 4.5B, red lines) with 
the permeability normalized by total insert area (Papp; Figure 4.5C, red lines), Pcell of CQ 
on 0.4µm-membrane is at least an order of magnitude higher than that on 3µm-
membrane. However, Papp of CQ on 3µm-membrane is only slightly higher than on 
0.4µm-membrane (<2-fold). Per cell, the total pore area on 3µm-membrane is more than 
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an order of magnitude greater than on 0.4µm-membrane. Arguably, Pcell most accurately 
reflects a difference in the actual flux of CQ molecules across the basolateral membrane 
of cells on 0.4µm- vs. 3µm-membrane, at the single cell level. Most importantly, for 
dM/dt, , Pcell, and Papp, most of measured values fall between 10% and 90% quantiles of 
simulated distributions, and very close to the median (Figure 4.5A-C and Table 4.3).  
Simulations also capture the CQ uptake after 5 minutes incubation for AP  BL 
transport (Figure 4.5D, rows 1 – 4 and Table 4.3), although measured CQ uptake in the 
BL  AP direction was greater than predicted by the model (Figure 4.5D, rows 5 – 8 and 
Table 4.3). 
Probing the Mechanisms of Mass Accumulation upon Prolonged CQ Exposure.   
Although the initial input parameters for the simulations yielded dM/dt, Pcell, Papp values 
and CQ uptake after 5 minutes incubation consistent with experimental measurements, 
they consistently underestimated the intracellular mass of CQ after 4 hours transport 
experiment (Figure 4.7A).  Based on the simulation, intracellular CQ mass should reach 
steady state levels by 5 min incubation, but this was not observed experimentally (Figure 
4.7A).  We also found that binding of CQ to detergent-extracted (triton-treated) or 
permeabilized (digitonin-treated) cells was much lower than its measured cellular uptake 
at 37ºC (Figure 4.6). Measurements on triton-extracted cells indicated that the high, 
measured intracellular CQ mass was not due to DNA binding or to absorption to 
insoluble proteins or cytoskeletal elements. CQ binding to digitonin-permeabilized cells 
is similar to that of triton-extracted cells, so CQ binding to soluble proteins, to 
intracellular membranes or to lipid droplets cannot account for the missing intracellular 
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mass. Biochemical analysis with LC/MS reveals no metabolites of CQ, with all the 
intracellular CQ present in intact form (data not shown).  
CQ is a weakly basic molecule that accumulates in lysosomes through an ion 
trapping mechanism dependent on the acidic microenvironment (pH 4.5 to 5.5) of 
lysosomes. CQ incubation gradually expanded the lysosomal compartment in MDCK 
cells (Figure 4.7B).  The average number of lysosomes per cell was slightly lower in CQ-
treated cells as compared with untreated cells: 200 ± 35 (n = 6) vs. 253 ± 45 (n = 5) 
(mean ± SD, p-value = 0.059). However, the diameter of lysosomes is significantly 
increased in treated cells in comparison with untreated cells: 1.74 ± 0.19 µm (n = 6) vs. 
0.50 ± 0.03 µm in untreated cells (n = 5) (mean ± SD, p-value = 7.8E-12). The total 
lysosomal volume is 16.5 µm3 in untreated cells and 551.4 µm3 after 4 hours treatment 
with 50 µM CQ.  Overall, there was a 33.5-fold increase in the total lysosomal volume.  
The measured lysosomal pH of untreated cells was 5.03 ± 0.18 (mean ± SD, n = 4) and 
the lysosomal pH of CQ-treated cells slowly increased from 5.2 ± 0.2 at 1 hour 
incubation to pH 6.0 ± 0.3 at 4 hour incubation (mean ± SD, n = 6).   
Given that CQ exposure alters the lysosomal volume and pH over a 4 hour period, 
simulations were repeated with an average lysosomal pH value of 5.5 and an expanded 
lysosomal volume (Figure 4.7C). The experimental measured intracellular mass 
accumulation of CQ was extrapolated down to 50 µM CQ using the regression equations 
in Figure 4.3 for different conditions. After taking lysosomal swelling and pH increase 
into account, the predicted intracellular CQ mass is closer to experimental measurement 
for AP BL transport with pH 7.4 in apical compartment. However, in BL AP 
transport, the measured intracellular accumulation of CQ still exceeded the simulated 
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distributions by more than an order of magnitude, at least as much as was observed 
during the shorter, 5 minutes exposure (Figure 4.5D). 
Discussion 
In this study, a mathematical model (11-13) was employed to analyze the 
transport route of CQ across an MDCK monolayer, while studying how extracellular pH, 
substratum porosity, and transcellular concentration gradients affected the drug’s 
transport behavior.  In the computational simulations, pore size and density effects on 
Pcell can be largely accounted for as a steric constraint on the basolateral membrane 
surface area (Ab) and the effective cell cross sectional area (Aaa) over which flux 
effectively occurs. Biological variability, experimental errors, and other uncertainties 
(such as the effective basolateral surface area over which transport takes place, and the 
absolute concentration and permeability of different ionic species of CQ at any given pH) 
may lead to variations in experimental measurements and predictions. Monte Carlo 
simulations were used to account for parameter variations and uncertainties in input 
variables, yielding probabilistic distributions of 1CellPK results that were reasonably 
accurate with respect to experimental measurements.  
In the 1CellPK model, CQ is postulated to undergo very fast (instantaneous) 
mixing within the each subcellular compartment, with the transport of CQ across cellular 
membranes being the rate-limiting step determining the net rate of mass transport across 
the cell monolayer.  Both simulations and experiments are consistent with CQ traversing 
MDCK cell monolayers via a passive, transcellular membrane-limited diffusion route. 
However, discrepancies between CQ uptake measured after 4 hour incubations and model 
predictions point to a physiological mechanism responsible for the gradual intracellular 
 
144 
mass accumulation of CQ that is not captured by the model.  Experimentally, CQ 
accumulated intracellularly to a level higher than expected by lipid partitioning, 
macromolecular binding, ion trapping or membrane potential dependent sequestration in 
cytosol, lysosomes or mitochondria –all of which were included in the 1CellPK model or 
were controlled for in the experimental measurements. Other amine-containing molecules 
also accumulate to very high concentrations inside cells(14). CQ induced a gradual but 
significant increase in lysosomal volume in MDCK cells.  
One of the limitations of 1CellPK is that the compartment volumes, pH, 
membrane potentials are fixed and constant from the start of the simulations.  Thus 
gradual biological effects of a drug on cell physiological parameters are not readily taken 
into account.  Nevertheless, by using an expanded lysosomal volume (and an increased 
lysosomal pH) as input, simulations revealed that this lysosomal volume change can 
account for a significant increase in the total intracellular CQ mass especially in the AP 
 BL with pH 7.4 (Figure 4.7C). In BL  AP direction, the volume expansion cannot 
fully account for the additional mass, so an unknown factor affecting higher-than-
expected BL  AP mass sequestration remains to be identified. Another plausible reason 
that leads to under-prediction could be missing of cations and acidic phospholipids 
interactions, which could be dominant for moderate to strong basic drugs (15) because 
the ionic species are the major forms at physiological pH. In order to test how the 
electrostatic interactions would affect predictions, the lipid partitioning coefficient for 
ionic species, logKd = 2.3, was used in Monte Carlo simulations in stead of logPd1 = 0.43 
and logPd2 = -0.91 in equation 2.17.  LogKd was estimated using digitonin experiments 
data as the following: (1). Get the slopes of pmol/cell vs. CQ concentration in 
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the supernatant. Pool them together and the mean = 1.0×10-5 (pmol/cell : µM); (2). 
Assume cell volume = 103 µm3 and lipid fraction = 5% in each compartment. (3). Kd = 
Ccell pellet:CQ in supernatant = 1.0×10-5 / (1000×5%) ×109 = 190, thus logKd = 2.3.  
Comparison of simulation and experimental measurement of intracellular accumulation 
of CQ after 4 hours accumulation is shown in Figure 4.8. After considering the 
electrostatic interactions, predictions for AP  BL intracellular uptake are close to 
measurements (red lines) after 4 hours simulation.  After considering the electrostatic 
interactions, lysosomal swelling effects, and intralysosomal pH increment, predictions are 
close to measurement for all conditions.  Thus our hypothesis is that under-prediction 
could be explained by missing of interactions between cations and acidic phospholipids. 
And the experiments will be designed to measure the partitioning of cations into acidic 
phospholipids.  
As related to drug discovery and development, permeability measurements, 
including in vitro, in situ, and in vivo methods are low throughput and costly.(16-18) 
Permeability assays on cell monolayers are usually done in vitro, growing cells on semi-
permeable support membranes, and monitoring the rate of mass transport across the 
membranes, through time.(19-21) Cell permeability measurements often show huge 
variability between laboratories.(22, 23) and many factors have been proposed to 
contribute to these experimental variations.  Indeed, mathematical models are being 
increasingly used to facilitate empirical interpretation of cell-based transport mechanisms 
(24, 25). The ability to make predictions by using a molecule’s physicochemical 
properties (e.g. logP and pKa) as input may allow 1CellPK to be applied at the earliest 
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phases of drug development, to facilitate the rational design of drug candidates with the 
most desirable, cellular pharmacokinetic characteristics (3, 4, 13). 
To conclude, although the interplay between the physicochemical properties of 
small molecules and their cellular transport and disposition mechanisms are complex, 
they can be analyzed quantitatively with the aid of mathematical models.(13),23, 24  As our 
analysis demonstrates, 1CellPK is a good starting point for formulating mechanism-
based, quantitative hypotheses to guide additional experimental design to further refine 
our understanding of transcellular transport and subcellular distribution in the presence of 
a transcellular concentration gradient. The 1CellPK model can capture the effects of cell 
biological variables (pH values in donor and receiver compartment, pore size and density 
of the support filter, transmembrane concentration gradients, organellar volumes and pH) 
on small molecule transport mechanisms.  To test 1CellPK, cells on pores can be used to 
manipulate intracellular transport routes of small molecules while minimally perturbing 
cellular biochemistry. In future experiments, more precise patterning of pore number and 
geometry should allow more detailed exploration of the phenotypic effects of spatial 
gradients of small molecules inside individual epithelial cells in a monolayer. In addition, 
with the Michaelis-Menten equation, transporters or enzymatic mechanisms can be 





Table 4.1.  Calculated distribution and logP values for each microspecies of CQ at 
pH 6.5 and pH 7.4, used as input for 1CellPK.  The numbers 7.47 and 9.96 correspond 











3.93 0.00 0.04 
 
0.43 5.49 31.55 
 




Table 4.2.  Parameter ranges for Monte Carlo simulations. 
 logPn  [3.43,  4.43] 
 pKa1 [9.46, 10.46]  
 pKa2 [6.97, 7.97] 
 logPd1 [-0.07,  0.93] 
 logPd2 [-1.41,  -0.41] 
 cell number / insert [ 2×105, 4×105] 
 pore density 
(pore number / cm2) 
[ 3.2×106, 4.8×106] for membranes with 0.4µm pores 
[ 1.6×106, 2.4×106] for membranes with 3µm pores 
 Aa (µm2) [100, 1000]  
 Ainsert (cm2) 1.12 
 Apore (µm2) 
insert





 Ab (µm2) [Apore, 100]  
 Vc  (µm3) [500, 3000]  
b Vl (µm3) [9.24, 23.8] / [196.5, 906.3] 
 Vm (µm3) [10.48, 262]  
a Al (µm2) 314 
a Am (µm2) 314 
a Vb (µm3) 1.5mL for AP->BL transport, volume of donor compartment 
0.5mL for BL->AP transport, volume of donor compartment 
 Ea (mV) [-14.3, -4.3]  
 El (mV) [5, 15] 
 Eb (mV) [6.9, 16.9] 
a Em (mV) -160mV 
 pHc  [7.0, 7.4] 
c pHl [4.8, 5.2] /  [4.63, 6.37] 
 pHm [7.8, 8.2] 
 pHa  [7.0, 7.4] for pH=7.4 in the donor compartment 
[6.4, 6.6] for pH=6.5 in the donor compartment 
 Lc [0.05, 0.15]  
 Lm [0.05, 0.15]  
 Ll [0.05, 0.15]  
a pHa/b  7.4; pH value in the receiver compartment 
 
a indicates parameters that do not influence permeability or intracellular accumulation 
calculations shown by performing parametric studies 
 
b Uniform distribution upper and lower boundaries for lysosomal volume were calculated 
based on experimental measurement and calculated as described below.  The measured 
lysosomal volume was calculated by equation (s)E1 using measured number and 
diameter of lysosomes. 
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31( ( ) )
6l
V n dπ= × ,  (s)E1 
where n is the number of lysosomes / cell, and d is the diameter of a lysosome.  The 
average number of lysosomes per cell was 200 ± 35 (n = 6) and 253 ± 45 (n = 5) for 
treated (50µM CQ for 4hours) and untreated cells, respectively.  The diameter of 
lysosomes was 1.74 ± 0.19 µm (n = 6) and 0.50 ± 0.03 µm (n = 5) for treated (50µM CQ 
for 4hours) and untreated cells, respectively.  Thus the measured lysosomal volume was 
551.4 ± 204.9 and 16.5 ± 4.19 µm3 (mean ± SD) for treated and untreated cells, 
respectively.  The standard deviation of lysosomal volume was estimated by equation 
(s)E2 (partial derivative method for error propagation estimation) (25) assuming there is 
no correlation between n and d.  









,  (s)E2 
The equations (s)E3 and (s)E4 were applied to calculate the upper (b) and lower (a) 
boundaries of the uniform distribution of Vl. . 
1 ( )
2
mean a b= + , (s)E3 
21variance ( )
12
b a= − , (s)E4 
By plugging in the above measurement, uniform distribution [9.24, 23.8] and [196.5, 
906.3] µm3 were used for Vl for untreated and treated cells, respectively.  
 
C Uniform distribution upper and lower boundaries of lysosomal pH for Monte Carlo 
Simulations with CQ-expanded lysosomal volume (Figure 4.7) were calculated as the 
following. The measured mean value and maximum standard deviation are 5.5 and 0.5, 
respectively. Thus the variance is 0.25.  The upper (b) and lower (a) boundaries of the 
distributions were calculated from equations (s)E3 and (s)E4, which are derived for 
uniform distribution probability function.  Thus uniform distribution [4.63, 6.37] was set 
for pH in lysosomes of cells under 50 µM CQ treatment.  
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Table 4.3. Simulation and quantitative experimental data of CQ transport across 
MDCK cells on polyester membranes of varying porosity, at donor compartment 
pH 6.5 and 7.4.  The prefix ‘sim.’ indicates simulation data corresponding to 10%, 50%, 
and 90% quantiles of simulated dM/dt (10-6 pmol/sec/cell), Pcell (10-6 cm/sec), Papp (10-
6cm/sec) and intracellular mass accumulation (10-3 pmol/cell) after 5 minutes incubation, 
using the parameters in Table 4.2 (non-lysosomal swelling cells). The prefix ‘exp.’ 
indicates the experimental data.  
 
 
   pH = 6.5, 0.4µm pH = 6.5, 3µm pH = 7.4, 0.4µm pH = 7.4, 3µm 
  10% 50% 90% 10% 50% 90% 10% 50% 90% 10% 50% 90%
  A. overall effects of parameters (AP BL) 
sim.dM/dt 1.78 7.75 23.7 5.00 12.0 31.3 11.7 54.7 229 29.2 91.8 321
exp.dM/dt 2.20 ± 0.718 5.19 ± 1.01 22.8 ± 0.741 46.6 ± 6.28 
sim.Pcell 91.0 407 1264 9.26 22.6 59.7 602 2904 12401 54.1 172 612
exp. Pcell 218 ± 34.4 14.0 ± 3.33 1560 ± 161 85.9 ± 15.6 
sim.Papp 0.455 2.04 6.24 1.31 3.17 8.35 3.04 14.5 62.3 7.64 23.9 84.4
exp.Papp 1.35 ± 0.442 1.98 ± 0.471 7.85 ± 0.810 12.1 ± 2.21 
sim.mass 0.490 1.04 2.16 0.451 0.971 2.03 3.14 7.61 18.0 2.99 7.23 17.8
exp.mass 3.73 ± 0.14 1.88 ± 0.54 8.72 ± 0.94 8.90 ± 0.26 
  B. overall effects of parameters (BL AP) 
sim.dM/dt 1.70 7.42 22.9 4.88 12.0 30.9 10.7 52.9 214 27.2 84.6 309
exp.dM/dt 5.25 ± 1.24 7.12 ± 0.473 29.4 ± 1.54 63.8 ± 15.9 
sim.Pcell 85.4 390 1228 9.10 22.3 58.9 548 2767 11616 50.8 159 585
exp. Pcell 382 ± 81.7 15.8 ± 2.45 2000 ± 353 114 ± 19.0 
sim.Papp 0.439 1.96 6.19 1.28 3.13 8.18 2.77 13.8 57.4 7.11 22.4 82.3
exp.Papp 1.92 ± 0.411 2.24 ± 0.346 10.0 ± 1.77 16.2 ± 2.69 
sim.mass  0.020 0.091 0.309 0.060 0.151 0.425 0.137 0.679 2.56 0.378 1.11 3.56








Figure 4.1. Microscopic images of polyester membranes and MDCK cells grown on 
a 0.4µm-membrane. (A) shows orthogonal planes of 3D reconstructions of MDCK 
monolayers grown on a polyester membrane with 0.4 µm pores. Cells were stained with 
LTG, MTR and Hoechst and imaged as detailed in the methods. (B) and (C) show 
confocal microscope images of membranes with 0.4µm- and 3µm- pores, respectively. 
(D) and (E) are scan electron microscope (SEM) images of membranes with 0.4µm - and 
3µm- pores, respectively. The table details microscopic measurements of pore geometry, 





Figure 4.2. The relationship between mass transport rate and the initial 
concentration of CQ in the donor compartment. (A) represents AP  BL transport 
(pHa = 6.5), and (B) represents BL  AP transport (pHb = 6.5). (C) represents AP  BL 
transport (pHa = 7.4), and (D) represents BL  AP transport (pHb = 7.4). The linear 






   
 
Figure 4.3. The relationship between intracellular CQ mass and the initial 
concentration of CQ in the donor compartment. (A) represents AP  BL transport 
(pHa = 6.5), and (B) represents BL  AP transport (pHb = 6.5). (C) represents AP  BL 
transport (pHa = 7.4), and (D) represents BL  AP transport (pHb = 7.4). The linear 
regression equations shown in the table (right) were obtained by performing regressions 








Figure 4.4.  Cell images stained with DAPI after transport experiments. (A) Images 
were taken for AP BL transport. (B) Images were taken for BL AP transport. Images 
in the same row were taken for the transport experiments with the same concentration in 
the donor compartment.  Images in the same column were taken for the transport 




Figure 4.5.  Histogram plots of Monte Carlo simulations showing calculated dM/dt 
(A), Pcell (B), Papp (C), and intracellular CQ mass accumulation at 5 minutes incubation 
(D), for the various experimental conditions analyzed in this study.  The solid red lines 
indicate experimentally-measured mean values and the dashed red lines indicate 






Figure 4.6.  CQ binding experiments.  (A) The change of bound CQ mass is 
proportional to CQ concentration in digitonin-treated and triton-treated cells; (B) 
comparison of CQ binding at 4ºC (digitonin-treated and triton-treated cells) and 37ºC 
(triton-treated cells).  The values and standard deviations were calculated from the 
regression lines using CQ concentration equal to 500 or 1000 µM: for uptake at 4ºC, 
regression lines in the table of Figure 4.7A were used; for uptake at 37ºC, the regression 




Figure 4.7.  Effects of lysosomal swelling on CQ intracellular mass accumulation. 
(A) Comparison of simulated intracellular mass and experimental data at the end of a 5 
minute and 4 hour of AP BL transport experiment. 1CellPK model is capable of 
predicting CQ accumulation in MDCK cells at early time point but not after prolongued 
treatment, indicating the presence of biological changes in response to CQ treatment. The 
simulations in the panel were performed with non-swollen lysosomes. (B) Lysotracker 
Green (LTG) staining of MDCK cells treated with CQ free medium (left) and 50 µM CQ 
diluted in medium (right) for 4 hours. (C) Histograms of Monte Carlo simulation of 
lysosomal expansion and pH effect on intracellular CQ mass accumulation. All model 
parameters were kept the same as in Figure 4.5 except that the measured lysosomal 
volume and pH values were used as input (as median values of a uniform distribution, see 
legend of Table 4.2 for boundary calculation). The red lines show intracellular mass 
accumulation of CQ with initial concentration of 50 µM extrapolated from regression 
lines of experimental measurements (Figure 4.3C). The left-most histograms in each 






Figure 4.8. Histograms of log10(intracellular mass, pmol/cell). X-axis indicates 
log10(intracellular mass, pmol/cell) and y-axis indicates density.  Red solid lines indicate 
mean values of measured intracellular accumulation of CQ (pmol/cell) after 4 hours 
incubation.  The first and third column indicates simulations without lysosomal swelling 
or intra-lysosomal pH incensement. The second and fourth column indicated simulation 
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SINGLE-CELL PHYSIOLOGICALLY-BASED PHARMACOKINETIC 
(1CELLPBPK) MODELING OF DRUG DISTRIBUTION IN THE LUNG 
Abstract 
 
Purpose:  Use a computational, multiscale predictive model to explore the effects of drug 
sequestration within lysosomes and mitochondria on the uptake, accumulation, and efflux 
of small molecule drugs in rat lungs. 
Methods:  A single cell-based virtual lung model (the Cyberlung) was developed. This 
Cyberlung (including airways and alveoli) was plugged into a whole body 
physiologically-based pharmacokinetic model. Using this 1CellPBPK model, we 
explored the theoretical distribution of beta-blockers (atenolol, metoprolol, and 
propranolol). For the Cyberlung, input parameters were physicochemical properties (pKa 
and logP) of the drugs, and physiological parameters for each type of cells in the lung, 
such as intracellular pH values, cellular membrane areas, cellular membrane potential, 
cellular/subcellular organelle volumes, lipid fractions, number of cells, etc.  For the rest 
of the PBPK model, input parameters are blood flow rate to each organ, volume of each 
organ, tissue : blood partition coefficients (Kp) for each drug in each organ, and clearance 
rate.  Tissue distribution data were obtained from different published research articles to 
validate models. Differential equations were solved numerically using Matlab® . 
 
162 
Results:  For all three drugs, the model predicts lung distribution kinetics close to 
experimental measurements (atenolol and propranolol) or experimentally measured Kp 
for the lung (metoprolol).  If subcellular organelles (lysosomes and mitochondria) are 
included the drug accumulation in the lung will be increased, but not significantly, due to 
the small volume of lung.  The volume and lipid fraction of mitochondria or lysosomes in 
the lung has a minimal effect on the systemic drug concentration in blood.  
Conclusions:  Weak basic molecules show significant sequestration in acidic subcellular 
organelles at cellular level. However, at tissue level, subcellular sequestration contributes 
to increment of drug distribution in the lung but not significantly, because the relative 
volume fraction of subcellular compartment is small.  Successful integration of a single-
cell based Cyberlung model with a whole-body PBPK model constitutes an important 
step towards ab initio single-cell based predictive modeling of drug pharmacokinetics at 
the whole body level. 
 
Keywords: Cellular pharmacokinetics; Physiologically-based pharmacokinetic (PBPK) 




Quantitative predictions from pre-clinical data to human situation are always 
challenging, however are critical to drive the decision making as drug candidates move to 
later stage of drug development (1-3). Whole body physiologically-based 
pharmacokinetic (WBPBPK) models are mathematical models that integrate anatomical 
and physiological parameters (such as organ regional blood flow rate and organ 
volumes), and compound specific properties (such as physicochemical properties, tissue-
to-blood partition coefficient, blood-to-plasma partition coefficient, unbound fraction in 
plasma, intrinsic clearance, and even formulation effects) to predict absorption, 
distribution, metabolism and excretion (ADME) of compounds in animals and humans 
(1-7).  Beside WBPBPK models, specific PBPPK models also have been reported to 
predict absorption (8-11), clearance (12), volume of distribution (13), tissue distribution 
(14-18), and drug-drug interaction in humans (19-23).   
In WBPBPK modeling, tissue-to-plasma partition coefficients (Kp) are one of the 
most costly and labor intensive parameters to be experimentally measured.  To facilitate 
the application of PBPK modeling various in silico models have been developed to 
predict Kp values (13, 16, 17, 24-27).  Poulin and coworkers (24-27) developed tissue-
composition based equations to predict compound distribution in various tissues.  Their 
models assumed that compounds are homogenously distributed within each tissue, or 
predominantly distributed in the interstitial space of the tissue.  Passive diffusion was 
assumed to govern the distribution of molecules.  In their prediction, the most 
pronounced discrepancy observed between predicted and measured Kp values was for the 
lung for lipophilic basic molecules (pKa > 7).  Rodgers and coworkers (16, 17) modified 
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Poulin et al. equations. They categorized molecules into moderate-to-strong bases and 
acids, very weak bases, neutrals, and zwitterions.  For the moderate-to-strong bases, 
electrostatic interactions between the ionized form and intracellular acidic phospholipids 
were assumed to be predominant (16).  Passive distribution between compartments and 
non-saturating binding were also assumed (16).   Although by incorporating electrostatic 
interactions, Kp predictions in the lung were improved, under-prediction was still 
prevailed, suggesting other mechanisms contributing to the distribution in the lung (16). 
Previously, single cell-based pharmacokinetic model (1CellPK) has been 
developed to predict intracellular / subcellular accumulation and transcellular 
permeability of small molecules in polarized and non-polarized cells (28-31).  The 
1CellPK model was validated for compounds with published measured permeability (28), 
and ninety-nine monobasic amines (29).  It was tested quantitatively for prediction of 
intracellular mass accumulation and transcellular permeability of a lipophilic basic 
compound, chloroquine (CQ), and showed good agreement with measured transcellular 
permeability up to 4 hours and intracellular mass accumulation after 5 minutes 
incubation.  Based on single cell prediction, we observed that for monobasic amines, their 
intracellular distribution was not homogenous. For most of them, high lysosomal or 
mitochondrial accumulation was observed (29). 
 Extensive distribution in the lung has been observed for many lipophilic bases 
(32-37). Lysosomal trapping was proposed as a mechanism contributing to high 
accumulation in the lung (35-39).  Here we constructed WBPBPK models incorporating a 
Cyberlung, which was developed based on 1CellPK, to quantitatively explore the impact 
of organellar accumulation on the distribution in the lung of several beta-blockers 
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(atenolol, metoprolol, and propranolol) with similar structures, similar pKa values, 
different logP values, and different plasma binding affinity. We test the hypothesis that 
organellar accumulation of drugs could have a significant effect on lung tissue 
pharmacokinetics depending on the drugs’ physicochemical properties.  
Methods  
Development of the 1CellPBPK model 
 The structure of the cell-based PBPK model (1CellPBPK) is illustrated in Figure 
5.1.  Briefly, the Cyberlung consists of eight cellular compartments: 1: surface lining 
liquid (aEp); 2: macrophage (imEp); 3: epithelial cells (cEp); 4: interstitium (int); 5: 
immune cells (imInt); 6: smooth muscle (sm); 7: endothelial cells (cEd); and 8: plasma 
(plung).  Both tracheobronchial airways and alveolar region were included in the model. 
Amongst the eight compartments, epithelial cells and endothelial cells are modeled with 
the R-model and other compartments are modeled with the T-model (J. Yu, manuscript in 
preparation). Lysosomes and mitochondria are integrated in the cEp (cEpMito and 
cEpLyso) and cEd (cEdMito and cEdLyso) for alveolar region and in the cEp (cEpMito 
and cEpLyso), cEd (cEdMito and cEdLyso), and sm (smMito and smLyso) for the 
tracheobronchial airways.  Mass change with time (dM/dt) can be expressed by mass 
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The subscripts indicate each compartment as described above. A and J indicate 
membrane surface area and flux, respectively.  The two subscripts of J indicate the 
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transport direction.  For example, in equation 5.1, ,plung cEdJ  is the flux from lung plasma 
to endothelial cytosol.  ,e mucusK  is the mucus clearance.  The Cyberlung is connected with 
other tissues by the plasma compartment (Figure 5.1, equation 5.1).  Vv,lu is the blood 
volume in the lung, Cv,lu is the venous blood concentration in the lung, and Qlu is the 
blood flow of the lung. 
All other organs were assumed to be well-stirred compartments (perfusion-limited 
model).  For a non-elimination organ/tissue, the mass change within that organ/tissue can 
be expressed by equation 5.15. 
,
t
t t ab t v t
dCV Q C Q C
dt
= − ,         (5.15) 
where, subscript t stands for a non-elimination organ, such as heart (ca), bone (bo), 
muscle (mu), fat (fa), skin (sk), thymus (th), brain (br), spleen (sp), gut (gu), and rest of 
body (rob). V stands for volume of the tissue; Ct stands for total tissue concentration; Qt 
stands for blood flow rate of that organ; Cab stands for arterial blood concentration; and 
Cv,t is venous tissue concentration. Venous tissue concentration can be converted to total 








= ,          (5.16) 
where, Kp,t is tissue : plasma partition coefficient, and B:P is blood : plasma partition 
coefficient. If a drug is delivered orally, the mass balance equation for the gut is 
described by equation (5.17). 
,
gu
gu abs gu ab gu v gu
dC
V R Q C Q C
dt
= + − ,       (5.17) 
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where, Rabs is the absorption rate.  For liver (hv) mass balance is expressed by equation 
5.18 (7). 
, , , int, , , hvhv ha ab sp v sp gu v gu hv v hv u v hv u
dCV Q C Q C Q C Q C in vivo CL C
dt
= + + − − ,  (5.18) 
where, in vivo CLint,u is scaled, unbound in vivo intrinsic clearance, Cv,hv,u is unbound 
venous liver  concentration, Qha is hepatic arterial blood flow, and Qhv is the total liver 
blood flow.  For kidney (re) mass balance is expressed by equation 5.19.  
, , , ,
re
re re ab re v re re u v re u
dCV Q C Q C CL C
dt
= − − ,      (5.19) 
where, CLre,u is unbound renal clearance. For arterial blood and venous blood, mass 
balance can be expressed by equation (5.20) and (5.21), respectively. 
,
ab
ab lu v lu lu ab
dCV Q C Q C
dt
= − ,        (5.20) 
,
vb
vb i v i lu vb iv
i
dCV Q C Q C K
dt
= − +∑ ,       (5.21) 
where, Kiv is the intravenous injection or infusion rate, Cvb is venous blood concentration, 
and QiCv,i is production of blood flow rate (Qi) and venous tissue concentration (Cv,i). 
 Input parameters for the Cyberlung are described in another paper (J. Yu, 
manuscript submitted, appendix E). The thickness of surface lining liquid in alveoli = 
5µm is used in all simulations; otherwise, it will be specified.  Other physiological 
parameters were collected from published research papers and summarized in Table 5.1 




Modeling pharmacokinetics of atenolol using the 1CellPBPK model 
 For atenolol, a semi-empirical PBPK model was constructed due to the limited 
experimental data for tissue : plasma partition coefficients (Kp,t).  A seventeen-
compartment model was constructed including arterial blood, venous blood, brain, liver, 
Cyberlung (as described by equation 5.1-5.14), and rest of body.  Observed 
pharmacokinetic data in each tissue were extracted from Street J.A. et al. (34) by a 
computer program ‘Grab graph data’ (http://www.frantz.fi/software/g3data.php). Tissue 
kinetic data were analyzed using noncompartmental analysis with WinNonlin (Pharsight 
Corporation, Mountain View, CA).  Tissue : blood partition coefficient (Kp,b) was 
calculated by the ratio of AUC0-inf, tissue / AUC0-inf, blood and summarized in Table 5.2.  The 
tissue concentration was measured by total radioactivity (34). However since the most 
component in the major circulation is parent compound (40), total radioactivity can be 
considered as a surrogate of parent compound concentration.  To determine the Kp,b for 
the rest of body, several values were tested (0.1, 0.5, 1, 5, and 10), and  the Kp,b,rest of body 
value that gave the best prediction was chosen.  Atenolol is mainly eliminated by the 
kidney and negligibly bound to plasma proteins (41).  In vivo plasma clearance was 
obtained from published literature (41) and converted to blood clearance by assuming the 







= ,          (5.22) 
where, CLb and CLp are blood and plasma clearance, respectively. Clearance was 
allocated to venous blood compartment.  Thus the mass change in venous blood is 
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= + + − − +
,  (5.23) 
 In the simulation, a 300mg rat was given 1mg/kg i.v. bolus injection to mimic the  
experiment (34).  Thus Kiv was set to 0 and the initial concentration given to venous blood 
was dose / venous blood volume. Initial concentration given to other compartments was 
0.  Two scenarios were simulated: with lyso/mito and without lyso/mito. With lyso/mito 
was defined as: Vmito or Vlyso = 0.1 Vcyto and lipid fraction in mitochondria and lysosome 
= 0.05. Experimental data were obtained from literature to compare with simulation (34). 
Modeling pharmacokinetics of metoprolol using the 1CellPBPK model 
 Metoprolol is a beta-blocker with intermediate lipophilicity and plasma binding.  
The difference is not significant between R- and S- metoprolol for blood : plasma ratio, 
unbound fraction in plasma, and tissue : plasma partition coefficient of most tissues (42) 
as summarized in Table 5.2. Observed values for S-metoprolol were used in simulations.  
A 39-compartment model was developed including arterial blood, venous blood, heart, 
brain, liver, gut, spleen, kidney, muscle, skin, adipose, bone, rest of body, and the 
Cyberlung (14 compartments in the tracheobronchial airways and 12 compartments in the 
alveolar region). Clearance of metoprolol was obtained from literature (43), and was 
modeled using equation 5.24. 
max
, , , , ,
, ,
hv hv
hv ha ab sp v sp gu v gu hv v hv vp hv u
m vp hv u
dC V VV Q C Q C Q C Q C C
dt K C
= + + − −
+ , (5.24) 
where Vmax has the unit of ng/min/g liver, and Km has the unit of ng/mL, Cvp,hv,u is the 
unbound plasma concentration in the liver.  For the tissue, it is assumed that 1g = 1mL. 
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Vhv is the weight / volume of the liver. Intravenous injection was modeled with the 
infusion rate = 2.3µg/min. 
Modeling pharmacokinetics of propranolol using the 1CellPBPK model 
 Propranolol is a beta-blocker with high lipophilicity and high plasma binding.  
Unbound fraction in the plasma may differ ten fold for R-propranolol and S-propranolol 
(0.017 and 0.13, respectively), and blood : plasma ratio differs within two fold (0.77 and 
1.29, respectively) (16).  Input parameters were obtained from literature and summarized 
in Table 5.2 (27). The liver was modeled using equation 5.25 (27). 
, , , ,( ( ) )hvhv ha ab sp v sp gu v gu ha ab gu v gu sp v sp h
dCV Q C Q C Q C Q C Q C Q C E
dt
= + + − + + , (5.25) 
where Eh is the hepatic extraction ratio and was calculated by equation 5.26 and the 
intrinsic clearance CLint was also obtained from Poulin et al.  (27). 
int int/ ( )h hvE CL CL Q= + ,         (5.26) 
 Simulated kinetics in tissues were compared with experimental data (44). For 
simulation in this study, dose = 1.5mg/kg was used.  For i.v. injection, initial 
concentration in venous blood was calculated by equation 5.27. 
0, /vb vbC Dose V= ,          (5.27) 
Effects of the thickness of surface lining liquid in alveoli on drug accumulation in 
the lung 
 Since the volume of surface lining liquid contribute a large proportion to the total 
lung volume, we investigated the effect of the thickness of surface lining liquid in alveoli 




Subcellular sequestration affects accumulation of atenolol, metoprolol, and 
propranolol in the lung but not significantly, and has little effect on distribution 
kinetics in other tissues and plasma  
 To validate the 1CellPBPK model, experimental pharmacokinetic data were 
obtained from literature (34, 42, 44) and plotted to compare with simulated results. For 
atenolol, only lung, brain, and liver were included, which are organs with relatively small 
volumes (Table 5.1).  Other organs were lumped together as the rest of body.  Several 
Kp,b for the rest of body were tested (0.1, 0.5, 1, 5, and 10), and Kp,b,rest of body = 1 gave the 
best prediction for all tissues and plasma among five tested values, and thus was chosen.  
Pharmacokinetics in all tissues was closely predicted for atenolol (Figure 5.2 and 5.3).  
Figure 5.2 shows the lung accumulation (plotted in mass, right axis) and plasma 
concentration - time profile (plotted in concentration, left axis).  After adding subcellular 
compartments (lysosomes / mitochondria), the total lung mass was increased, but not 
significantly. The pharmacokinetics in the lung follows the pharmacokinetics in the 
plasma because lung is a highly perfused organ and the elimination phase is mainly 
clearance driven.  Tissue distribution in other organs is not affected by subcellular 
sequestration in the lung because the volumes of subcellular organelles are small. On the 
other hand, the rest of body has significant effects on the pharmacokinetics in other 
tissues and plasma, due to its large volume.   
 For metoprolol, since pharmacokinetics in tissues are not available, predicted 
lung: unbound plasma partition coefficient (Kp,u) was compared with observed Kp,u and 
values predicted by other two in silico method (16, 26).  Cyberlung predicted Kp,u is 
closer to observed value than other two in silico methods (Table 5.3).  Since current 
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Cyberlung model does not include non-specific binding, such as binding to proteins, and 
the binding fraction of metoprolol in the lung is not available, the calculated values in 
Table 5.3 represent unbound lung : unbound plasma partition coefficient.  If binding 
fraction is considered for the lung, predicted lung accumulation by the Cyberlung will be 
increased based on current prediction.  Comparing with and without subcellular 
organelles, Kp,u values predicted by the Cyberlung are not significantly different. 
 For propranolol, 1CellPBPK predictions closely agree with observed 
pharmacokinetics in tissues and plasma (Figure 5.4 and 5.5) (44).  Propranolol highly 
binds to plasma (87%) (27) and lung tissue (90%) (45). Current Cyberlung does not 
include protein binding component, thus predicted values are compared with lung 
accumulation after binding correction (Figure 5.4). Free lung mass predicted by 
Cyberlung is slightly higher than observed lung accumulation. Subcellular sequestration 
increases lung accumulation but not significantly, and has no effects on distribution in 
other tissues and organs.  
Drug accumulation in the lung decreases with the decreasing thickness of surface 
lining liquid in alveoli 
 Total lung volume calculated for the Cyberlung (Table 5.1) is slightly higher than 
measured total lung volume (2.8 mL vs. 1.25 mL). Surface lining liquid contribute a large 
proportion to lung volume. The measure thickness of surface lining liquid may vary from 
1 µm to 10 µm. To investigate the effect of thickness of surface lining liquid on drug 
accumulation in the lung, simulations were running with two values, 1 µm and 5 µm. 
Figure 5.6 shows the results for atenolol and propranolol. After the thickness of surface 
liquid lining is decreased to 1 µm, the mass accumulation in the lung is decreased as well 
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due to the decreasing of total lung volume. The difference between with and without 
subcellular organelles is more significant, which is because the volume of surface lining 
liquid is a large proportion of lung volume, but it does not contain subcellular organelles. 
The drug concentration in the lung also decreases with the decreasing volume of surface 
lining liquid (Table 5.3). 
Conclusion and Discussion 
The ultimate goal of cell based pharmacokinetic modeling and simulation is to 
predict human situation.  This chapter includes some preliminary study of integrating cell 
based pharmacokinetic model to whole body PBPK model.  The first organ developed 
based on cellular pharmacokinetic model was the lung (J. Yu, manuscript submitted).  
Lung is a functionally important, but with relatively simple anatomy organ.   
In PBPK modeling, tissue : plasma partition coefficients (Kp) are one of the most 
costly input parameters, which are time consuming and labor intensive.  Tissue 
composition-based in silico methods have been developed to predict Kp (13, 16, 17, 24-
27). Kp values in the lung are often under-predicted for lipophilic moderate-to-strong 
bases (16). We modeled three beta-blockers with different lipophilicity, different protein 
binding, but similar pKa values using 1CellPBPK.  For all three compounds, atenolol, 
metoprolol, and propranolol, predicted lung accumulation is close to observed kinetics 
(Figure 5.2, 5.4, and Table 5.3).  After adjusting the thickness of surface lining liquid 
within a physiologically reasonable range, the prediction accuracy can be improved 
(Figure 5.5).  Adding 10% subcellular compartment (i.e. Vmito = Vlyso = 0.1 Vcyto), lung 
accumulation of three compounds is increased, but not significantly, depending on the 
relative volume fraction of subcellular organelles. With whole body PBPK model, we can 
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evaluate the effects that have been observed at cellular level to systemic level.  Similar to 
subcellular sequestration, 1CellPBPK could also be used as a cost effective tool to 
evaluate the effects transporters and metabolic enzymes at systemic level.  
Exploring current 1CellPBPK model, it can be used: (1). to optimize 
physicochemical properties (logP and pKa) to find compounds having lung distribution 
that does not follow plasma pharmacokinetics; (2). to simulate the pharmacokinetics for 
pulmonary delivery drugs; (3) to analyze the drug distribution in the airways, alveoli, and 
different cell types in the lung.  
With the increasing number of parameters in the PBPK models, uncertainties and 
variabilities associated with the parameters will become important and need to be paid 




Table 5.1. Physiological parameters for tissue volumes and blood flow rates in a 250 
g rat. Values are obtained from Poulin et al. (27). Both tissue volumes and blood flow 
rates are expressed as fractions or functions of body weight. 
 
 Volumes (V) Blood Flow Rates (Q) 
Tissues fraction of 
total body 
volume 






Arterial blood 0.0272 6.8 --- --- 
Venous blood 0.0544 13.6 --- --- 
Adipose 0.076 19.0 0.07 5.82 
Bone 0.04148 10.37 0.122 10.14 
Brain 0.0057 1.425 0.02 1.66 
Gut 0.027 6.75 0.131 10.88 
Heart 0.0033 0.825 0.049 4.07 
Kidney 0.0073 1.825 0.141 11.72 
Liver 0.0366 9.15 0.175 b 14.54 
  total surface lining liquid   
airways 0.005 a 0.292 0.162 0.01 0.831 Lung 
alveoli  2.544 1.935 1 83.09 c 
Muscle 0.404 101.0 0.278 23.10 
Skin 0.19 47.5 0.058 4.82 
Spleen 0.002 0.5 0.02 1.66 
Rest of body 0.12002 30.005 0.077 6.3979 
 
a. The lung volume used in this study was calculated by summing up the total cell volume 
and surface lining liquid volume of the Cyberlung (including airways and alveoli).  The 
reported lung volume is 0.005 of body weight by Poulin et al. (27), thus for a 250g rat, 
the lung volume is about 1.25 mL by assuming that tissue density is 1 g/mL. The lung 
volume of rat reported by different studies may vary from 0.0045 – 0.0071 of body 
weight for different strains and genders of rats (46).  
b. The blood flow rate for the liver corresponds to the summation of portal vein and 
hepatic artery. The portal vein represents 15.1%, where 13.1% for gut and other and 2% 
for spleen. 
c. Total cardiac output was calculated with an allometric equation (0.235·body weight0.75) 
in L/min (27).  
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Table 5.2. Summary of in vivo, in vitro and physicochemical properties for atenolol, 
metoprolol, and propranolol    
 
 atenolol metoprolol 
(R- / S-) 
propranolol 
MW 266.3 267.4 259.4 
logPn 0.16 a 1.88 a 2.98  a 
logPd -3.54 a -1.82 a -0.72 a 
pKa 9.6 a 9.70 a 9.49  a 
unbound fraction in plasma (fup) 0.96 b 0.80 / 0.81 e 0.13 (27) g 
blood : plasma ratio (B:P) 1.11 b 1.52 / 1.51 e 0.80 (27) g 
Adipose --- 1.05 / 0.97 e 0.18 (27) h 
Bone --- 5.17 / 5.35 e 6.90 (27) h 
Brain 0.11 c 6.47 / 6.97 e 9.20 (27) h 
Gut --- 13.12 / 11.34 e 8.22 (27) h 
Heart --- 6.90 / 6.24 e 4.97 (27) i 
Kidney --- 26.72 / 26.73 e 3.80 (27) i 
Liver 3.21 c 40.08 / 44.55 e 5.67 (27) h 
Lung --- --- --- 
Muscle --- 5.64 / 5.59 e 2.20 (27) i 
Skin --- 3.18 / 2.92 e 7.22 (27) i 






tissue : plasma 
partition 
coefficient (Kp)  
Rest of body 1.00 c 0.66 c 1.25 c 
CL   38.9 
ml/min/kg 
(41) d 
Vmax = 10215 
ng/min/g liver 




cells (27) d 
 
a  Physicochemical properties of atenolol were obtained from Zhang et al. (28) 
b  In vitro data measured in humans were used as surrogate for rats. 
c  Tissue : blood partition coefficients were calculated as described in method “Modeling 
pharmacokinetics of atenolol using the 1CellPBPK model”. For atenolol Kp of rest of 
body was optimized, for metoprolol and propranolol, Kp values of rest of body were 
arbitrary numbers and not optimized. 
d  Observed clearance was adapted from literature.  
e  Measured tissue : plasma partition coefficients were obtained from Rodgers T. et al. 
(42) 
f  Tissue : plasma partition coefficients for the spleen were calculated in GastroPlusTM 
using the equations published by Rodgers T., Leahy D., and Rowland M.  (16, 17) 
g  Measured values were obtained from Poulin P. et al. (27) 
h  Calculated tissue : plasma partition coefficients were obtained from Poulin P. et al. (27) 
i   Measured tissue : plasma partition coefficient obtained from Poulin P. et al. (27) 
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Table 5.3. Comparison of tissue : unbound plasma partition coefficient (Kp,u )values 
in the lung of S-metoprolol  
 
 
Observed (42) 32 ± 4.9 
In silico (Rodgers T. et al.) (16) 22.9 
In silico (Poulin P. et al.) (26) 3.72 
Cyberlung without lyso/mito a 23.56 
Cyberlung with lyso/mito  a 25.52 
Cyberlung without lyso/mito b 15.67 
Cyberlung with lyso/mito  b 20.32 
 
a. The thickness of surface lining liquid in alveoli = 5µm.  












Figure 5.2.  Comparison of predicted pharmacokinetics of atenolol in the lung and 




Figure 5.3.  Comparison of predicted pharmacokinetics of atenolol in the various 





Figure 5.4.  Comparison of predicted pharmacokinetics of propranolol in the lung 





Figure 5.5.  Comparison of predicted pharmacokinetics of propranolol in the 
various tissues with observed pharmacokinetics. (A) lung and blood, (B) liver, (C) 






Figure 5.6.  Effects of the thickness of surface lining liquid in alveoli on drug 
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 A mechanism base cellular pharmacokinetic model (1CellPK) has been developed 
to simulate the transcellular permeability and subcellular distribution (1).  This project is 
the first step toward building a ‘bottom-up” model to simulate drug transport in humans.  
Cells are the smallest living unit in organism. Understanding and modeling of drug 
transport at cellular and subcellular level are essential for developing physiologically-
based pharmacokinetic (PBPK) models.  In the current model, the simplest but the most 
important transport mechanism, passive diffusion, was considered. For the transport 
ionized molecules across biomembrane, the combination of Fick’s law of diffusion and 
Nernst–Planck equation was used.  Input parameters of the model are cellular 
physiological parameters and physicochemical properties of small molecules, including 
pH values in each compartment, membrane potential of each biomembrane, volume and 
surface area of each compartment, lipid fraction in each compartment, and lipophilicity 
and acid dissociation constant of small molecules.  The model performs well in predicting 
highly permeable molecules and lysosomotropic phenomenon.  Nevertheless, the model 
is still a relatively simple model and many important factors have not been included.  In 
the following we will be discussing several aspects that the current 1CellPK model can be 
improved and the future outlook of 1CellPK. 
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Integration of molecular size 
 Current 1CellPK model assumes the diffusion coefficient of small molecules is 
constant, which limits the application 1CellPK model to molecules with certain range of 
molecular radius.  Diffusion coefficient in liquid essentially is a function of molecular 
radius s described by Stoke-Einstein equation (equation 6.1) (2). 
4 6       kTD n
n aπ η
= ≤ ≤ ,    (6.1) 
where k is the Boltzmann’s constant, a is the radius of the solute and η is the solution 
viscosity, and n is related to the radii of solute. When the solutes are large with radii 
grater than 5-10 Å, n = 6. From Stokes-Einstein equation, one sees that the diffusion 
coefficient is proportional to the reciprocal of the radius, which is approximately 
proportional to the cube root of the molecular weight.  Studies showed that paracellular 
pathway is molecular size and charge selective (3-5).  Paracellular passive permeability 
might play a major role in small molecules passive transport with molecular weight less 
than 200 Dalton (6).  Thus integrating the molecular size into current 1CellPK may 
improve both the transcellular and paracellular transport prediction. 
Integration of molecular interactions 
 During the transport process across the cells or into the cells, there are many steps 
may involve molecular interactions.  For example, when the molecules transport across 
the biomembrane, they may interact with the lipid and be trapped in the lipid bilayer.  
After entering the cellular membrane, molecules many interact with macro molecules 
located inside cells, such as DNA and proteins. Current 1CellPK model takes into 
account lipid partitioning with neutral lipid in each compartment (cytosol, mitochondria, 
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and lysosomes).  However for moderate - to - strong bases (pKa ≥ 7), they exist mainly as 
ionic species in physiological pH (~7).  Thus electrostatic interaction between ionic 
species and acidic phospholipids might be an important factor determining intracellular 
accumulation of small molecules (7), which is not included in the current 1CellPK model.  
 Besides passive interactions with macromolecules and acidic phospholipids, 
interactions with transporters and metabolic enzymes are also important mechanisms to 
be included for specific classes of molecules.  With the discovery of structures of 
transporter proteins, 1CellPK model can also include the structures of transmembrane 
transporters for modeling of transporter mediated transport.  
Mechanistic models for hypothesis testing and experimental design 
 In chapter 4, chloroquine was used as a compound to test 1CellPK prediction of 
permeability and intracellular accumulation. While 1CellPK can capture the transcellular 
permeability and intracellular accumulation after short time incubation, the intracellular 
accumulation was under-predicted after 4 hours incubation.  That suggests that the 
current 1CellPK does not include some mechanisms that are involved in chloroquine 
uptake up to 4 hours.  We observed lysosomal swelling and intralysosomal pH increment 
during the uptake.  In order to capture the lysosomal volume and intralysosomal pH 
increment, we ran Monte Carlos simulation with measured lysosomal volume and pH 
after incubation.  Lysosomal swelling can explain part of the under-prediction but the 
model still under-predicts the uptake of chloroquine after long time incubation.  We 
further observed two-phase uptake kinetics of chloroquine within 4 hours incubation 
while the model predicts the steady state reached within 1 minute.   To bridge the 
discrepancy between model prediction and observation, the model is proposed to include 
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the following mechanisms for chloroquine or other similar drugs uptake. (1) To include 
the volume change as a function time.  Monte Carlo simulation suggests the volume 
change has significant effects on chloroquine uptake. However, it was a rough estimation. 
A more accurate method is to integrate volume change as a function of time or 
concentration in 1CellPK model. (2) Another mechanism that may cause under-
prediction is intracellular inclusion formation due to the high intracellular concentration 
(8). (3) Chloroquine is well known to induce autophagy, organellar sequestration in 
autophagosomes and cytoplasmic vacuolization, followed by chromatin condensation, 
caspase activation, DNA loss and shrinkage (9-12). That complicated process may also 
increase chloroquine uptake assuming the autophagosome is an acidic compartment.   
 It is always desired that prediction closely agrees with observed data.  However, if 
discrepancies between predictions and observations are observed, it encourages 
researchers to explore the mechanisms that are not included in the current model. 
Extension of 1CellPK towards multiorgan PBPK modeling 
 In this thesis, the 1CellPK was developed into a multiscale virtual lung model (the 
Cyberlung). And the lung model was further integrated into whole body PBPK model to 
study the effects of subcellular distribution on systemic distribution.  That will be one of 
the directions for future development. Potentially, multiscale organs developed from the 
cell-based pharmacokinetic model can be used to predict absorption, tissue distribution, 
and clearance.  1CellPK has been used to predict transcellular permeability, which is one 
of the critical factors determining oral absorption (13-17). By combining the GI anatomy, 
drug dissolution profiles, transit time, precipitation, metabolism enzymes in the GI track, 
transporters, and other procedures involved in absorption, 1CellPK can be extended to 
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predict drug absorption (18-21).  The Cyberlung has shown the ability of predicting the 
distribution of several beta-blockers in the lung. With the same strategy, 1CellPK model 
can be extended to other organs or tissues for tissue distribution predictions (22).  The 
cellular pharmacokinetic model may also be extended for clearance prediction by 
integrating transporters and metabolic enzymes (23-25).  The ultimate goal is to elaborate 
cell based pharmacokinetic model to multiorgan PBPK models for absorption, 
distribution, and elimination predictions, and furthermore link to pharmacodynamic 
modeling.  
 While extrapolating 1CellPK to the virtual lung, we have not considered 
microcirculation, which is responsible for the distribution of blood within tissues. The 
flow rate could be different from the macro blood flow rate to or from the tissue or organ 
to account fro heterogeneity in tissue distribution (26). The flow rate could be determined 
by the diameter and the length of the vessels of the microcirculation and could be 
predicted by Hagen-Poiseuille equation. Some models have been reported to model the 
solute change between blood and tissue including microcirculation and cell metabolism 
of nutrients (26, 27). For the lung computational models of the human pulmonary 
microcirculation was developed to simulate regional variations in blood flow (28, 29). 
They could be adapted and integrated with 1CellPK to take into account of the 
heterogeneous distribution of compounds.  
Disseminating 1CellPK 
 Current 1CellPK model, the Cyberlung, and 1CellPBPK model are all developed 
in Matlab® platform, which is not user-friendly software and requires programming 
skills.  In order to share the 1CellPK model with other pharmaceutical scientists, 
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implementing the model in user-friendly software is necessary.  Virtual Cell is a user-
friendly computational tool for systems biologists to model, analyze, and interpret 
complicated cellular events, such as calcium dynamics in a neuronal cell, and 
nucleocytoplasmic transport (26, 27).  By porting 1CellPK into Virtual Cell, 
mathematical models of small molecule transport could be easily shared amongst the 
systems biology community, and used to study the synthesis, metabolism and transport of 
lipophilic hormones and xenobiotics, as well as studying of the effect of exogenous 
membrane-permeant small molecule probes on biochemical signaling networks. Within 
Virtual Cell, 1CellPK can be integrated with biochemical signaling networks or reaction-




1. X. Zhang, K. Shedden, and G.R. Rosania. A cell-based molecular transport 
simulator for pharmacokinetic prediction and cheminformatic exploration. Mol 
Pharm. 3:704-716 (2006). 
2. R. Baker. Membrane Technology and Applications, 2004. 
3. V. Pade and S. Stavchansky. Estimation of the relative contribution of the 
transcellular and paracellular pathway to the transport of passively absorbed drugs 
in the Caco-2 cell culture model. Pharm Res. 14:1210-1215 (1997). 
4. P. Stenberg, K. Luthman, and P. Artursson. Virtual screening of intestinal drug 
permeability. J Control Release. 65:231-243 (2000). 
5. G.M. Pauletti, F.W. Okumu, and R.T. Borchardt. Effect of size and charge on the 
passive diffusion of peptides across Caco-2 cell monolayers via the paracellular 
pathway. Pharm Res. 14:164-168 (1997). 
6. H. Lennernas. Does fluid flow across the intestinal mucosa affect quantitative oral 
drug absorption? Is it time for a reevaluation? Pharm Res. 12:1573-1582 (1995). 
7. T. Rodgers, D. Leahy, and M. Rowland. Physiologically based pharmacokinetic 
modeling 1: predicting the tissue distribution of moderate-to-strong bases. J 
Pharm Sci. 94:1259-1276 (2005). 
8. F. Rashid, R.W. Horobin, and M.A. Williams. Predicting the behaviour and 
selectivity of fluorescent probes for lysosomes and related structures by means of 
structure-activity models. Histochem J. 23:450-459 (1991). 
9. P. Boya, R.A. Gonzalez-Polo, N. Casares, J.L. Perfettini, P. Dessen, N. 
Larochette, D. Metivier, D. Meley, S. Souquere, T. Yoshimori, G. Pierron, P. 
Codogno, and G. Kroemer. Inhibition of macroautophagy triggers apoptosis. Mol 
Cell Biol. 25:1025-1040 (2005). 
10. P. Boya, K. Andreau, D. Poncet, N. Zamzami, J.L. Perfettini, D. Metivier, D.M. 
Ojcius, M. Jaattela, and G. Kroemer. Lysosomal membrane permeabilization 
induces cell death in a mitochondrion-dependent fashion. J Exp Med. 197:1323-
1334 (2003). 
11. P. Boya, R.A. Gonzalez-Polo, D. Poncet, K. Andreau, H.L. Vieira, T. Roumier, 
J.L. Perfettini, and G. Kroemer. Mitochondrial membrane permeabilization is a 
critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. 
Oncogene. 22:3927-3936 (2003). 
12. J.J. Shacka, B.J. Klocke, M. Shibata, Y. Uchiyama, G. Datta, R.E. Schmidt, and 
K.A. Roth. Bafilomycin A1 inhibits chloroquine-induced death of cerebellar 
granule neurons. Mol Pharmacol. 69:1125-1136 (2006). 
13. B. Press and D. Di Grandi. Permeability for intestinal absorption: Caco-2 assay 
and related issues. Curr Drug Metab. 9:893-900 (2008). 
14. V.E. Thiel-Demby, J.E. Humphreys, L.A. St John Williams, H.M. Ellens, N. 
Shah, A.D. Ayrton, and J.W. Polli. Biopharmaceutics Classification System: 
Validation and Learnings of an in Vitro Permeability Assay. Mol Pharm (2008). 
15. D.A. Volpe. Variability in Caco-2 and MDCK cell-based intestinal permeability 
assays. J Pharm Sci. 97:712-725 (2008). 
 
196 
16. C.Y. Han, Y. Li, and G. Liu. Drug-likeness: Predication and practice. Prog Chem. 
20:1335-1344 (2008). 
17. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a 
biopharmaceutic drug classification: the correlation of in vitro drug product 
dissolution and in vivo bioavailability. Pharm Res. 12:413-420 (1995). 
18. K.S. Pang. Modeling of intestinal drug absorption: roles of transporters and 
metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos. 31:1507-
1519 (2003). 
19. D. Tam, H. Sun, and K.S. Pang. Influence of P-glycoprotein, transfer clearances, 
and drug binding on intestinal metabolism in Caco-2 cell monolayers or 
membrane preparations: a theoretical analysis. Drug Metab Dispos. 31:1214-1226 
(2003). 
20. D. Tam, R.G. Tirona, and K.S. Pang. Segmental intestinal transporters and 
metabolic enzymes on intestinal drug absorption. Drug Metab Dispos. 31:373-383 
(2003). 
21. D. Cong, M. Doherty, and K.S. Pang. A new physiologically based, segregated-
flow model to explain route-dependent intestinal metabolism. Drug Metab 
Dispos. 28:224-235 (2000). 
22. L. Yan, S. Sheihk-Bahaei, S. Park, G.E.P. Ropella, and C.A. Hunt. Predictions of 
hepatic disposition properties using a mechanistically realistic, physiologically 
based model. Drug Metab Dispos. 36:759-768 (2008). 
23. T. Watanabe, H. Kusuhara, K. Maeda, Y. Shitara, and Y. Sugiyama. 
Physiologically based pharmacokinetic modeling to predict transporter-mediated 
clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 
328:652-662 (2009). 
24. K.S. Pang, M. Weiss, and P. Macheras. Advanced pharmacokinetic models based 
on organ clearance, circulatory, and fractal concepts. AAPS J. 9:E268-283 (2007). 
25. L. Liu and K.S. Pang. An integrated approach to model hepatic drug clearance. 
Eur J Pharm Sci. 29:215-230 (2006). 
26. J.B. Bassingthwaighte, G.M. Raymond, J.D. Ploger, L.M. Schwartz, and T.R. 
Bukowski. GENTEX, a general multiscale model for in vivo tissue exchanges and 
intraorgan metabolism. Philos Transact A Math Phys Eng Sci. 364:1423-1442 
(2006). 
27. D.A. Beard, F. Wu, M.E. Cabrera, and R.K. Dash. Modeling of Cellular 
Metabolism and Microcirculatory Transport. Microcirculation. 15:777-793 
(2008). 
28. K.S. Burrowes, M.H. Tawhai, and P.J. Hunter. Modeling RBC and neutrophil 
distribution through an anatomically based pulmonary capillary network. Ann 
Biomed Eng. 32:585-595 (2004). 
29. Y. Huang, C.M. Doerschuk, and R.D. Kamm. Computational modeling of RBC 












1CellPK Matlab Code  
% The following section is to calculate the intracellular 
% concentration and permeability of each drug given pKa, logPn(o/c) and  
% electrical charges. 
  




T = 273.15+37;           % Body temperature (37centigrade) 
R = 8.314;               % Universal gas constant 
F = 96484.56;            % Faraday constant 
La = 0;                  % Lipid fraction in apical compartment 
Lc = 0.05;               % Lipid fraction in cytosol 
Lm = 0;                  % Lipid fraction in mitochondria 
Lb = 0;                  % Lipid fraction in basolateral compartment 
Wa = 1-La;               % Water fraction in apical compartment 
Wc = 1-Lc;               % Water fraction in cytosol 
Wm = 1-Lm;              % Water fraction in mitochondria  
Wb = 1-Lb;               % Water fraction in basolateral compartment 
gamma_na = 1;           % Activity coefficient of neutral molecules in apical compartment 
gamma_da = 1;           % Activity coefficient of ionic molecules in apical compartment 
gamma_nc = 1.23026877;  % Activity coefficient of neutral molecules in cytosol 
gamma_dc = 0.73799822;  % Activity coefficient of ionic molecules in cytosol 
gamma_nm = 1;           % Activity coefficient of neutral molecules in mitochondria 
gamma_dm = 1;           % Activity coefficient of ionic molecules in mitochondria 
gamma_nb = 1;     % Activity coefficient of neutral molecules in basolateral compartment 
gamma_db = 1;     % Activity coefficient of ionic molecules in basolateral compartment 
Ca = 1 ;                 % Apical initical drug concentration (mM) 
  
% Areas and volumes (units in m^2 and m^3) 
Aa = 50*10^(-10) ;           % The apical membrane surface area 
Aaa = 20*10^(-10) ;          % The monolayer area 
Am = 100*3.14*10^(-12);     % The mitochondrial membrane surface area 
Ab = 10^(-10);              % The basolateral membrane surface area 
Vc = 10*10^(-15);            % The cytosolic volume 
Vm = 100*5.24*10^(-19);     % The mitochondrial volume 
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Vb = 4.7*10^(-3);           % The volume of basolateral compartment 
     
% Membrane potential (units in 'Voltage') 
Ea = -0.0093 ;              % The membrane potential of apical membrane 
Em = -0.16;                 % The membrane potential of mitochondrial membrane 
Eb = 0.0119 ;               % The membrane potential of basolateral membrane 
  
% pH values 
pHa = 6.8;                  % pH in apical compartment 
pHc = 7.0;                  % pH in cytosol 
pHm = 8.0;                 % pH in mitochondria 
pHb = 7.4;                  % pH in basolateral compartment 
  
% Read the drug properties 
% If the drug is neutral at physiological pH 
% the z is given 10^(-6) in stead of 0 since if z=0 the differenctial 
% equations can't be solved 
[DrugName,pKaall,logPnall,ZNall] = textread('drug.dat', '%s %f 
%f%f','commentstyle','matlab'); 
  
% Calculate the ionized logP(o/w); 
logPdall = logPnall-3.7 ; 
  
% The calculated results are saved in this file 'Peff_all.dat' 
len = length(pKaall) ; 
fid1 = fopen('Peff_all.dat','w'); 
str1 = ' Name --------------- pKa ----- logP_n,lip ---logP_d,lip---Cc(mM)-----Cm(mM)-----
--Cb(mM)-------Peff(cm/sec) ' ; 
fprintf(fid1,'%s\n',str1) ; 
  
for n = 1:len 
    if ( abs(ZNall(n)-1) <= 10^(-6) )  
        logP_nlipT(n) = 0.33*logPnall(n)+2.2 ; 
        logP_dlipT(n) = 0.37*logPdall(n)+2 ; 
    end 
    if ( abs(ZNall(n)+1) <= 10^(-6) )  
        logP_nlipT(n) = 0.37*logPnall(n)+2.2 ; 
        logP_dlipT(n) = 0.33*logPdall(n)+2.6 ; 
    end 
    if ( abs(ZNall(n)-0) <= 10^(-5) )  
        logP_nlipT(n) = 0.33*logPnall(n)+2.2 ; 
        logP_dlipT(n) = 0.33*logPdall(n)+2.2 ; 
    end 
end 
  
% Get the first two decimals 
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logP_nlip = round(logP_nlipT*100)/100 ; 
logP_dlip = round(logP_dlipT*100)/100 ; 
  
  
% Solve the differential equation system for each drug: 
% Given a system of linear ODE's expressed in matrix form: 
% Y' = AY+G with initial conditions Y(0) = RR, 
  
for n = 1:len 
    pKa = pKaall(n); 
    logP_n = logP_nlip(n) ; 
    logP_d = logP_dlip(n) ; 
    z = ZNall(n) ;       
  
    % Parameters Calculation 
    i = -sign(z) ; 
    Na = ((z)*(Ea)*F)/(R*T); 
    Nm = ((z)*(Em)*F)/(R*T); 
    Nb = ((z)*(-Eb)*F)/(R*T); 
     
    Pn = 10^(logP_n-6.7);                
    Pd = 10^(logP_d-6.7);                
    Kn_a = La*1.22*10^(logP_n);          
    Kd_a = La*1.22*10^(logP_d);          
    Kn_c = Lc*1.22*10^(logP_n);          
    Kd_c = Lc*1.22*10^(logP_d);          
    Kn_m = Lm*1.22*10^(logP_n);          
    Kd_m = Lm*1.22*10^(logP_d);          
    Kn_b = Lb*1.22*10^(logP_n);          
    Kd_b = Lb*1.22*10^(logP_d);          
     
    % Construct the matrix A and G 
    fn_a = 1/(Wa/gamma_na+Kn_a/gamma_na+Wa*10^(i*(pHa-pKa))/gamma_da... 
           +Kd_a*10^(i*(pHa-pKa))/gamma_da); 
    fd_a = fn_a*10^(i*(pHa-pKa)); 
    fn_c = 1/(Wc/gamma_nc+Kn_c/gamma_nc+Wc*10^(i*(pHc-pKa))/gamma_dc... 
           +Kd_c*10^(i*(pHc-pKa))/gamma_dc); 
    fd_c = fn_c*10^(i*(pHc-pKa)); 
    fn_m = 1/(Wm/gamma_nm+Kn_m/gamma_nm+Wm*10^(i*(pHm-
pKa))/gamma_dm... 
           +Kd_m*10^(i*(pHm-pKa))/gamma_dm); 
    fd_m = fn_m*10^(i*(pHm-pKa)); 
    fn_b = 1/(Wb/gamma_nb+Kn_b/gamma_nb+Wb*10^(i*(pHb-pKa))/gamma_db... 
            +Kd_b*10^(i*(pHb-pKa))/gamma_db); 




    k11 = -(Aa/Vc)*Pn*fn_c-(Aa/Vc)*Pd*Na*fd_c*exp(Na)/(exp(Na)-1)... 
           -(Am/Vc)*Pn*fn_c-(Am/Vc)*Pd*Nm*fd_c/(exp(Nm)-1)... 
           -(Ab/Vc)*Pn*fn_c-(Ab/Vc)*Pd*Nb*fd_c/(exp(Nb)-1) ; 
    k12 = (Am/Vc)*Pn*fn_m+(Am/Vc)*Pd*Nm*fd_m*exp(Nm)/(exp(Nm)-1) ;  
    k13 = (Ab/Vc)*Pn*fn_b+(Ab/Vc)*Pd*Nb*fd_b*exp(Nb)/(exp(Nb)-1) ; 
    S1 = (Aa/Vc)*Ca*(Pn*fn_a+Pd*Na*fd_a/(exp(Na)-1)) ; 
     
    k21 = (Am/Vm)*Pn*fn_c+(Am/Vm)*Pd*Nm*fd_c/(exp(Nm)-1) ; 
    k22 = -(Am/Vm)*Pn*fn_m-(Am/Vm)*Pd*Nm*fd_m*exp(Nm)/(exp(Nm)-1) ;  
    k23 = 0; 
    S2 = 0; 
  
    k31 = (Ab/Vb)*Pn*fn_c+(Ab/Vb)*Pd*Nb*fd_c/(exp(Nb)-1) ; 
    k32 = 0; 
    k33 = -(Ab/Vb)*Pn*fn_b-(Ab/Vb)*Pd*Nb*fd_b*exp(Nb)/(exp(Nb)-1) ; 
    S3 = 0; 
  
    A = [k11, k12, k13; k21, k22, k23; k31, k32, k33]; 
    G = [S1, S2, S3]'; 
    RR = [0,0,0]'; 
    t = 1000;   % Calculate the intracellular concentration and permeability and t=1000s, 
which is at steady state 
     
    [V,E] = eig(A); 
    E = diag(E); 
    H = inv(V)*G; 
    B = V \ RR; 
    C = B + H./E; 
    Z = -(H./E) + exp(t * E).*C ; 
    Y = real(V * Z); 
    Y = Y'; 
    Peff = Y(3)*Vb/(t*Aaa*Ca); 
    NA = [pKa, logP_n, logP_d, Y, Peff*10^(8)]; 
    str = DrugName{n}; 
    fprintf(fid1,'%s\t %12.2f %12.2f %12.2f %12.2f %12.2f  %+12.4e  %12.2f\n',str, NA') 
;   
end 





Examples of Matlab Code of Monte Carlo Simulations  
% This script is to perform Monte Carlo simulations for 1CellPK 
% This script uses Case#1 as and example: 
% Case# 1: AP->BL transport, pHa = 6.5, 0.4um-membrane, 5min 
% Case# 2: AP->BL transport, pHa = 6.5,   3um-membrane, 5min 
% Case# 3: AP->BL transport, pHa = 7.4, 0.4um-membrane, 5min 
% Case# 4: AP->BL transport, pHa = 7.4,   3um-membrane, 5min 
 
% Case# 5: BL->AP transport, pHb = 6.5, 0.4um-membrane, 5min 
% Case# 6: BL->AP transport, pHb = 6.5,   3um-membrane, 5min 
% Case# 7: BL->AP transport, pHb = 7.4, 0.4um-membrane, 5min 
% Case# 8: BL->AP transport, pHb = 7.4,   3um-membrane, 5min 
 
% Case#1: AP->BL transport, pHa = 6.5, 0.4um-membrane,5min 
clear ;                     % Clear the memory 
z1 = 1 ;                   % ionization group 1 of CQ 
z2 = 2 ;                   % ionization group 2 of CQ 
i1 = sign(z1) ; 
i2 = sign(z2) ; 
 
T = 310.15 ;              % temperature 
R = 8.314 ;                % universal gas constant 
F = 96484.56 ;          % faraday constant 
C_a = 1 ;                   % initial drug concentration (mM) 
 
sim = 10000;             % number of simulations 
paraNo = 25;                 
outputNo = 7;           % number of output parameters 
Para = zeros(sim,paraNo); 
Results = zeros(sim,outputNo); 
 
dMdt_exp = 2.2E-6;              % +/- 7.18E-7, pmol/sec/cell, measured after 4hrs  
Ppore_exp = 2.18E+02;         % +/- 34.4, 10^-6 cm/sec, measured after 4hrs 
Peff_exp = 1.35;                     % +/- 0.442, 10^-6 cm/sec, measured after 4hrs 
IntraMass_exp = 0.00373;      % +/- 0.00014 pmol/cell , measured after 5min 
 




    % Drug information -- ChemAxon calculation including logPn, pKa1, and pKa2 
    logPn = 3.93-0.5+rand();    % unif [3.43, 4.43] ;  
    pKa1 = 9.96-0.5+rand();     % unif [9.46, 10.46] ; 
    pKa2 = 7.47-0.5+rand();     % unif [6.97, 7.97] ; 
    logPd1 = 0.43-0.5+rand();   % unif [-0.07, 0.93] ; 
    logPd2 = -0.91-0.5+rand();  % unif [-1.41, 0.41] ; 
    Pn = 10^(logPn-6.7);                
    Pd1 = 10^(logPd1-6.7);   
    Pd2 = 10^(logPd2-6.7);   
         
    CellNo = 2*10^5*(1+rand());              % cell number/insert: unif [2*10^5, 4*10^5] 
    PoreDens = 4*10^6*0.4*(2+rand());   % pore number/cm^2: unif [3.2*10^6, 4.8*10^6] 
    A_insert = 1.12*10^(-4) ;                     % insert area: 1.12 cm^2 
    PoreNo_insert = PoreDens*A_insert*10^(4);          % pore number/insert 
    PoreNo_cell = PoreNo_insert/CellNo ;                    % average pore number/cell 
    A_pore_insert = 3.14*((0.4/2)*10^(-6))^2*PoreNo_insert ;   % pore area / insert (m^2) 
    A_pore_cell = 3.14*((0.4/2)*10^(-6))^2*PoreNo_cell ;   % average pore area / cell 
(m^2) 
     
    A_a = 10^(-10)*(1+9*rand());     % apical membrane surface area: unif [10^(-
10),10*(10)^(-10))] (m^2) 
    A_aa = A_pore_cell;               % pore area/cell (m^2) 
    A_b = A_aa+(10^(-10)-A_aa)*rand();     % basolateral membrane surface area: unif 
[A_aa, 10^(-10))] (m^2) 
    A_l = 100*3.14*10^(-12);                     % lysosomal membrane surface area (m^2) 
    A_m = 100*3.14*10^(-12);                   % mitochondrial membrane surface area (m^2) 
    V_c = 0.5*10^(-15)*(1+5*rand());        % cytosolic volume: unif [0.5*10^(-15), 
3*10^(-15)] (m^3) 
    V_l = 10^(-18)*(9.24+(23.8-9.24)*rand());    % lysosomal volume: unif [9.24*10^(-
18), 23.8*10^(-18)] (m^3) 
    V_m = 100*5.24*10^(-19)/5*(1+24*rand());  % mitochondrial volume: unif 
[10.48*10^(-18), 262*10^(-18)](m^3) 
    V_b = 1.5*10^(-6);                                          % basolateral volume: 1.5 mL 
   
    % Membrane potential (unit in 'Voltage') 
    E_a = -0.0093-0.005+0.01*rand();  % apical membrane potential: unif [-0.0143, -
0.0043]  
    E_l = 0.01-0.005+0.01*rand();    % lysosomal membrane potential: unif [0.005, 0.015] 
    E_m = -0.16 ;                               % mitochondrial membrane potential 
    E_b = 0.0119-0.005+0.01*rand();     % basolateral membrane potential: unif [0.0069, 
0.0169] 
     
    % pH values 
    pH_a = 6.4+0.2*rand();     % pH in apical compartment: unif [6.4, 6.6] 
    pH_c = 7.0+0.4*rand();      % pH in cytosol: unif [7.0, 7.4] 
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    pH_l = 4.8+0.4*rand();       % pH in lysosomes: unif [4.8, 5.2] 
    pH_m = 7.8+0.4*rand();     % pH in mitochondria: unif[7.8, 8.2] 
    pH_b = 7.4;                          % pH in basolateral compartment 
 
    % Apical Compartment 
    fn_a = 1 / (1 + 10^(i1*(pKa1-pH_a)) + 10^(i1*(pKa1-pH_a)+i2*(pKa2-pH_a))) ; 
    fd2_a = fn_a * 10^(i1*(pKa1-pH_a)+i2*(pKa2-pH_a)) ; 
    fd1_a = fn_a * 10^(i1*(pKa1-pH_a)) ; 
    Nd2_a = z2*E_a*F/(R*T) ; 
    Nd1_a = z1*E_a*F/(R*T) ; 
 
    % Cytoplasm 
    L_c = 0.05+0.1*rand();       % lipid fraction in cytosol: unif [0.05, 0.15]  
    W_c = 1-L_c ;                     % water fraction in cytosol 
    Is_c = 0.3 ;                           % ion strength in cytosol (mol) 
    gamman_c = 10^(0.3*Is_c) ;    % activity coefficient of neutral molecules in cytosol 
    gammad1_c = 10^(-0.5*z1*z1*(sqrt(Is_c)/(1+sqrt(Is_c))-0.3*Is_c));   % activity 
coefficient of monovalent base in cytosol 
    gammad2_c = 10^(-0.5*z2*z2*(sqrt(Is_c)/(1+sqrt(Is_c))-0.3*Is_c));   % activity 
coefficient of bivalent base in cytosol 
    Kn_c = L_c*1.22*10^(logPn) ; 
    Kd1_c = L_c*1.22*10^(logPd1) ; 
    Kd2_c = L_c*1.22*10^(logPd2) ; 
    an_c = 1 / (1 + 10^(i1*(pKa1-pH_c)) + 10^(i1*(pKa1-pH_c)+i2*(pKa2-pH_c))) ; 
    ad2_c = an_c * 10^(i1*(pKa1-pH_c)+i2*(pKa2-pH_c)) ; 
    ad1_c = an_c * 10^(i1*(pKa1-pH_c)) ; 
    Dd2_c = ad2_c / an_c ; 
    Dd1_c = ad1_c / an_c ; 
    fn_c = 1 / (W_c/gamman_c + Kn_c/gamman_c + Dd2_c*W_c/gammad2_c + 
Dd2_c*Kd2_c/gammad2_c  + Dd1_c*W_c/gammad1_c + Dd1_c*Kd1_c/gammad1_c ) ; 
    fd2_c = fn_c * Dd2_c ; 
    fd1_c = fn_c * Dd1_c ; 
 
    % Mitochondria 
    L_m = 0.05+0.1*rand();   % lipid fraction in mitochondria: unif [0.05, 0.15] 
    W_m = 1-L_m ;                % water fraction in mitochondria  
    Is_m = 0.3 ;                       % ion strength in mitochondria (mol) 
    Nd2_m = z2*E_m*F/(R*T) ; 
    Nd1_m = z1*E_m*F/(R*T) ; 
    gamman_m = 10^(0.3*Is_m) ;    % activity coefficient of neutral molecules in 
mitochondria 
    gammad1_m = 10^(-0.5*z1*z1*(sqrt(Is_m)/(1+sqrt(Is_m))-0.3*Is_m));   % activity 
coefficient of monovalent base in mitochondria 
    gammad2_m = 10^(-0.5*z2*z2*(sqrt(Is_m)/(1+sqrt(Is_m))-0.3*Is_m));   % activity 
coefficient of bivalent base in mitochondria 
    Kn_m = L_m*1.22*10^(logPn) ; 
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    Kd1_m = L_m*1.22*10^(logPd1) ; 
    Kd2_m = L_m*1.22*10^(logPd2) ; 
    an_m = 1 / (1 + 10^(i1*(pKa1-pH_m)) + 10^(i1*(pKa1-pH_m)+i2*(pKa2-pH_m))) ; 
    ad2_m = an_m * 10^(i1*(pKa1-pH_m)+i2*(pKa2-pH_m)) ; 
    ad1_m = an_m * 10^(i1*(pKa1-pH_m)) ; 
    Dd2_m = ad2_m / an_m ; 
    Dd1_m = ad1_m / an_m ; 
    fn_m = 1 / (W_m/gamman_m + Kn_m/gamman_m + Dd2_m*W_m/gammad2_m + 
Dd2_m*Kd2_m/gammad2_m ... 
           + Dd1_m*W_m/gammad1_m + Dd1_m*Kd1_m/gammad1_m ) ; 
    fd2_m = fn_m * Dd2_m ; 
    fd1_m = fn_m * Dd1_m ; 
 
    % Lysosomes 
    L_l = 0.05+0.1*rand();     % lipid fraction in mitochondria: unif [0.05, 0.15] 
    W_l = 1-L_l ;                    % water fraction in lysosomes 
    Is_l = 0.3 ;                         % ion strength in lysosomes (mol) 
    Nd2_l = z2*E_l*F/(R*T) ; 
    Nd1_l = z1*E_l*F/(R*T) ; 
    gamman_l = 10^(0.3*Is_l) ;   % activity coefficient of neutral molecules in lysosomes 
    gammad1_l = 10^(-0.5*z1*z1*(sqrt(Is_l)/(1+sqrt(Is_l))-0.3*Is_l));   % activity 
coefficient of monovalent base in lysosomes 
    gammad2_l = 10^(-0.5*z2*z2*(sqrt(Is_l)/(1+sqrt(Is_l))-0.3*Is_l));   % activity 
coefficient of bivalent base in lysosomes 
    Kn_l = L_l*1.22*10^(logPn) ; 
    Kd1_l = L_l*1.22*10^(logPd1) ; 
    Kd2_l = L_l*1.22*10^(logPd2) ; 
    an_l = 1 / (1 + 10^(i1*(pKa1-pH_l)) + 10^(i1*(pKa1-pH_l)+i2*(pKa2-pH_l))) ; 
    ad2_l = an_l * 10^(i1*(pKa1-pH_l)+i2*(pKa2-pH_l)) ; 
    ad1_l = an_l * 10^(i1*(pKa1-pH_l)) ; 
    Dd2_l = ad2_l / an_l ; 
    Dd1_l = ad1_l / an_l ; 
    fn_l = 1 / (W_l/gamman_l + Kn_l/gamman_l + Dd2_l*W_l/gammad2_l + 
Dd2_l*Kd2_l/gammad2_l ... 
           + Dd1_l*W_l/gammad1_l + Dd1_l*Kd1_l/gammad1_l ) ; 
    fd2_l = fn_l * Dd2_l ; 
    fd1_l = fn_l * Dd1_l ; 
 
    % Basolaterial Compartment 
    fn_b = 1 / (1 + 10^(i1*(pKa1-pH_b)) + 10^(i1*(pKa1-pH_b)+i2*(pKa2-pH_b))) ; 
    fd2_b = fn_b * 10^(i1*(pKa1-pH_b)+i2*(pKa2-pH_b)) ; 
    fd1_b = fn_b * 10^(i1*(pKa1-pH_b)) ; 
    Nd2_b = z2*(-E_b)*F/(R*T) ; 
    Nd1_b = z1*(-E_b)*F/(R*T) ; 
 
    % Solve the differential equation system: 
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    % Given a system of linear ODE's expressed in matrix form: 
    % Y' = AY+G with initial conditions Y(0) = RR, 
        k11 = -(A_a/V_c)*Pn*fn_c-
(A_a/V_c)*Pd1*Nd1_a*fd1_c*exp(Nd1_a)/(exp(Nd1_a)-1)... 
               -(A_a/V_c)*Pd2*Nd2_a*fd2_c*exp(Nd2_a)/(exp(Nd2_a)-1)... 
               -(A_m/V_c)*Pn*fn_c-(A_m/V_c)*Pd1*Nd1_m*fd1_c/(exp(Nd1_m)-1)... 
               -(A_m/V_c)*Pd2*Nd2_m*fd2_c/(exp(Nd2_m)-1)... 
               -(A_l/V_c)*Pn*fn_c-(A_l/V_c)*Pd1*Nd1_l*fd1_c/(exp(Nd1_l)-1)... 
               -(A_l/V_c)*Pd2*Nd2_l*fd2_c/(exp(Nd2_l)-1)... 
               -(A_b/V_c)*Pn*fn_c-(A_b/V_c)*Pd1*Nd1_b*fd1_c/(exp(Nd1_b)-1)... 
               -(A_b/V_c)*Pd2*Nd2_b*fd2_c/(exp(Nd2_b)-1) ; 
        k12 = 
(A_m/V_c)*Pn*fn_m+(A_m/V_c)*Pd1*Nd1_m*fd1_m*exp(Nd1_m)/(exp(Nd1_m)-1)... 
               +(A_m/V_c)*Pd2*Nd2_m*fd2_m*exp(Nd2_m)/(exp(Nd2_m)-1);  
        k13 = (A_l/V_c)*Pn*fn_l+(A_l/V_c)*Pd1*Nd1_l*fd1_l*exp(Nd1_l)/(exp(Nd1_l)-
1)... 
               +(A_l/V_c)*Pd2*Nd2_l*fd2_l*exp(Nd2_l)/(exp(Nd2_l)-1);    
        k14 = 
(A_b/V_c)*Pn*fn_b+(A_b/V_c)*Pd1*Nd1_b*fd1_b*exp(Nd1_b)/(exp(Nd1_b)-1)... 
               +(A_b/V_c)*Pd2*Nd2_b*fd2_b*exp(Nd2_b)/(exp(Nd2_b)-1); 
        S1 = (A_a/V_c)*C_a*(Pn*fn_a+Pd1*Nd1_a*fd1_a/(exp(Nd1_a)-1)... 
               +Pd2*Nd2_a*fd2_a/(exp(Nd2_a)-1)) ; 
 
        k21 = (A_m/V_m)*Pn*fn_c+(A_m/V_m)*Pd1*Nd1_m*fd1_c/(exp(Nd1_m)-1)... 
               +(A_m/V_m)*Pd2*Nd2_m*fd2_c/(exp(Nd2_m)-1) ; 
        k22 = -(A_m/V_m)*Pn*fn_m-
(A_m/V_m)*Pd1*Nd1_m*fd1_m*exp(Nd1_m)/(exp(Nd1_m)-1)... 
               -(A_m/V_m)*Pd2*Nd2_m*fd2_m*exp(Nd2_m)/(exp(Nd2_m)-1) ;  
        k23 = 0; 
        k24 = 0 ; 
        S2 = 0; 
 
        k31 = (A_l/V_l)*Pn*fn_c+(A_l/V_l)*Pd1*Nd1_l*fd1_c/(exp(Nd1_l)-1)... 
               +(A_l/V_l)*Pd2*Nd2_l*fd2_c/(exp(Nd2_l)-1) ; 
        k32 = 0;   
        k33 = -(A_l/V_l)*Pn*fn_l-(A_l/V_l)*Pd1*Nd1_l*fd1_l*exp(Nd1_l)/(exp(Nd1_l)-
1)... 
               -(A_l/V_l)*Pd2*Nd2_l*fd2_l*exp(Nd2_l)/(exp(Nd2_l)-1) ;  
 
        k34 = 0 ; 
        S3 = 0;     
 
        k41 = (A_b/V_b)*Pn*fn_c+(A_b/V_b)*Pd1*Nd1_b*fd1_c/(exp(Nd1_b)-1)... 
               +(A_b/V_b)*Pd2*Nd2_b*fd2_c/(exp(Nd2_b)-1) ; 
        k42 = 0; 
        k43 = 0; 
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        k44 = -(A_b/V_b)*Pn*fn_b-
(A_b/V_b)*Pd1*Nd1_b*fd1_b*exp(Nd1_b)/(exp(Nd1_b)-1)... 
                -(A_b/V_b)*Pd2*Nd2_b*fd2_b*exp(Nd2_b)/(exp(Nd2_b)-1); 
        S4 = 0; 
 
        A = [k11, k12, k13, k14; k21, k22, k23, k24; k31, k32, k33, k34; k41, k42, k43, 
k44]; 
        G = [S1, S2, S3, S4]'; 
        RR = [0,0,0,0]'; 
        t = 300 ;   % time in sec (5min) 
 
 
        [V,E] = eig(A); 
        E = diag(E); 
        H = inv(V)*G; 
        B = V \ RR; 
        C = B + H./E; 
        Z = -(H./E) + exp(t * E).*C ; 
        Y = real(V * Z); 
        Y = Y' ; 
         
        Ppore = Y(4)*V_b /(t*A_aa*C_a)*10^(2)*10^6 ;   % Pcell, 10^(-6)cm/sec 
        Peff = Y(4)*V_b*CellNo/(t*A_insert*C_a)*10^(2)*10^6;  % Peff, 10^(-6)cm/sec, 
normalized by insert area, which is 1.12 cm^2 
        Mass_cell = (Y(1)*V_c + Y(2)*V_m + Y(3)*V_l)*10^12 ; % cellular mass, 
pmol/cell 
        dMdt = Y(4)*V_b/t*10^12;        % transport rate: pmol/sec/cell 
         
    Para(i,:) = [A_a*10^12,PoreNo_cell, 
A_l*10^12,A_m*10^12,A_b*10^12,V_c*10^18,V_l*10^18,V_m*10^18,V_b*10^6,E_a
*1000,E_l*1000,E_m*1000,E_b*1000,... 
                     pH_a,pH_c,pH_l,pH_m,pH_b,CellNo,PoreDens, pKa1,pKa2,logPn,logPd1, 
logPd2]; 
    Results(i,:)=[Y(1),Y(2),Y(3),Ppore, Peff, dMdt, Mass_cell]; 
          
end 
 
comb = [Results(:,1:7),Para]; 
fid5 = fopen('AtoB_pH65_04um_5min.dat','w'); 
fprintf(fid5,'%12.4e %12.4e %12.4e %12.4e %12.4e  %12.4e %12.4e %12.2e %12.0f 
%12.4e %12.4e %12.4e  %12.4e %12.4e %12.4e %12.4e %12.4f %12.4f %12.4f %12.4f 
%12.2f %12.2f %12.2f %12.2f %12.2f %12.0f %12.0f %12.2f %12.2f %12.2f %12.2f 
%12.2f \n', comb') ;  
fclose(fid5); 
 






xlabel('log_{10} (P_{cell}, 10^{-6} 
cm/sec)','FontSize',30,'FontWeight','Bold','FontName','Times'); 
xlim([0, 6]); 




title ('histogram of cell 
permeability','FontSize',30,'FontWeight','Bold','FontName','Times') ; 
 





xlabel('log_{10} (P_{app}, 10^{-6} 
cm/sec)','FontSize',30,'FontWeight','Bold','FontName','Times'); 




title ('histogram of apparent 
permeability','FontSize',30,'FontWeight','Bold','FontName','Times') ; 
 











title ('histogram of transport rate','FontSize',30,'FontWeight','Bold','FontName','Times') ; 
 







xlabel('log_{10} (intracellular mass, pmol/cell) 
','FontSize',30,'FontWeight','Bold','FontName','Times'); 











a ---- activity  
A ---- membrane area 
Aaa ---- effective cross-sectional area 
B:P ---- blood : plasma partition coefficient 
C ---- concentration  
CL ---- clearance 
E ---- membrane potential 
F ---- the Faraday constant  
J ---- net flux cross the membrane  
K ---- sorption coefficients 
Kow ---- lipophilicity of small molecules 
Kp,t  ---- tissue : plasma partition coefficient  
Kiv ----  the intravenous injection or infusion rate 
L ---- lipid fraction  
logP ---- octanol water partition coefficient 
logPlip ---- liposomal partition coefficient  
m  ---- mass 
pKa ---- the negative logarithm(log10) of the dissociation constant 
P ---- permeability of molecules through the membrane  
Papp ---- apparent permeability 
Pcell ---- cell permeability 
Peff  ---- effective permeability 
Q  ---- blood flow rate  
R ---- the universal gas constant  
Rabs ---- absorption rate 
T ---- temperature 
V ---- volume  
W ----Volumetric water fraction 
z ---- electric charge 
γ --- activity coefficient 
 
Subscripts 
a ---- apical 
b ---- basolateral 
c ---- cytosol 
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d ---- ionic form 
m ---- mitochondria 
n ---- neutral form 
aEp ---- surface lining liquid 
imEp  ---- macrophage 
cEp  ---- epithelial cells 
cEpMito ---- mitochondria in epithelial cells 
cEpLyso ---- lysosomes in epithelial cells 
int ---- interstitium 
imInt  ---- immune cells 
sm  ---- smooth muscle cells 
smMito ---- mitochondria in smooth muscle cells 
smLyso ---- lysosomes in smooth muscle cells 
cEd  ---- endothelial cells  
cEdMito ---- mitochondria in endothelial cells 
cEdLyso ---- lysosomes in endothelial cells 
plung  ---- plasma in the lung 
ca  ---- heart 
bo  ---- bone 
mu  ---- muscle 
fa  ---- fat 
sk  ---- skin 
th  ---- thymus  
br  ---- brain 
sp  ---- spleen 
gu  ---- gut  
rob  ----rest of body 
hv  ---- liver 
ha  ---- hepatic arterial blood 
vb  ---- venous blood 









Table Appd.D.1. Structures, physicochemical properties, average Caco2 permeabilities, and predictive permeabilities of seven β-





Ccyto (mM) Cmito (mM) Name Structures pKa logPn  logPn, lip Caco-2 Peff 




9.60 3.10 3.22  95.70  91.18 7.89 7.82 
atenolol 
 
9.60 0.16 2.25  1.07  7.44 2.07 5.99 
metoprolol 
 
9.70 1.88 2.82  40.15  32.28 3.82 8.69 
oxprenolol 
 
9.50 2.10 2.89  97.25  39.16 4.25 5.76 
pindolol 
 
9.70 1.75 2.78  54.53  28.78 3.57 8.50 
practolol 
 
9.50 0.79 2.46  2.91  12.71  2.41  5.03  
propranolol 
 




Table Appd.D.2.  Comparison of predicted permeability with average Caco2 permeability and PAMA permeability of drugs within 
the predictive circle in Figure Appd.D.3.  Permeability values are in unit of 10-6 cm/sec.  Metoprolol was chosen a reference 
















alprenolol 91.18  H 11.5 H    15.1 H     
antipyrine 209.00 H 2.87 L 0.82 L 13.2 H 560 H H  
chlorpromazine 653.08  H     4.0 H    1 
clonidine 43.82  H 10.41 H   14.0 H     
desipramine 410.18  H 16.98 H   14.6 H 450 H   
diazepam 196.71  H           
diltiazem 122.32  H 19.21 H 14 H 18.5 H    2 
ibuprophen 321.84  H 21.15 H   6.8 H    2 
imipramine 391.33  H 19.36 H   8.4 H     
indomethacin 406.52  H     2.4 L     
ketoprofen 167.04  H 2.84 L 0.043 L 16.7 H 870 H H  
lidocaine 126.50  H           
metoprolol 32.28  ref 7.93 ref 1.2 ref 3.5 ref 134 ref H  
naproxen 175.61  H 5.01 L 0.23 L 10.6 H 850 H H  
oxprenolol 39.16  H 14.64 H         
phenytoin 86.02  H 38.53 H   5.1 H     
pindolol 28.78  L 4.91 L   4.9 H     
piroxicam 1541.60  H 10.87 H   8.2 H 665 H   
propranolol 79.41 H 26.33 H 12 H 23.5 H 291 H H 1 
trimethoprim 194.22  H 3.14 L 2.2 H 5.0 H    4 




verapamil 191.16  H 23.02 H 14 H 7.4 H 680 H H 1 




Table Appd.D.3: Correlation of predicted permeability vs. human intestinal 










antipyrine 560.00 -3.25 209.00 -3.68 
atenolol 20.00 -4.70 7.44 -5.13 
desipramine 450.00 -3.35 410.18 -3.39 
ketoprofen 870.00 -3.06 167.04 -3.78 
metoprolol 134.00 -3.87 32.28 -4.49 
naproxen 850.00 -3.07 175.61 -3.76 
piroxicam 665.00 -3.18 1542.75 -2.81 
propranolol 291.00 -3.54 81.73 -4.09 
terbutaline 30.00 c -4.52 22.96 -4.64 





Figure Appd.D.1. Correlation of Caco2 permeability and predicted permeability of 
seven β-adrenergic blockers. The X-axis indicates the logarithm values of average 
measured Caco2 permeability (cm/sec) and the Y-axis indicate the logarithm values of 
predicted permeability (cm/sec).  The dotted line is the linear regression line.  The linear 
regression equation is )76.0(4.244.0 2 =−= Rxy , the significance F of regression given 
by EXCEL is 0.011 (confidence level is 95%).  Numbers 1 through 7 indicate alprenolol, 
atenolol, metoprolol, oxprenolol, pindolol, practolol, and propranolol respectively.  The 
structures, physicochemical properties, average Caco2 permeability and predictive 





Figure Appd.D.2. Correlation of Caco2 permeability and predicted permeability of 
thirty-six drugs. The X-axis indicates the logarithm values of average measured Caco2 
permeability (cm/sec) and the Y-axis indicate the logarithm values of predicted 
permeability (cm/sec).  Metoprolol (No.18) was used as a reference drug. Details of 






Figure Appd.D.3. Correlation of human intestinal permeability and predicted 
permeability. The X-axis indicates the logarithm values of measured human intestinal 
permeability (cm/sec) and the Y-axis indicate the logarithm values of predicted 
permeability (cm/sec).  A simple linear relation was obtained and expressed by the 
equation: )73.0(57.095.0 2 =−= Rxy , the significance F of regression given by EXCEL 
is 0.0016 (confidence level is 95%).  Calculated permeability and human intestinal 




Figure Appd.D.4.   Effects of physicochemical properties on intracellular concentration 
(solid line = cytosolic; dark dotted line = mitochondrial) and permeability (light stippled 
line) at steady state, of a molecule with metoprolol-like properties (arrows). A. logPn and 
logPd are not associated. B. logPn and logPd are associated by a simple linear relationship 
expressed as equations 2.27-2.29.  The arrows indicate the liposomal logPn, lip and logPd, 






Parameters for the Tracheobronchial Airways and Alveolar Region in the Rat 



















liquid 15b  108 0.162 5 3870 1.935 
Macrophage - - - - 42 0.0282 
Epithelium 24-9c  108 0.072d 0.384 3870 0.148 
Interstitium 1d 108 0.0108d 0.693 3870 0.268 
Immune cells - 1.08b 0.000108d - 4.2d 0.00282d
Smooth muscle 19.3-4.3e  216d 0.047d - - - 
Endothelium 0.4f  5.4d 0.000216d 0.358 4520 0.162 
a. All parameters were extracted from (1) unless otherwise specified 
b.  (2) c. (3) d. Calculated or estimated e. (4) f. (5) 
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